{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Eli Lilly, in 2022 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \nIndiana |  | 35-0470950\n(State or other jurisdiction of |  | (I.R.S. Employer\nincorporation or organization) |  | Identification No.)  |  |  |  |  |  |  |  | \nTitle of Each Class | Trading Symbols | Name of Each Exchange On Which Registered\nCommon Stock (no par value) | LLY | New York Stock Exchange\n7 1/8% Notes due 2025 | LLY25 | New York Stock Exchange\n1.625% Notes due 2026 | LLY26 | New York Stock Exchange\n2.125% Notes due 2030 | LLY30 | New York Stock Exchange\n0.625% Notes due 2031 | LLY31 | New York Stock Exchange\n0.500% Notes due 2033 | LLY33 | New York Stock Exchange\n6.77%\u00a0Notes due 2036 | LLY36 | New York Stock Exchange\n1.625% Notes due 2043 | LLY43 | New York Stock Exchange\n1.700% Notes due 2049 | LLY49A | New York Stock Exchange\n1.125% Notes due 2051 | LLY51 | New York Stock Exchange\n1.375% Notes due 2061 | LLY61 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  |  |  |  | Accelerated\u00a0filer | \u2610\nNon-accelerated filer | \u2610 |  |  | Smaller reporting company | \u2610\n |  |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  | \nClass |  | Number of Shares Outstanding\nCommon |  | 950,159,559 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\nPART I. Financial Information |  |  |  | 5\n |  |  |  | \nItem 1. |  | Financial Statements |  | 5\n |  | Consolidated Condensed Statements of Operations |  | 5\n |  | Consolidated Condensed Statements of Comprehensive Income |  | 6\n |  | Consolidated Condensed Balance Sheets |  | 7\n |  | Consolidated Condensed Statements of Equity |  | 8\n |  | Consolidated Condensed Statements of Cash Flows |  | 9\n |  | Notes to Consolidated Condensed Financial Statements |  | 10\nItem 2. |  | Management's Discussion and Analysis of Results of Operations and Financial Condition |  | 35\n |  | Executive Overview |  | 35\n |  | Revenue |  | 41\n |  | Gross Margin, Costs, and Expenses |  | 44\n |  | Financial Condition and Liquidity |  | 45\n |  |  |  | \n |  | Critical Accounting Estimates |  | 45\n |  | Available Information on our Website |  | 45\nItem 4. |  | Controls and Procedures |  | 46\n |  |  |  | \nPART II. Other Information |  |  |  | 47\n |  |  |  | \nItem 1. |  | Legal Proceedings |  | 47\nItem 1A. |  | Risk Factors |  | 47\nItem 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 47\nItem 6. |  | Exhibits |  | 48\n |  |  |  | \nSignatures |  |  |  | 48  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nRevenue (Note 2) | $ | 7,810.0 |  |  | $ | 6,805.6 |  |  |  |  | \nCosts, expenses, and other: |  |  |  |  |  |  | \nCost of sales | 2,072.1 |  |  | 1,878.6 |  |  |  |  | \nResearch and development | 1,610.1 |  |  | 1,672.1 |  |  |  |  | \nMarketing, selling, and administrative | 1,557.9 |  |  | 1,576.0 |  |  |  |  | \nAcquired in-process research and development and development milestones (Note 3) | 165.6 |  |  | 312.0 |  |  |  |  | \nAsset impairment, restructuring, and other special charges (Note 5) | \u2014 |  |  | 211.6 |  |  |  |  | \nOther\u2013net, (income) expense (Note 11) | 350.7 |  |  | (321.1) |  |  |  |  | \n | 5,756.4 |  |  | 5,329.2 |  |  |  |  | \nIncome before income taxes | 2,053.6 |  |  | 1,476.4 |  |  |  |  | \nIncome taxes (Note 7) | 150.7 |  |  | 121.1 |  |  |  |  | \nNet income | $ | 1,902.9 |  |  | $ | 1,355.3 |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nEarnings per share: |  |  |  |  |  |  | \nBasic | $ | 2.11 |  |  | $ | 1.49 |  |  |  |  | \n |  |  |  |  |  |  | \nDiluted | $ | 2.10 |  |  | $ | 1.49 |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nShares used in calculation of earnings per share: |  |  |  |  |  |  | \nBasic | 903.7 |  | 908.8 |  |  |  | \nDiluted | 906.4 |  | 912.4 |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nNet income | $ | 1,902.9 |  |  | $ | 1,355.3 |  |  |  |  | \nOther comprehensive income, net of tax (Note 10) | 117.8 |  |  | 100.8 |  |  |  |  | \nComprehensive income | $ | 2,020.7 |  |  | $ | 1,456.1 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nAssets | (Unaudited) |  | \nCurrent Assets |  |  | \nCash and cash equivalents (Note 6) | $ | 2,459.2 |  |  | $ | 3,818.5 | \nShort-term investments (Note 6) | 109.1 |  |  | 90.1 | \nAccounts receivable, net of allowances of$22.0(2022)and $22.5(2021) | 6,322.5 |  |  | 6,672.8 | \nOther receivables | 1,483.2 |  |  | 1,454.4 | \nInventories | 3,893.0 |  |  | 3,886.0 | \nPrepaid expenses and other | 2,697.7 |  |  | 2,530.6 | \nTotal current assets | 16,964.7 |  |  | 18,452.4 | \nInvestments (Note 6) | 2,727.3 |  |  | 3,212.6 | \nGoodwill | 3,892.0 |  |  | 3,892.0 | \nOther intangibles, net | 7,482.4 |  |  | 7,691.9 | \nDeferred tax assets | 2,464.9 |  |  | 2,489.3 | \nProperty and equipment, net of accumulated depreciation of$10,138.3(2022)and $9,976.7(2021) | 9,102.7 |  |  | 8,985.1 | \nOther noncurrent assets | 4,285.3 |  |  | 4,082.7 | \nTotal assets | $ | 46,919.3 |  |  | $ | 48,806.0 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nShort-term borrowings and current maturities of long-term debt | $ | 1,355.9 |  |  | $ | 1,538.3 | \nAccounts payable | 1,433.3 |  |  | 1,670.6 | \nEmployee compensation | 693.1 |  |  | 958.1 | \nSales rebates and discounts | 6,768.7 |  |  | 6,845.8 | \nDividends payable | \u2014 |  |  | 885.5 | \nIncome taxes payable | 598.3 |  |  | 126.9 | \nOther current liabilities | 2,536.7 |  |  | 3,027.5 | \nTotal current liabilities | 13,386.0 |  |  | 15,052.7 | \nOther Liabilities |  |  | \nLong-term debt | 15,152.9 |  |  | 15,346.4 | \nAccrued retirement benefits (Note 8) | 1,940.3 |  |  | 1,954.1 | \nLong-term income taxes payable | 3,978.1 |  |  | 3,920.0 | \nDeferred tax liabilities | 1,286.1 |  |  | 1,733.7 | \nOther noncurrent liabilities | 1,713.9 |  |  | 1,644.3 | \nTotal other liabilities | 24,071.3 |  |  | 24,598.5 | \nCommitments and Contingencies (Note 9) |  |  | \nEli Lilly and Company Shareholders' Equity |  |  | \nCommon stock | 594.1 |  |  | 596.3 | \nAdditional paid-in capital | 6,656.3 |  |  | 6,833.4 | \nRetained earnings | 9,369.4 |  |  | 8,958.5 | \nEmployee benefit trust | (3,013.2) |  |  | (3,013.2) | \nAccumulated other comprehensive loss (Note 10) | (4,225.3) |  |  | (4,343.1) | \nCost of common stock in treasury | (50.5) |  |  | (52.7) | \nTotal Eli Lilly and Company shareholders' equity | 9,330.8 |  |  | 8,979.2 | \nNoncontrolling interests | 131.2 |  |  | 175.6 | \nTotal equity | 9,462.0 |  |  | 9,154.8 | \nTotal liabilities and equity | $ | 46,919.3 |  |  | $ | 48,806.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at January 1, 2021 | 957,077 |  |  | $ | 598.2 |  |  | $ | 6,778.5 |  |  | $ | 7,830.2 |  |  | $ | (3,013.2) |  |  | $ | (6,496.4) |  |  | 487 |  |  | $ | (55.7) |  |  | $ | 183.6 | \nNet income |  |  |  |  |  |  | 1,355.3 |  |  |  |  |  |  |  |  |  |  | 16.4 | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 100.8 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIssuance of stock under employee stock plans, net | 2,405 |  |  | 1.5 |  |  | (283.9) |  |  |  |  |  |  |  |  | (24) |  |  | 3.0 |  |  | \nStock-based compensation |  |  |  |  | 85.5 |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  | (0.9) |  |  | (4.2) |  |  |  |  |  |  |  |  |  |  | 0.6 | \nBalance at March 31, 2021 | 959,482 |  |  | $ | 599.7 |  |  | $ | 6,579.2 |  |  | $ | 9,181.3 |  |  | $ | (3,013.2) |  |  | $ | (6,395.6) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 200.6 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January 1, 2022 | 954,116 |  |  | $ | 596.3 |  |  | $ | 6,833.4 |  |  | $ | 8,958.5 |  |  | $ | (3,013.2) |  |  | $ | (4,343.1) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 175.6 | \nNet income (loss) |  |  |  |  |  |  | 1,902.9 |  |  |  |  |  |  |  |  |  |  | (36.6) | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 117.8 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (5,607) |  |  | (3.5) |  |  |  |  | (1,496.5) |  |  |  |  |  |  | (5,607) |  |  | 1,500.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 5,607 |  |  | (1,500.0) |  |  | \nIssuance of stock under employee stock plans, net | 2,096 |  |  | 1.3 |  |  | (278.1) |  |  |  |  |  |  |  |  | (13) |  |  | 2.2 |  |  | \nStock-based compensation |  |  |  |  | 101.0 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | 4.5 |  |  |  |  |  |  |  |  |  |  | (7.8) | \nBalance at March 31, 2022 | 950,605 |  |  | $ | 594.1 |  |  | $ | 6,656.3 |  |  | $ | 9,369.4 |  |  | $ | (3,013.2) |  |  | $ | (4,225.3) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 131.2 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2022 |  | 2021\nCash Flows from Operating Activities | \nNet income | $ | 1,902.9 |  |  | $ | 1,355.3 | \nAdjustments to Reconcile Net Income to Cash Flows from Operating Activities: |  |  | \n |  |  | \nDepreciation and amortization | 435.7 |  |  | 350.3 | \nChange in deferred income taxes | (506.6) |  |  | (119.1) | \n |  |  | \nStock-based compensation expense | 101.0 |  |  | 85.5 | \n |  |  | \nNet investment (gains) losses | 426.1 |  |  | (302.2) | \nAcquired in-process research and development | 153.0 |  |  | 299.3 | \nOther changes in operating assets and liabilities, net of acquisitions and divestitures | (45.5) |  |  | (102.8) | \nOther non-cash operating activities, net | 32.6 |  |  | 131.1 | \nNet Cash Provided by Operating Activities | 2,499.2 |  |  | 1,697.4 | \nCash Flows from Investing Activities |  |  | \nNet purchases of property and equipment | (365.4) |  |  | (300.3) | \nProceeds from sales and maturities of short-term investments | 26.7 |  |  | 4.0 | \nPurchases of short-term investments | (14.6) |  |  | (19.4) | \nProceeds from sales of noncurrent investments | 81.4 |  |  | 284.8 | \nPurchases of noncurrent investments | (116.7) |  |  | (291.5) | \nCash paid for acquisitions, net of cash acquired (Note 3) | \u2014 |  |  | (747.4) | \n |  |  | \nPurchases of in-process research and development | (491.8) |  |  | (191.8) | \nOther investing activities, net | (133.4) |  |  | (21.9) | \nNet Cash Used for Investing Activities | (1,013.8) |  |  | (1,283.5) | \nCash Flows from Financing Activities |  |  | \nDividends paid | (885.5) |  |  | (774.8) | \nNet change in short-term borrowings | 499.7 |  |  | (3.7) | \n |  |  | \nRepayments of long-term debt | (710.1) |  |  | \u2014 | \nPurchases of common stock | (1,500.0) |  |  | \u2014 | \n |  |  | \nOther financing activities, net | (282.4) |  |  | (279.9) | \nNet Cash Used for Financing Activities | (2,878.3) |  |  | (1,058.4) | \nEffect of exchange rate changes on cash and cash equivalents | 33.6 |  |  | (10.2) | \n |  |  | \nNet decrease in cash and cash equivalents | (1,359.3) |  |  | (654.7) | \nCash and cash equivalents at January\u00a01 | 3,818.5 |  |  | 3,657.1 | \nCash and Cash Equivalents at March 31 | $ | 2,459.2 |  |  | $ | 3,002.4 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nNet product revenue | $ | 7,132.9 |  |  | $ | 6,320.0 |  |  |  |  | \nCollaboration and other revenue(1) | 677.1 |  |  | 485.6 |  |  |  |  | \nRevenue | $ | 7,810.0 |  |  | $ | 6,805.6 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nContract liabilities | $ | 251.6 |  |  | $ | 262.6 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2022 |  | 2021\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\nRevenue\u2014to unaffiliated customers: |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity\u00ae | $ | 1,313.9 |  | $ | 427.4 |  | $ | 1,741.3 |  |  | $ | 1,116.8 |  | $ | 335.7 |  | $ | 1,452.4 | \nHumalog\u00ae (1) | 368.9 |  | 249.3 |  | 618.2 |  |  | 332.7 |  | 284.4 |  | 617.0 | \nJardiance(2) | 229.8 |  | 189.7 |  | 419.4 |  |  | 151.2 |  | 160.8 |  | 312.0 | \nHumulin\u00ae | 190.4 |  | 82.8 |  | 273.2 |  |  | 219.0 |  | 102.7 |  | 321.7 | \nBasaglar\u00ae | 119.3 |  | 72.2 |  | 191.5 |  |  | 175.2 |  | 71.4 |  | 246.6 | \nOther diabetes | 54.3 |  | 90.2 |  | 144.6 |  |  | 66.3 |  | 94.9 |  | 161.4 | \nTotal diabetes | 2,276.6 |  | 1,111.6 |  | 3,388.2 |  |  | 2,061.2 |  | 1,049.9 |  | 3,111.1 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio\u00ae | 301.5 |  | 167.9 |  | 469.4 |  |  | 172.8 |  | 96.2 |  | 269.0 | \nAlimta\u00ae | 254.3 |  | 89.7 |  | 343.9 |  |  | 261.1 |  | 297.8 |  | 559.0 | \nCyramza\u00ae | 79.2 |  | 151.1 |  | 230.3 |  |  | 80.2 |  | 160.3 |  | 240.5 | \nErbitux\u00ae | 109.7 |  | 13.0 |  | 122.7 |  |  | 107.9 |  | 14.4 |  | 122.4 | \nTyvyt\u00ae | \u2014 |  | 85.5 |  | 85.5 |  |  | \u2014 |  | 109.7 |  | 109.7 | \nOther oncology | 39.0 |  | 62.0 |  | 101.2 |  |  | 20.5 |  | 51.3 |  | 71.6 | \nTotal oncology | 783.7 |  | 569.2 |  | 1,353.0 |  |  | 642.5 |  | 729.7 |  | 1,372.2 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz\u00ae | 307.2 |  | 180.8 |  | 488.1 |  |  | 249.6 |  | 153.6 |  | 403.2 | \nOlumiant\u00ae (3) | 71.3 |  | 184.3 |  | 255.6 |  |  | 24.7 |  | 169.1 |  | 193.8 | \nOther immunology | \u2014 |  | 4.5 |  | 4.5 |  |  | 10.5 |  | 6.4 |  | 16.9 | \nTotal immunology | 378.5 |  | 369.6 |  | 748.1 |  |  | 284.8 |  | 329.1 |  | 613.9 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nEmgality\u00ae | 108.3 |  | 41.0 |  | 149.3 |  |  | 101.5 |  | 18.0 |  | 119.5 | \nZyprexa\u00ae | 9.6 |  | 83.5 |  | 93.1 |  |  | 6.9 |  | 88.9 |  | 95.8 | \nCymbalta\u00ae | 9.1 |  | 71.9 |  | 81.1 |  |  | 11.0 |  | 165.7 |  | 176.6 | \n |  |  |  |  |  |  | \nOther neuroscience | 26.4 |  | 48.0 |  | 74.2 |  |  | 22.3 |  | 51.1 |  | 73.5 | \nTotal neuroscience | 153.4 |  | 244.4 |  | 397.7 |  |  | 141.7 |  | 323.7 |  | 465.4 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nCOVID-19 antibodies(4) | 1,455.2 |  | 14.7 |  | 1,469.8 |  |  | 650.6 |  | 159.5 |  | 810.1 | \nCialis\u00ae | 6.9 |  | 210.8 |  | 217.7 |  |  | 8.6 |  | 118.1 |  | 126.8 | \nForteo\u00ae | 70.2 |  | 67.3 |  | 137.4 |  |  | 97.7 |  | 100.8 |  | 198.5 | \nOther | 50.1 |  | 47.8 |  | 98.1 |  |  | 54.2 |  | 53.4 |  | 107.5 | \nTotal other | 1,582.4 |  | 340.6 |  | 1,923.0 |  |  | 811.1 |  | 431.8 |  | 1,242.9 | \nRevenue | $ | 5,174.6 |  | $ | 2,635.4 |  | $ | 7,810.0 |  |  | $ | 3,941.3 |  | $ | 2,864.3 |  | $ | 6,805.6 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nRevenue\u2014to unaffiliated customers(1): |  |  |  |  |  |  | \nU.S. | $ | 5,174.6 |  |  | $ | 3,941.3 |  |  |  |  | \nEurope | 1,067.3 |  |  | 1,321.2 |  |  |  |  | \nJapan | 410.2 |  |  | 571.8 |  |  |  |  | \nChina | 406.5 |  |  | 362.2 |  |  |  |  | \nOther foreign countries | 751.5 |  |  | 609.1 |  |  |  |  | \nRevenue | $ | 7,810.0 |  |  | $ | 6,805.6 |  |  |  |  |   |  |  |  |  | \nEstimated Fair Value at January 22, 2021 | \nCash | $ | 90.5 | \nAcquired IPR&D(1) | 824.0\nGoodwill(2) | 126.8\nDeferred tax liabilities | (106.0) | \nOther assets and liabilities, net | (31.5) | \nAcquisition date fair value of consideration transferred | 903.8\nLess: | \nCash acquired | (90.5) | \nFair value of CVR liability(3) | (65.9) | \nCash paid, net of cash acquired | $ | 747.4 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCounterparty | Compound(s), Therapy or Asset | Acquisition Month |  | Phase of Development(1) |  | Acquired IPR&D Expense\nBioMarin Pharmaceutical Inc. | Priority Review Voucher | February 2022 |  | Not applicable |  | $ | 110.0 | \n |  |  |  |  |  | \nRigel Pharmaceuticals, Inc. | R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases | March 2021 |  | Phase I |  | 125.0 | \nPrecision Biosciences, Inc. | Potential in vivo therapies for genetic disorders | January 2021 |  | Pre-clinical |  | 107.8 | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  | \n | Net Milestones Capitalized (Deferred)(1)as of:\n | March 31, 2022 | December 31, 2021\nJardiance | $ | 131.1 |  | $ | 136.1 | \nTrajenta | 82.0 |  | 88.5 | \nBasaglar | (144.6) |  | (149.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nJardiance | $ | 419.4 |  |  | $ | 312.0 |  |  |  |  | \nBasaglar | 191.5 |  |  | 246.6 |  |  |  |  | \nTrajenta | 92.0 |  |  | 94.6 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nOlumiant | $ | 255.6 |  |  | $ | 193.8 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nTyvyt | $ | 85.5 |  |  | $ | 109.7 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nSeverance | $ | \u2014 |  |  | $ | 11.5 |  |  |  |  | \nAsset impairment and other special charges | \u2014 |  |  | 200.1 |  |  |  |  | \nTotal asset impairment, restructuring, and other special charges | $ | \u2014 |  |  | $ | 211.6 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nFair value hedges: |  |  |  |  |  |  | \nEffect from hedged fixed-rate debt | $ | (94.6) |  |  | $ | (81.5) |  |  |  |  | \nEffect from interest rate contracts | 94.6 |  |  | 81.5 |  |  |  |  | \nCash flow hedges: |  |  |  |  |  |  | \nEffective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss | 4.1 |  |  | 4.1 |  |  |  |  | \nCross-currency interest rate swaps | 8.3 |  |  | 71.5 |  |  |  |  | \nNet (gains) losses on foreign currency exchange contracts not designated as hedging instruments | (6.1) |  |  | 133.0 |  |  |  |  | \nTotal | $ | 6.3 |  |  | $ | 208.6 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nNet investment hedges: |  |  |  |  |  |  | \nForeign currency-denominated notes | $ | 54.4 |  |  | $ | 207.7 |  |  |  |  | \nCross-currency interest rate swaps | 10.8 |  |  | 150.6 |  |  |  |  | \n |  |  |  |  |  |  | \nCash flow hedges: |  |  |  |  |  |  | \nForward-starting interest rate swaps | 122.5 |  |  | 295.1 |  |  |  |  | \nCross-currency interest rate swaps | 17.1 |  |  | 26.3 |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Cost(1) |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | Significant OtherObservable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nMarch 31, 2022 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents | $ | 1,104.1 |  |  | $ | 1,104.1 |  |  | $ | 1,095.0 |  |  | $ | 9.1 |  |  | $ | \u2014 |  |  | $ | 1,104.1 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 45.1 |  |  | $ | 45.4 |  |  | $ | 45.1 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 45.1 | \nCorporate debt securities | 50.6 |  |  | 50.7 |  |  | \u2014 |  |  | 50.6 |  |  | \u2014 |  |  | 50.6 | \nMortgage-backed securities | 0.2 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 | \nAsset-backed securities | 2.9 |  |  | 3.0 |  |  | \u2014 |  |  | 2.9 |  |  | \u2014 |  |  | 2.9 | \nOther securities | 10.3 |  |  | 10.3 |  |  | \u2014 |  |  | \u2014 |  |  | 10.3 |  |  | 10.3 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 109.1 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 116.2 |  |  | $ | 123.0 |  |  | $ | 116.2 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 116.2 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities | 212.3 |  |  | 224.3 |  |  | \u2014 |  |  | 224.3 |  |  | \u2014 |  |  | 224.3 | \nMortgage-backed securities | 105.1 |  |  | 109.0 |  |  | \u2014 |  |  | 105.1 |  |  | \u2014 |  |  | 105.1 | \nAsset-backed securities | 34.6 |  |  | 35.4 |  |  | \u2014 |  |  | 34.6 |  |  | \u2014 |  |  | 34.6 | \nOther securities | 112.5 |  |  | 15.3 |  |  | \u2014 |  |  | \u2014 |  |  | 112.5 |  |  | 112.5 | \nMarketable equity securities | 807.9 |  |  | 481.9 |  |  | 807.9 |  |  | \u2014 |  |  | \u2014 |  |  | 807.9 | \nEquity investments without readily determinable fair values(2) | 569.5 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(2) | 769.2 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 2,727.3 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents | $ | 2,379.5 |  |  | $ | 2,379.5 |  |  | $ | 2,361.0 |  |  | $ | 18.5 |  |  | $ | \u2014 |  |  | $ | 2,379.5 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 25.7 |  |  | $ | 25.6 |  |  | $ | 25.7 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 25.7 | \nCorporate debt securities | 43.7 |  |  | 43.7 |  |  | \u2014 |  |  | 43.7 |  |  | \u2014 |  |  | 43.7 | \nMortgage-backed securities | 0.2 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 | \nAsset-backed securities | 6.2 |  |  | 6.2 |  |  | \u2014 |  |  | 6.2 |  |  | \u2014 |  |  | 6.2 | \nOther securities | 14.3 |  |  | 14.3 |  |  | \u2014 |  |  | \u2014 |  |  | 14.3 |  |  | 14.3 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 90.1 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 137.0 |  |  | $ | 136.8 |  |  | $ | 137.0 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 137.0 | \nCorporate debt securities | 235.3 |  |  | 232.7 |  |  | \u2014 |  |  | 235.3 |  |  | \u2014 |  |  | 235.3 | \nMortgage-backed securities | 109.8 |  |  | 108.1 |  |  | \u2014 |  |  | 109.8 |  |  | \u2014 |  |  | 109.8 | \nAsset-backed securities | 23.1 |  |  | 23.1 |  |  | \u2014 |  |  | 23.1 |  |  | \u2014 |  |  | 23.1 | \nOther securities | 108.1 |  |  | 22.2 |  |  | \u2014 |  |  | \u2014 |  |  | 108.1 |  |  | 108.1 | \nMarketable equity securities | 1,279.7 |  |  | 487.0 |  |  | 1,279.7 |  |  | \u2014 |  |  | \u2014 |  |  | 1,279.7 | \nEquity investments without readily determinable fair values(2) | 548.1 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(2) | 771.5 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 3,212.6 |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nShort-term commercial paper borrowings |  |  |  |  |  |  |  |  | \nMarch 31, 2022 | $ | (499.7) |  |  | $ | \u2014 |  |  | $ | (499.7) |  |  | $ | \u2014 |  |  | $ | (499.7) | \nDecember 31, 2021 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nLong-term debt, including current portion |  |  |  |  |  |  |  |  | \nMarch 31, 2022 | $ | (16,009.1) |  |  | $ | \u2014 |  |  | $ | (15,798.9) |  |  | $ | \u2014 |  |  | $ | (15,798.9) | \nDecember 31, 2021 | (16,884.7) |  |  | \u2014 |  |  | (18,157.7) |  |  | \u2014 |  |  | (18,157.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  |  |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue |  | \nMarch 31, 2022 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | $ | 1.3 |  |  | $ | \u2014 |  |  | $ | 1.3 |  |  | $ | \u2014 |  |  | $ | 1.3 |  |  | \nOther noncurrent assets | 22.8 |  |  | \u2014 |  |  | 22.8 |  |  | \u2014 |  |  | 22.8 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (43.2) |  |  | \u2014 |  |  | (43.2) |  |  | \u2014 |  |  | (43.2) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 140.0 |  |  | \u2014 |  |  | 140.0 |  |  | \u2014 |  |  | 140.0 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 2.0 |  |  | \u2014 |  |  | 2.0 |  |  | \u2014 |  |  | 2.0 |  |  | \nOther noncurrent assets | 40.0 |  |  | \u2014 |  |  | 40.0 |  |  | \u2014 |  |  | 40.0 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 40.8 |  |  | \u2014 |  |  | 40.8 |  |  | \u2014 |  |  | 40.8 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 38.8 |  |  | \u2014 |  |  | 38.8 |  |  | \u2014 |  |  | 38.8 |  |  | \nOther current liabilities | (45.8) |  |  | \u2014 |  |  | (45.8) |  |  | \u2014 |  |  | (45.8) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nContingent consideration liability: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (70.0) |  |  | \u2014 |  |  | \u2014 |  |  | (70.0) |  |  | (70.0) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | $ | 4.8 |  |  | $ | \u2014 |  |  | $ | 4.8 |  |  | $ | \u2014 |  |  | $ | 4.8 |  |  | \nOther noncurrent assets | 78.3 |  |  | \u2014 |  |  | 78.3 |  |  | \u2014 |  |  | 78.3 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (7.6) |  |  | \u2014 |  |  | (7.6) |  |  | \u2014 |  |  | (7.6) |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 49.2 |  |  | \u2014 |  |  | 49.2 |  |  | \u2014 |  |  | 49.2 |  |  | \nOther noncurrent liabilities | (31.7) |  |  | \u2014 |  |  | (31.7) |  |  | \u2014 |  |  | (31.7) |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 31.3 |  |  | \u2014 |  |  | 31.3 |  |  | \u2014 |  |  | 31.3 |  |  | \nOther current liabilities | (1.2) |  |  | \u2014 |  |  | (1.2) |  |  | \u2014 |  |  | (1.2) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 33.2 |  |  | \u2014 |  |  | 33.2 |  |  | \u2014 |  |  | 33.2 |  |  | \nOther noncurrent liabilities | (1.3) |  |  | \u2014 |  |  | (1.3) |  |  | \u2014 |  |  | (1.3) |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 9.9 |  |  | \u2014 |  |  | 9.9 |  |  | \u2014 |  |  | 9.9 |  |  | \nOther current liabilities | (35.3) |  |  | \u2014 |  |  | (35.3) |  |  | \u2014 |  |  | (35.3) |  |  | \nContingent consideration liabilities: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (70.5) |  |  | \u2014 |  |  | \u2014 |  |  | (70.5) |  |  | (70.5) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturities by Period\n | Total |  | Less\u00a0Than1 Year |  | 1-5Years |  | 6-10Years |  | More\u00a0Than10 Years\nFair value of debt securities | $ | 567.1 |  |  | $ | 98.9 |  |  | $ | 197.7 |  |  | $ | 110.7 |  |  | $ | 159.8 |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2022 |  | December 31, 2021\nUnrealized gross gains | $ | 1.3 |  |  | $ | 9.7 | \nUnrealized gross losses | 25.2 |  |  | 5.2 | \nFair value of securities in an unrealized gain position | 89.5 |  |  | 250.7 | \nFair value of securities in an unrealized loss position | 440.6 |  |  | 290.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nProceeds from sales | $ | 35.2 |  |  | $ | 43.3 |  |  |  |  | \nRealized gross gains on sales | 0.1 |  |  | 1.1 |  |  |  |  | \nRealized gross losses on sales | 0.8 |  |  | 0.4 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Defined Benefit Pension Plans\n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nComponents of net periodic benefit cost: |  |  |  |  |  |  | \nService cost | $ | 89.1 |  |  | $ | 92.0 |  |  |  |  | \nInterest cost | 100.5 |  |  | 84.3 |  |  |  |  | \nExpected return on plan assets | (239.5) |  |  | (238.0) |  |  |  |  | \nAmortization of prior service cost | 0.7 |  |  | 1.1 |  |  |  |  | \nRecognized actuarial loss | 87.0 |  |  | 121.8 |  |  |  |  | \n |  |  |  |  |  |  | \nNet periodic benefit cost | $ | 37.8 |  |  | $ | 61.2 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Retiree Health Benefit Plans\n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nComponents of net periodic benefit income: |  |  |  |  |  |  | \nService cost | $ | 11.2 |  |  | $ | 11.7 |  |  |  |  | \nInterest cost | 9.4 |  |  | 8.1 |  |  |  |  | \nExpected return on plan assets | (37.9) |  |  | (36.6) |  |  |  |  | \nAmortization of prior service benefit | (13.7) |  |  | (14.9) |  |  |  |  | \nRecognized actuarial loss | 0.2 |  |  | 0.8 |  |  |  |  | \n |  |  |  |  |  |  | \nNet periodic benefit income | $ | (30.8) |  |  | $ | (30.9) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at January 1, 2022 | $ | (1,550.2) |  |  | $ | 3.7 |  |  | $ | (2,583.6) |  |  | $ | (213.0) |  |  |  |  | $ | (4,343.1) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (25.0) |  |  | (21.3) |  |  | (6.6) |  |  | 109.4 |  |  |  |  | 56.5 | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | (0.5) |  |  | 58.6 |  |  | 3.2 |  |  |  |  | 61.3 | \nNet other comprehensive income (loss) | (25.0) |  |  | (21.8) |  |  | 52.0 |  |  | 112.6 |  |  |  |  | 117.8 | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at March 31, 2022 | $ | (1,575.2) |  |  | $ | (18.1) |  |  | $ | (2,531.6) |  |  | $ | (100.4) |  |  |  |  | $ | (4,225.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at January 1, 2021 | $ | (1,427.5) |  |  | $ | 14.8 |  |  | $ | (4,751.0) |  |  | $ | (332.7) |  |  |  |  | $ | (6,496.4) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (249.7) |  |  | (10.8) |  |  | 18.8 |  |  | 252.8 |  |  |  |  | 11.1 | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | 0.5 |  |  | 85.9 |  |  | 3.3 |  |  |  |  | 89.7 | \nNet other comprehensive income (loss) | (249.7) |  |  | (10.3) |  |  | 104.7 |  |  | 256.1 |  |  |  |  | 100.8 | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at March 31, 2021 | $ | (1,677.2) |  |  | $ | 4.5 |  |  | $ | (4,646.3) |  |  | $ | (76.6) |  |  |  |  | $ | (6,395.6) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \nTax benefit (expense) | 2022 |  | 2021 |  |  |  | \nForeign currency translation gains/losses | $ | (13.7) |  |  | $ | (75.3) |  |  |  |  | \nUnrealized net gains/losses on securities | 6.7 |  |  | 4.4 |  |  |  |  | \nDefined benefit pension and retiree health benefit plans | (28.4) |  |  | (31.3) |  |  |  |  | \nEffective portion of cash flow hedges | (29.9) |  |  | (68.1) |  |  |  |  | \nBenefit (expense) for income taxes allocated to other comprehensive income (loss) items | $ | (65.3) |  |  | $ | (170.3) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDetails about Accumulated Other Comprehensive Loss Components |  | Three Months Ended March 31, |  |  | Affected Line Item in the Consolidated Condensed Statements of Operations\n\n | 2022 |  | 2021 |  |  |  | \nAmortization of retirement benefit items: |  |  |  |  |  |  |  |  | \nPrior service benefits, net |  | $ | (13.0) |  |  | $ | (13.8) |  |  |  |  |  | Other\u2013net, (income) expense\nActuarial losses, net |  | 87.2 |  |  | 122.6 |  |  |  |  |  | Other\u2013net, (income) expense\nTotal before tax |  | 74.2 |  |  | 108.8 |  |  |  |  |  | \nTax benefit |  | (15.6) |  |  | (22.9) |  |  |  |  |  | Income taxes\nNet of tax |  | 58.6 |  |  | 85.9 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \nOther, net of tax |  | 2.7 |  |  | 3.8 |  |  |  |  |  | Other\u2013net, (income) expense\n |  |  |  |  |  |  |  |  | \nTotal reclassifications, net of tax |  | $ | 61.3 |  |  | $ | 89.7 |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 |  | 2021 |  |  |  | \nInterest expense | $ | 84.9 |  |  | $ | 87.8 |  |  |  |  | \nInterest income | (7.0) |  |  | (5.5) |  |  |  |  | \nNet investment (gains) losses on equity securities (Note 6) | 425.4 |  |  | (301.5) |  |  |  |  | \nRetirement benefit plans | (93.3) |  |  | (73.4) |  |  |  |  | \n |  |  |  |  |  |  | \nOther (income) expense | (59.3) |  |  | (28.5) |  |  |  |  | \nOther\u2013net, (income) expense | $ | 350.7 |  |  | $ | (321.1) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2022 |  | 2021 |  | Percent Change |  |  |  |  |  | \nRevenue | $ | 7,810.0 |  |  | $ | 6,805.6 |  |  | 15 |  |  |  |  |  | \nGross margin | 5,737.9 |  |  | 4,927.0 |  |  | 16 |  |  |  |  |  | \nGross margin as a percent of revenue | 73.5 | % |  | 72.4 | % |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nResearch and development | $ | 1,610.1 |  |  | $ | 1,672.1 |  |  | (4) |  |  |  |  |  | \nMarketing, selling, and administrative | 1,557.9 |  |  | 1,576.0 |  |  | (1) |  |  |  |  |  | \nAcquired in-process research and development (IPR&D) and development milestones | 165.6 |  |  | 312.0 |  |  | (47) |  |  |  |  |  | \nAsset impairment, restructuring, and other special charges | \u2014 |  |  | 211.6 |  |  | NM |  |  |  |  |  | \nOther\u2013net, (income) expense | 350.7 |  |  | (321.1) |  |  | NM |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNet income | 1,902.9 |  |  | 1,355.3 |  |  | 40 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nEPS - diluted | 2.10 |  |  | 1.49 |  |  | 41 |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nDiabetes | \nTirzepatide | Type 2 diabetes | Submitted | Submitted in the U.S. using a Priority Review Voucher and in Europe and Japan in 2021. | \nHeart failure with preserved ejection fraction | Phase III | Phase III trials are ongoing. | \nObesity | Phase III | Announced in April 2022 that the initial Phase III trial met co-primary and all key secondary endpoints. Phase III trials are ongoing. | \nNonalcoholic steatohepatitis | Phase II | Phase II trial is ongoing. | \nBasal Insulin-Fc | Type 1 and 2 diabetes | Phase III | Phase III trial initiated in the first quarter of 2022. | \nGGG Tri-Agonist | Obesity | Phase II | Phase II trials are ongoing. | \nType 2 diabetes | \nGLP-1R NPA | Obesity | Phase II | Phase II trials are ongoing. | \nType 2 diabetes | \nImmunology | \nMirikizumab | Ulcerative colitis | Submitted | Submitted in the U.S. in first quarter of 2022. | \nCrohn's Disease | Phase III | Phase III trials are ongoing. | \nLebrikizumab(1) | Atopic dermatitis | Phase III | Granted FDA Fast Track designation(2). Announced in 2021 that Phase III trials met primary and all key secondary endpoints. Phase III trials are ongoing. | \nCXCR1/2 Ligands Monoclonal Antibody | Hidradenitis suppurativa | Phase II | Phase II trial is ongoing. | \nIL-2 Conjugate | Systemic lupus erythematosus | Phase II | Phase II trial is ongoing. | \nUlcerative colitis | Discontinued | Announced in April 2022 that we have discontinued the Phase II trial due to lack of efficacy based on interim analysis. | \nPeresolimab (PD-1 MAB Agonist) | Rheumatoid arthritis | Phase II | Phase II trial is ongoing. |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nNeuroscience | \nDonanemab | Early Alzheimer's disease | Submission initiated | Granted FDA Breakthrough Therapy designation(3). Initiated a rolling submission in the U.S. for accelerated approval in 2021. Phase III trials are ongoing. | \nPreclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nSolanezumab | Preclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nGBA1 Gene Therapy (PR001) | Parkinson's disease | Phase II | Granted FDA Fast Track designation(2). Phase II trials are ongoing. | \nGRN Gene Therapy (PR006) | Frontotemporal dementia | Phase II | \nO-glc-NAcase | Alzheimer's disease | Phase II | Phase II trial is ongoing. | \nPACAP38 Antibody | Chronic pain | Phase II | Phase II trial is ongoing. | \nSSTR4 Agonist | Chronic pain | Phase II | Phase II trials are ongoing. | \nTRPA1 Antagonist | Pain | Phase II | Phase II trials are ongoing. | \nEpiregulin/TGF\u03b1 MAB | Chronic pain | Discontinued | Announced in April 2022 that we have discontinued the Phase II trial because it did not meet criteria for proceeding. | \nOncology | \nSelpercatinib (Retevmo\u00ae) | Lung cancer | Approved(4) | Phase III trials are ongoing. | \nThyroid cancer | \nPirtobrutinib (LOXO-305) | Mantle cell lymphoma | Submission initiated | Initiated a rolling submission in the U.S. for accelerated approval in 2021. Phase II and Phase III trials are ongoing. | \nChronic lymphocytic leukemia | Phase III | Phase III trials are ongoing. | \nB-cell malignancies | Phase II | Phase II trial is ongoing. | \nImlunestrant | ER+HER2- metastatic breast cancer | Phase III | Phase III trial is ongoing. | \nSintilimab injection(5) | Lung cancer | Not approved | In the first quarter of 2022 the FDA issued a complete response letter indicating that the FDA did not approve the application in its current form and recommended an additional multiregional clinical study be performed. In collaboration with Innovent, we are assessing next steps in the U.S. |   |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments\nDiabetes\nEmpagliflozin (Jardiance\u00ae)(1) | Heart failure with preserved ejection fraction | Approved | Approved in the U.S. and Europe in the first quarter of 2022 and in Japan in April 2022.\nChronic kidney disease | Phase III | Granted FDA Fast Track designation(2). In the first quarter of 2022 the Independent Data Monitoring Committee recommended stopping the Phase III trial early due to clear positive efficacy.\nImmunology\nBaricitinib (Olumiant\u00ae) | COVID-19 | Emergency Use Authorization(3) | Submitted in the U.S. and the FDA granted priority review in the first quarter of 2022.\nAlopecia areata | Submitted | Granted FDA Breakthrough Therapy designation(4). Submitted in U.S., Europe, and Japan in 2021. In the first quarter of 2022 the FDA granted priority review in severe alopecia areata.\nOncology\nAbemaciclib (Verzenio\u00ae) | Prostate cancer | Phase III | Phase III trials are ongoing.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  | \n | 2022 |  | 2021 |  | Percent Change |  |  |  |  | \nU.S. | $ | 5,174.6 |  |  | $ | 3,941.3 |  |  | 31 |  |  |  |  | \nOutside U.S. | 2,635.4 |  |  | 2,864.3 |  |  | (8) |  |  |  |  | \nRevenue | $ | 7,810.0 |  |  | $ | 6,805.6 |  |  | 15 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2022 vs. 2021 |  | \n | U.S. | Outside U.S. | Consolidated |  |  |  | \nVolume | 32 | % | 4 | % | 20 | % |  |  |  | \nPrice | (1) |  | (7) |  | (3) |  |  |  |  | \nForeign exchange rates | \u2014 |  | (5) |  | (2) |  |  |  |  | \nPercent change | 31 | % | (8) | % | 15 | % |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  | \n | 2022 |  | 2021 | \nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | Percent Change | \nTrulicity | $ | 1,313.9 |  |  | $ | 427.4 |  |  | $ | 1,741.3 |  |  | $ | 1,452.4 |  |  | 20 | \nCOVID-19 antibodies(1) | 1,455.2 |  |  | 14.7 |  |  | 1,469.8 |  |  | 810.1 |  |  | 81 | \nHumalog(2) | 368.9 |  |  | 249.3 |  |  | 618.2 |  |  | 617.0 |  |  | \u2014 | \nTaltz | 307.2 |  |  | 180.8 |  |  | 488.1 |  |  | 403.2 |  |  | 21 | \nVerzenio | 301.5 |  |  | 167.9 |  |  | 469.4 |  |  | 269.0 |  |  | 74 | \nJardiance(3) | 229.8 |  |  | 189.7 |  |  | 419.4 |  |  | 312.0 |  |  | 34 | \nAlimta | 254.3 |  |  | 89.7 |  |  | 343.9 |  |  | 559.0 |  |  | (38) | \nHumulin\u00ae | 190.4 |  |  | 82.8 |  |  | 273.2 |  |  | 321.7 |  |  | (15) | \nOlumiant(4) | 71.3 |  |  | 184.3 |  |  | 255.6 |  |  | 193.8 |  |  | 32 | \nCyramza\u00ae | 79.2 |  |  | 151.1 |  |  | 230.3 |  |  | 240.5 |  |  | (4) | \nCialis | 6.9 |  |  | 210.8 |  |  | 217.7 |  |  | 126.8 |  |  | 72 | \nBasaglar\u00ae | 119.3 |  |  | 72.2 |  |  | 191.5 |  |  | 246.6 |  |  | (22) | \nEmgality\u00ae | 108.3 |  |  | 41.0 |  |  | 149.3 |  |  | 119.5 |  |  | 25 | \nForteo | 70.2 |  |  | 67.3 |  |  | 137.4 |  |  | 198.5 |  |  | (31) | \nErbitux\u00ae | 109.7 |  |  | 13.0 |  |  | 122.7 |  |  | 122.4 |  |  | \u2014 | \nZyprexa\u00ae | 9.6 |  |  | 83.5 |  |  | 93.1 |  |  | 95.8 |  |  | (3) | \nTyvyt | \u2014 |  |  | 85.5 |  |  | 85.5 |  |  | 109.7 |  |  | (22) | \nCymbalta | 9.1 |  |  | 71.9 |  |  | 81.1 |  |  | 176.6 |  |  | (54) | \nOther products | 169.8 |  |  | 252.5 |  |  | 422.5 |  |  | 431.0 |  |  | (2) | \nRevenue | $ | 5,174.6 |  |  | $ | 2,635.4 |  |  | $ | 7,810.0 |  |  | $ | 6,805.6 |  |  | 15 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | Total Number ofShares Purchased(in thousands) |  | Average\u00a0Price Paidper Share |  | Total\u00a0Number of SharesPurchased\u00a0as Part ofPublicly AnnouncedPlans or Programs(in thousands) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(in millions)\nJanuary 2022 | \u2014 |  |  | $ | \u2014 |  |  | \u2014 |  |  | $ | 4,750.0 | \nFebruary 2022 | 3,394 |  |  | 261.69 |  |  | 3,394 |  |  | 3,861.9 | \nMarch 2022 | 2,213 |  |  | 276.52 |  |  | 2,213 |  |  | 3,250.0 | \nTotal | 5,607 |  |  | 267.54 |  |  | 5,607 |  |  |   |  |  |  |  |  |  |  | \nExhibit |  | Description\nEXHIBIT 3.1 |  | Amended Articles of Incorporation are incorporated by reference to Exhibit 3.1 to the Company's Annual Report on Form 10-K for the year ended December 31, 2013\n |  | \nEXHIBIT 3.2 |  | Bylaws, as amended, are incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on December 16, 2021\n |  | \nEXHIBIT\u00a031.1 |  | Rule\u00a013a-14(a) Certification of David A. Ricks, Chair, President, and Chief Executive Officer\n |  | \nEXHIBIT 31.2 |  | Rule\u00a013a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer\n | \nEXHIBIT 32. |  | Section 1350 Certification\n |  | \nEXHIBIT 101. |  | Interactive Data Files (embedded within the Inline XBRL document)\n |  | \nEXHIBIT 104. |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)  |  |  |  |  |  |  |  | \n |  | ELI LILLY AND COMPANY\n |  | (Registrant)\n |  | \nDate: | April 29, 2022 | /s/ Anat Ashkenazi\n |  | Anat Ashkenazi\n |  | Senior Vice President and Chief Financial Officer\nDate: | April 29, 2022 | /s/ Donald A. Zakrowski\n |  | Donald A. Zakrowski\n |  | Vice President, Finance, and Chief Accounting Officer"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Eli Lilly, in 2022 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \nIndiana |  | 35-0470950\n(State or other jurisdiction of |  | (I.R.S. Employer\nincorporation or organization) |  | Identification No.)  |  |  |  |  |  |  |  | \nTitle of Each Class | Trading Symbols | Name of Each Exchange On Which Registered\nCommon Stock (no par value) | LLY | New York Stock Exchange\n7 1/8% Notes due 2025 | LLY25 | New York Stock Exchange\n1.625% Notes due 2026 | LLY26 | New York Stock Exchange\n2.125% Notes due 2030 | LLY30 | New York Stock Exchange\n0.625% Notes due 2031 | LLY31 | New York Stock Exchange\n0.500% Notes due 2033 | LLY33 | New York Stock Exchange\n6.77%\u00a0Notes due 2036 | LLY36 | New York Stock Exchange\n1.625% Notes due 2043 | LLY43 | New York Stock Exchange\n1.700% Notes due 2049 | LLY49A | New York Stock Exchange\n1.125% Notes due 2051 | LLY51 | New York Stock Exchange\n1.375% Notes due 2061 | LLY61 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  |  |  |  | Accelerated\u00a0filer | \u2610\nNon-accelerated filer | \u2610 |  |  | Smaller reporting company | \u2610\n |  |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  | \nClass |  | Number of Shares Outstanding\nCommon |  | 950,174,817 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\nPART I. Financial Information |  |  |  | 5\n |  |  |  | \nItem 1. |  | Financial Statements |  | 5\n |  | Consolidated Condensed Statements of Operations |  | 5\n |  | Consolidated Condensed Statements of Comprehensive Income |  | 6\n |  | Consolidated Condensed Balance Sheets |  | 7\n |  | Consolidated Condensed Statements of Equity |  | 8\n |  | Consolidated Condensed Statements of Cash Flows |  | 10\n |  | Notes to Consolidated Condensed Financial Statements |  | 11\nItem 2. |  | Management's Discussion and Analysis of Results of Operations and Financial Condition |  | 36\n |  | Executive Overview |  | 36\n |  | Revenue |  | 44\n |  | Gross Margin, Costs, and Expenses |  | 48\n |  | Financial Condition and Liquidity |  | 49\n |  |  |  | \n |  | Critical Accounting Estimates |  | 49\n |  | Available Information on our Website |  | 49\nItem 4. |  | Controls and Procedures |  | 50\n |  |  |  | \nPART II. Other Information |  |  |  | 51\n |  |  |  | \nItem 1. |  | Legal Proceedings |  | 51\nItem 1A. |  | Risk Factors |  | 51\nItem 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 51\nItem 6. |  | Exhibits |  | 52\n |  |  |  | \nSignatures |  |  |  | 52  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue (Note 2) | $ | 6,488.0 |  |  | $ | 6,740.1 |  |  | $ | 14,298.0 |  |  | $ | 13,545.7 | \nCosts, expenses, and other: |  |  |  |  |  |  | \nCost of sales | 1,430.5 |  |  | 1,953.2 |  |  | 3,502.6 |  |  | 3,831.8 | \nResearch and development | 1,781.9 |  |  | 1,655.0 |  |  | 3,392.0 |  |  | 3,327.1 | \nMarketing, selling, and administrative | 1,625.1 |  |  | 1,685.7 |  |  | 3,183.0 |  |  | 3,261.7 | \nAcquired in-process research and development and development milestones (Note 3) | 440.4 |  |  | 42.8 |  |  | 606.0 |  |  | 354.8 | \nAsset impairment, restructuring, and other special charges (Note 5) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 211.6 | \nOther\u2013net, (income) expense (Note 11) | 119.2 |  |  | (190.5) |  |  | 469.9 |  |  | (511.6) | \n | 5,397.1 |  |  | 5,146.2 |  |  | 11,153.5 |  |  | 10,475.4 | \nIncome before income taxes | 1,090.9 |  |  | 1,593.9 |  |  | 3,144.5 |  |  | 3,070.3 | \nIncome taxes (Note 7) | 138.4 |  |  | 203.7 |  |  | 289.1 |  |  | 324.8 | \nNet income | $ | 952.5 |  |  | $ | 1,390.2 |  |  | $ | 2,855.4 |  |  | $ | 2,745.5 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nEarnings per share: |  |  |  |  |  |  | \nBasic | $ | 1.06 |  |  | $ | 1.53 |  |  | $ | 3.17 |  |  | $ | 3.02 | \n |  |  |  |  |  |  | \nDiluted | $ | 1.05 |  |  | $ | 1.53 |  |  | $ | 3.16 |  |  | $ | 3.01 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nShares used in calculation of earnings per share: |  |  |  |  |  |  | \nBasic | 900.3 |  | 907.3 |  | 902.0 |  | 908.2\nDiluted | 902.9 |  | 910.4 |  | 904.4 |  | 911.6  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet income | $ | 952.5 |  |  | $ | 1,390.2 |  |  | $ | 2,855.4 |  |  | $ | 2,745.5 | \nOther comprehensive income (loss), net of tax (Note 10) | (62.4) |  |  | 108.5 |  |  | 55.4 |  |  | 209.3 | \nComprehensive income | $ | 890.1 |  |  | $ | 1,498.7 |  |  | $ | 2,910.8 |  |  | $ | 2,954.8 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nAssets | (Unaudited) |  | \nCurrent Assets |  |  | \nCash and cash equivalents (Note 6) | $ | 2,622.9 |  |  | $ | 3,818.5 | \nShort-term investments (Note 6) | 113.8 |  |  | 90.1 | \nAccounts receivable, net of allowances of$19.2(2022)and $22.5(2021) | 6,364.5 |  |  | 6,672.8 | \nOther receivables | 1,307.9 |  |  | 1,454.4 | \nInventories | 3,899.4 |  |  | 3,886.0 | \nPrepaid expenses and other | 2,806.7 |  |  | 2,530.6 | \nTotal current assets | 17,115.2 |  |  | 18,452.4 | \nInvestments (Note 6) | 2,587.2 |  |  | 3,212.6 | \nGoodwill | 3,891.8 |  |  | 3,892.0 | \nOther intangibles, net | 7,497.7 |  |  | 7,691.9 | \nDeferred tax assets | 2,371.9 |  |  | 2,489.3 | \nProperty and equipment, net of accumulated depreciation of$10,119.7(2022)and $9,976.7(2021) | 9,128.2 |  |  | 8,985.1 | \nOther noncurrent assets | 4,471.6 |  |  | 4,082.7 | \nTotal assets | $ | 47,063.6 |  |  | $ | 48,806.0 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nShort-term borrowings and current maturities of long-term debt | $ | 2,121.8 |  |  | $ | 1,538.3 | \nAccounts payable | 1,659.3 |  |  | 1,670.6 | \nEmployee compensation | 835.8 |  |  | 958.1 | \nSales rebates and discounts | 7,991.4 |  |  | 6,845.8 | \nDividends payable | 882.2 |  |  | 885.5 | \nIncome taxes payable | 126.6 |  |  | 126.9 | \nOther current liabilities | 2,003.5 |  |  | 3,027.5 | \nTotal current liabilities | 15,620.6 |  |  | 15,052.7 | \nOther Liabilities |  |  | \nLong-term debt | 14,692.0 |  |  | 15,346.4 | \nAccrued retirement benefits (Note 8) | 1,888.6 |  |  | 1,954.1 | \nLong-term income taxes payable | 3,557.6 |  |  | 3,920.0 | \nDeferred tax liabilities | 862.5 |  |  | 1,733.7 | \nOther noncurrent liabilities | 1,783.1 |  |  | 1,644.3 | \nTotal other liabilities | 22,783.8 |  |  | 24,598.5 | \nCommitments and Contingencies (Note 9) |  |  | \nEli Lilly and Company Shareholders' Equity |  |  | \nCommon stock | 594.1 |  |  | 596.3 | \nAdditional paid-in capital | 6,746.0 |  |  | 6,833.4 | \nRetained earnings | 8,556.0 |  |  | 8,958.5 | \nEmployee benefit trust | (3,013.2) |  |  | (3,013.2) | \nAccumulated other comprehensive loss (Note 10) | (4,287.7) |  |  | (4,343.1) | \nCost of common stock in treasury | (50.5) |  |  | (52.7) | \nTotal Eli Lilly and Company shareholders' equity | 8,544.7 |  |  | 8,979.2 | \nNoncontrolling interests | 114.5 |  |  | 175.6 | \nTotal equity | 8,659.2 |  |  | 9,154.8 | \nTotal liabilities and equity | $ | 47,063.6 |  |  | $ | 48,806.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions, except per-share data, and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at April 1, 2021 | 959,482 |  |  | $ | 599.7 |  |  | $ | 6,579.2 |  |  | $ | 9,181.3 |  |  | $ | (3,013.2) |  |  | $ | (6,395.6) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 200.6 | \nNet income |  |  |  |  |  |  | 1,390.2 |  |  |  |  |  |  |  |  |  |  | 31.4 | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 108.5 |  |  |  |  |  |  | \nCash dividends declared per share: $1.70 |  |  |  |  |  |  | (1,542.9) |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (2,467) |  |  | (1.6) |  |  |  |  | (498.5) |  |  |  |  |  |  | (2,467) |  |  | 500.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 2,467 |  |  | (500.0) |  |  | \nIssuance of stock under employee stock plans, net | 23 |  |  |  |  | (1.9) |  |  |  |  |  |  |  |  |  |  |  |  | \nStock-based compensation |  |  |  |  | 91.9 |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (12.9) | \nBalance at June 30, 2021 | 957,038 |  |  | $ | 598.1 |  |  | $ | 6,669.2 |  |  | $ | 8,530.1 |  |  | $ | (3,013.2) |  |  | $ | (6,287.1) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 219.1 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at April 1, 2022 | 950,605 |  |  | $ | 594.1 |  |  | $ | 6,656.3 |  |  | $ | 9,369.4 |  |  | $ | (3,013.2) |  |  | $ | (4,225.3) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 131.2 | \nNet income (loss) |  |  |  |  |  |  | 952.5 |  |  |  |  |  |  |  |  |  |  | (11.4) | \nOther comprehensive loss, net of tax |  |  |  |  |  |  |  |  |  |  | (62.4) |  |  |  |  |  |  | \nCash dividends declared per share: $1.96 |  |  |  |  |  |  | (1,765.9) |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIssuance of stock under employee stock plans, net | 14 |  |  |  |  | (2.4) |  |  |  |  |  |  |  |  |  |  |  |  | \nStock-based compensation |  |  |  |  | 92.1 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (5.3) | \nBalance at June 30, 2022 | 950,619 |  |  | $ | 594.1 |  |  | $ | 6,746.0 |  |  | $ | 8,556.0 |  |  | $ | (3,013.2) |  |  | $ | (4,287.7) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 114.5 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions, except per-share data, and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at January 1, 2021 | 957,077 |  |  | $ | 598.2 |  |  | $ | 6,778.5 |  |  | $ | 7,830.2 |  |  | $ | (3,013.2) |  |  | $ | (6,496.4) |  |  | 487 |  |  | $ | (55.7) |  |  | $ | 183.6 | \nNet income |  |  |  |  |  |  | 2,745.5 |  |  |  |  |  |  |  |  |  |  | 47.8 | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 209.3 |  |  |  |  |  |  | \nCash dividends declared per share: $1.70 |  |  |  |  |  |  | (1,542.9) |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (2,467) |  |  | (1.6) |  |  |  |  | (498.5) |  |  |  |  |  |  | (2,467) |  |  | 500.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 2,467 |  |  | (500.0) |  |  | \nIssuance of stock under employee stock plans, net | 2,428 |  |  | 1.5 |  |  | (285.8) |  |  |  |  |  |  |  |  | (24) |  |  | 3.0 |  |  | \nStock-based compensation |  |  |  |  | 177.4 |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  | (0.9) |  |  | (4.2) |  |  |  |  |  |  |  |  |  |  | (12.3) | \nBalance at June 30, 2021 | 957,038 |  |  | $ | 598.1 |  |  | $ | 6,669.2 |  |  | $ | 8,530.1 |  |  | $ | (3,013.2) |  |  | $ | (6,287.1) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 219.1 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January 1, 2022 | 954,116 |  |  | $ | 596.3 |  |  | $ | 6,833.4 |  |  | $ | 8,958.5 |  |  | $ | (3,013.2) |  |  | $ | (4,343.1) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 175.6 | \nNet income (loss) |  |  |  |  |  |  | 2,855.4 |  |  |  |  |  |  |  |  |  |  | (48.0) | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 55.4 |  |  |  |  |  |  | \nCash dividends declared per share: $1.96 |  |  |  |  |  |  | (1,765.9) |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (5,607) |  |  | (3.5) |  |  |  |  | (1,496.5) |  |  |  |  |  |  | (5,607) |  |  | 1,500.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 5,607 |  |  | (1,500.0) |  |  | \nIssuance of stock under employee stock plans, net | 2,110 |  |  | 1.3 |  |  | (280.5) |  |  |  |  |  |  |  |  | (13) |  |  | 2.2 |  |  | \nStock-based compensation |  |  |  |  | 193.1 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | 4.5 |  |  |  |  |  |  |  |  |  |  | (13.1) | \nBalance at June 30, 2022 | 950,619 |  |  | $ | 594.1 |  |  | $ | 6,746.0 |  |  | $ | 8,556.0 |  |  | $ | (3,013.2) |  |  | $ | (4,287.7) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 114.5 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2022 |  | 2021\nCash Flows from Operating Activities | \nNet income | $ | 2,855.4 |  |  | $ | 2,745.5 | \nAdjustments to Reconcile Net Income to Cash Flows from Operating Activities: |  |  | \n |  |  | \nDepreciation and amortization | 784.6 |  |  | 719.6 | \nChange in deferred income taxes | (1,125.0) |  |  | (413.8) | \n |  |  | \nStock-based compensation expense | 193.1 |  |  | 177.4 | \n |  |  | \nNet investment (gains) losses | 545.6 |  |  | (518.1) | \nAcquired in-process research and development | 233.0 |  |  | 324.3 | \nOther changes in operating assets and liabilities, net of acquisitions and divestitures | (117.6) |  |  | 118.4 | \nOther non-cash operating activities, net | (49.2) |  |  | 319.6 | \nNet Cash Provided by Operating Activities | 3,319.9 |  |  | 3,472.9 | \nCash Flows from Investing Activities |  |  | \nNet purchases of property and equipment | (736.4) |  |  | (681.6) | \nProceeds from sales and maturities of short-term investments | 57.6 |  |  | 21.3 | \nPurchases of short-term investments | (32.9) |  |  | (26.6) | \nProceeds from sales of noncurrent investments | 168.5 |  |  | 461.9 | \nPurchases of noncurrent investments | (251.4) |  |  | (503.1) | \nCash paid for acquisitions, net of cash acquired (Note 3) | \u2014 |  |  | (747.4) | \n |  |  | \nPurchases of in-process research and development | (571.8) |  |  | (341.8) | \nOther investing activities, net | (111.3) |  |  | 50.5 | \nNet Cash Used for Investing Activities | (1,477.7) |  |  | (1,766.8) | \nCash Flows from Financing Activities |  |  | \nDividends paid | (1,769.2) |  |  | (1,543.1) | \nNet change in short-term borrowings | 2,117.2 |  |  | 196.3 | \n |  |  | \nRepayments of long-term debt | (1,560.0) |  |  | \u2014 | \nPurchases of common stock | (1,500.0) |  |  | (500.0) | \n |  |  | \nOther financing activities, net | (290.0) |  |  | (294.8) | \nNet Cash Used for Financing Activities | (3,002.0) |  |  | (2,141.6) | \nEffect of exchange rate changes on cash and cash equivalents | (35.8) |  |  | (1.6) | \n |  |  | \nNet decrease in cash and cash equivalents | (1,195.6) |  |  | (437.1) | \nCash and cash equivalents at January\u00a01 | 3,818.5 |  |  | 3,657.1 | \nCash and Cash Equivalents at June 30 | $ | 2,622.9 |  |  | $ | 3,220.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet product revenue | $ | 5,870.9 |  |  | $ | 6,070.5 |  |  | $ | 13,003.8 |  |  | $ | 12,390.5 | \nCollaboration and other revenue(1) | 617.1 |  |  | 669.6 |  |  | 1,294.2 |  |  | 1,155.2 | \nRevenue | $ | 6,488.0 |  |  | $ | 6,740.1 |  |  | $ | 14,298.0 |  |  | $ | 13,545.7 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nContract liabilities | $ | 242.1 |  |  | $ | 262.6 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n | 2022 |  | 2021\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\nRevenue\u2014to unaffiliated customers: |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity\u00ae | $ | 1,430.1 |  | $ | 481.7 |  | $ | 1,911.9 |  |  | $ | 1,147.6 |  | $ | 388.0 |  | $ | 1,535.6 | \nJardiance(1) | 250.7 |  | 210.3 |  | 461.0 |  |  | 194.4 |  | 162.1 |  | 356.5 | \nHumalog\u00ae (2) | 238.8 |  | 208.3 |  | 447.1 |  |  | 329.1 |  | 278.6 |  | 607.6 | \nHumulin\u00ae | 202.3 |  | 71.7 |  | 274.0 |  |  | 221.1 |  | 94.3 |  | 315.3 | \nBasaglar\u00ae | 95.8 |  | 78.4 |  | 174.2 |  |  | 133.4 |  | 77.3 |  | 210.7 | \nOther diabetes | 74.5 |  | 95.6 |  | 170.0 |  |  | 54.2 |  | 95.4 |  | 149.8 | \nTotal diabetes | 2,292.2 |  | 1,146.0 |  | 3,438.2 |  |  | 2,079.8 |  | 1,095.7 |  | 3,175.5 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio\u00ae | 384.3 |  | 204.2 |  | 588.5 |  |  | 209.7 |  | 131.6 |  | 341.3 | \nCyramza\u00ae | 92.6 |  | 138.6 |  | 231.3 |  |  | 101.4 |  | 167.3 |  | 268.7 | \nAlimta\u00ae | 171.7 |  | 56.1 |  | 227.7 |  |  | 353.5 |  | 257.1 |  | 610.6 | \nErbitux\u00ae | 125.1 |  | 15.7 |  | 140.8 |  |  | 135.8 |  | 11.2 |  | 147.0 | \nTyvyt\u00ae | \u2014 |  | 73.6 |  | 73.6 |  |  | \u2014 |  | 105.0 |  | 105.0 | \nOther oncology | 45.3 |  | 61.6 |  | 106.8 |  |  | 27.9 |  | 53.5 |  | 81.4 | \nTotal oncology | 819.0 |  | 549.8 |  | 1,368.7 |  |  | 828.3 |  | 725.7 |  | 1,554.0 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz\u00ae | 411.6 |  | 194.7 |  | 606.2 |  |  | 399.8 |  | 169.3 |  | 569.1 | \nOlumiant\u00ae (3) | 10.4 |  | 175.8 |  | 186.2 |  |  | 17.8 |  | 190.6 |  | 208.4 | \nOther immunology | \u2014 |  | 4.0 |  | 4.0 |  |  | 4.8 |  | 3.2 |  | 7.9 | \nTotal immunology | 422.0 |  | 374.5 |  | 796.5 |  |  | 422.4 |  | 363.1 |  | 785.4 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nEmgality\u00ae | 108.6 |  | 48.9 |  | 157.5 |  |  | 112.1 |  | 44.2 |  | 156.3 | \nZyprexa\u00ae | 8.7 |  | 78.6 |  | 87.3 |  |  | 8.4 |  | 86.9 |  | 95.4 | \nCymbalta\u00ae | 8.1 |  | 67.4 |  | 75.5 |  |  | 12.4 |  | 163.3 |  | 175.6 | \n |  |  |  |  |  |  | \nOther neuroscience | 19.4 |  | 50.3 |  | 69.6 |  |  | 33.8 |  | 51.1 |  | 84.9 | \nTotal neuroscience | 144.8 |  | 245.2 |  | 389.9 |  |  | 166.7 |  | 345.5 |  | 512.2 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nCialis\u00ae | 10.8 |  | 136.2 |  | 147.0 |  |  | (5.2) |  | 286.3 |  | 281.0 | \nForteo\u00ae | 78.5 |  | 60.0 |  | 138.5 |  |  | 122.8 |  | 95.6 |  | 218.4 | \nCOVID-19 antibodies(4) | 129.1 |  | \u2014 |  | 129.1 |  |  | 83.4 |  | 65.7 |  | 148.9 | \nOther | 38.5 |  | 41.7 |  | 80.1 |  |  | 6.0 |  | 58.4 |  | 64.6 | \nTotal other | 256.9 |  | 237.9 |  | 494.7 |  |  | 207.0 |  | 506.0 |  | 712.9 | \nRevenue | $ | 3,934.8 |  | $ | 2,553.3 |  | $ | 6,488.0 |  |  | $ | 3,704.2 |  | $ | 3,035.9 |  | $ | 6,740.1 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2022 |  | 2021\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\nRevenue\u2014to unaffiliated customers: |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity | $ | 2,744.1 |  | $ | 909.1 |  | $ | 3,653.2 |  |  | $ | 2,264.3 |  | $ | 723.7 |  | $ | 2,988.1 | \nHumalog(1) | 607.7 |  | 457.6 |  | 1,065.3 |  |  | 661.7 |  | 562.9 |  | 1,224.6 | \nJardiance(2) | 480.4 |  | 400.0 |  | 880.4 |  |  | 345.6 |  | 322.9 |  | 668.5 | \nHumulin | 392.8 |  | 154.5 |  | 547.2 |  |  | 440.1 |  | 196.9 |  | 637.0 | \nBasaglar | 215.1 |  | 150.6 |  | 365.7 |  |  | 308.6 |  | 148.7 |  | 457.3 | \nOther diabetes | 128.6 |  | 185.8 |  | 314.5 |  |  | 120.7 |  | 190.4 |  | 311.1 | \nTotal diabetes | 4,568.7 |  | 2,257.6 |  | 6,826.3 |  |  | 4,141.0 |  | 2,145.5 |  | 6,286.6 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio | 685.7 |  | 372.1 |  | 1,057.9 |  |  | 382.5 |  | 227.8 |  | 610.3 | \nAlimta | 425.9 |  | 145.8 |  | 571.7 |  |  | 614.6 |  | 554.9 |  | 1,169.6 | \nCyramza | 171.8 |  | 289.7 |  | 461.5 |  |  | 181.5 |  | 327.7 |  | 509.2 | \nErbitux | 234.7 |  | 28.7 |  | 263.4 |  |  | 243.7 |  | 25.7 |  | 269.4 | \nTyvyt | \u2014 |  | 159.0 |  | 159.0 |  |  | \u2014 |  | 214.6 |  | 214.6 | \nOther oncology | 84.6 |  | 123.7 |  | 208.2 |  |  | 48.5 |  | 104.7 |  | 153.2 | \nTotal oncology | 1,602.7 |  | 1,119.0 |  | 2,721.7 |  |  | 1,470.8 |  | 1,455.4 |  | 2,926.3 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz | 718.8 |  | 375.5 |  | 1,094.3 |  |  | 649.4 |  | 322.9 |  | 972.4 | \nOlumiant(3) | 81.7 |  | 360.1 |  | 441.8 |  |  | 42.5 |  | 359.7 |  | 402.2 | \nOther immunology | \u2014 |  | 8.5 |  | 8.5 |  |  | 15.2 |  | 9.6 |  | 24.7 | \nTotal immunology | 800.5 |  | 744.1 |  | 1,544.6 |  |  | 707.1 |  | 692.2 |  | 1,399.3 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nEmgality | 216.9 |  | 89.8 |  | 306.7 |  |  | 213.6 |  | 62.2 |  | 275.7 | \nZyprexa | 18.3 |  | 162.1 |  | 180.4 |  |  | 15.3 |  | 175.8 |  | 191.1 | \nCymbalta | 17.2 |  | 139.4 |  | 156.6 |  |  | 23.3 |  | 328.9 |  | 352.3 | \n |  |  |  |  |  |  | \nOther neuroscience | 45.7 |  | 98.2 |  | 144.0 |  |  | 56.2 |  | 102.3 |  | 158.5 | \nTotal neuroscience | 298.1 |  | 489.5 |  | 787.7 |  |  | 308.4 |  | 669.2 |  | 977.6 | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nCOVID-19 antibodies(4) | 1,584.3 |  | 14.7 |  | 1,598.9 |  |  | 734.0 |  | 225.1 |  | 959.1 | \nCialis | 17.7 |  | 347.0 |  | 364.7 |  |  | 3.4 |  | 404.4 |  | 407.8 | \nForteo | 148.7 |  | 127.2 |  | 275.9 |  |  | 220.5 |  | 196.4 |  | 416.9 | \nOther | 88.5 |  | 89.6 |  | 178.2 |  |  | 60.2 |  | 111.9 |  | 172.1 | \nTotal other | 1,839.2 |  | 578.5 |  | 2,417.7 |  |  | 1,018.1 |  | 937.8 |  | 1,955.9 | \nRevenue | $ | 9,109.4 |  | $ | 5,188.7 |  | $ | 14,298.0 |  |  | $ | 7,645.5 |  | $ | 5,900.2 |  | $ | 13,545.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue\u2014to unaffiliated customers(1): |  |  |  |  |  |  | \nU.S. | $ | 3,934.8 |  |  | $ | 3,704.2 |  |  | $ | 9,109.4 |  |  | $ | 7,645.5 | \nEurope | 1,101.1 |  |  | 1,209.8 |  |  | 2,168.4 |  |  | 2,531.0 | \nJapan | 454.4 |  |  | 665.4 |  |  | 864.6 |  |  | 1,237.2 | \nChina | 352.1 |  |  | 522.5 |  |  | 758.5 |  |  | 884.7 | \nOther foreign countries | 645.7 |  |  | 638.1 |  |  | 1,397.2 |  |  | 1,247.3 | \nRevenue | $ | 6,488.0 |  |  | $ | 6,740.1 |  |  | $ | 14,298.0 |  |  | $ | 13,545.7 |   |  |  |  |  | \nEstimated Fair Value at January 22, 2021 | \nCash | $ | 90.5 | \nAcquired IPR&D(1) | 824.0\nGoodwill(2) | 126.8\nDeferred tax liabilities | (106.0) | \nOther assets and liabilities, net | (31.5) | \nAcquisition date fair value of consideration transferred | 903.8\nLess: | \nCash acquired | (90.5) | \nFair value of CVR liability(3) | (65.9) | \nCash paid, net of cash acquired | $ | 747.4 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCounterparty | Compound(s), Therapy or Asset | Acquisition Month |  | Phase of Development(1) |  | Acquired IPR&D Expense\nBioMarin Pharmaceutical Inc. | Priority Review Voucher | February 2022 |  | Not applicable |  | $ | 110.0 | \n |  |  |  |  |  | \nRigel Pharmaceuticals, Inc. | R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases | March 2021 |  | Phase I |  | 125.0 | \nPrecision Biosciences, Inc. | Potential in vivo therapies for genetic disorders | January 2021 |  | Pre-clinical |  | 107.8 | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  | \n | Net Milestones Capitalized (Deferred)(1)as of:\n | June 30, 2022 | December 31, 2021\nJardiance | $ | 126.1 |  | $ | 136.1 | \nTrajenta | 75.8 |  | 88.5 | \nBasaglar | (140.0) |  | (149.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nJardiance | $ | 461.0 |  |  | $ | 356.5 |  |  | $ | 880.4 |  |  | $ | 668.5 | \nBasaglar | 174.2 |  |  | 210.7 |  |  | 365.7 |  |  | 457.3 | \nTrajenta | 97.1 |  |  | 89.2 |  |  | 189.2 |  |  | 183.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nOlumiant | $ | 186.2 |  |  | $ | 208.4 |  |  | $ | 441.8 |  |  | $ | 402.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nTyvyt | $ | 73.6 |  |  | $ | 105.0 |  |  | $ | 159.0 |  |  | $ | 214.6 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Six Months Ended June 30,\n |  |  |  |  | 2022 |  | 2021\nSeverance |  |  |  |  | $ | \u2014 |  |  | $ | 11.5 | \nAsset impairment and other special charges |  |  |  |  | \u2014 |  |  | 200.1 | \nTotal asset impairment, restructuring, and other special charges |  |  |  |  | $ | \u2014 |  |  | $ | 211.6 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nFair value hedges: |  |  |  |  |  |  | \nEffect from hedged fixed-rate debt | $ | (58.2) |  |  | $ | 31.1 |  |  | $ | (152.8) |  |  | $ | (50.4) | \nEffect from interest rate contracts | 58.2 |  |  | (31.1) |  |  | 152.8 |  |  | 50.4 | \nCash flow hedges: |  |  |  |  |  |  | \nEffective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss | 4.1 |  |  | 4.2 |  |  | 8.2 |  |  | 8.3 | \nCross-currency interest rate swaps | 33.6 |  |  | (23.4) |  |  | 41.9 |  |  | 48.1 | \nNet (gains) losses on foreign currency exchange contracts not designated as hedging instruments | 151.1 |  |  | (73.2) |  |  | 145.0 |  |  | 59.8 | \nTotal | $ | 188.8 |  |  | $ | (92.4) |  |  | $ | 195.1 |  |  | $ | 116.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet investment hedges: |  |  |  |  |  |  | \nForeign currency-denominated notes | $ | 333.3 |  |  | $ | (57.8) |  |  | $ | 387.7 |  |  | $ | 149.9 | \nCross-currency interest rate swaps | 68.5 |  |  | (46.5) |  |  | 79.3 |  |  | 104.1 | \nForeign currency forward contracts | 13.6 |  |  | \u2014 |  |  | 13.6 |  |  | \u2014 | \nCash flow hedges: |  |  |  |  |  |  | \nForward-starting interest rate swaps | 157.7 |  |  | (165.2) |  |  | 280.2 |  |  | 129.9 | \nCross-currency interest rate swaps | 1.4 |  |  | (6.9) |  |  | 18.5 |  |  | 19.4 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Cost(1) |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | Significant OtherObservable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nJune 30, 2022 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents | $ | 1,047.9 |  |  | $ | 1,047.9 |  |  | $ | 1,041.8 |  |  | $ | 6.1 |  |  | $ | \u2014 |  |  | $ | 1,047.9 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 45.6 |  |  | $ | 46.1 |  |  | $ | 45.6 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 45.6 | \nCorporate debt securities | 51.9 |  |  | 52.0 |  |  | \u2014 |  |  | 51.9 |  |  | \u2014 |  |  | 51.9 | \nMortgage-backed securities | 0.2 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 | \nAsset-backed securities | 4.4 |  |  | 4.5 |  |  | \u2014 |  |  | 4.4 |  |  | \u2014 |  |  | 4.4 | \nOther securities | 11.7 |  |  | 11.7 |  |  | \u2014 |  |  | \u2014 |  |  | 11.7 |  |  | 11.7 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 113.8 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 109.5 |  |  | $ | 120.7 |  |  | $ | 109.5 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 109.5 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities | 202.4 |  |  | 226.2 |  |  | \u2014 |  |  | 202.4 |  |  | \u2014 |  |  | 202.4 | \nMortgage-backed securities | 97.7 |  |  | 105.5 |  |  | \u2014 |  |  | 97.7 |  |  | \u2014 |  |  | 97.7 | \nAsset-backed securities | 41.7 |  |  | 43.2 |  |  | \u2014 |  |  | 41.7 |  |  | \u2014 |  |  | 41.7 | \nOther securities | 171.2 |  |  | 81.2 |  |  | \u2014 |  |  | 47.9 |  |  | 123.3 |  |  | 171.2 | \nMarketable equity securities | 614.9 |  |  | 408.0 |  |  | 614.9 |  |  | \u2014 |  |  | \u2014 |  |  | 614.9 | \nEquity investments without readily determinable fair values(2) | 614.6 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(2) | 735.2 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 2,587.2 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents | $ | 2,379.5 |  |  | $ | 2,379.5 |  |  | $ | 2,361.0 |  |  | $ | 18.5 |  |  | $ | \u2014 |  |  | $ | 2,379.5 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 25.7 |  |  | $ | 25.6 |  |  | $ | 25.7 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 25.7 | \nCorporate debt securities | 43.7 |  |  | 43.7 |  |  | \u2014 |  |  | 43.7 |  |  | \u2014 |  |  | 43.7 | \nMortgage-backed securities | 0.2 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 | \nAsset-backed securities | 6.2 |  |  | 6.2 |  |  | \u2014 |  |  | 6.2 |  |  | \u2014 |  |  | 6.2 | \nOther securities | 14.3 |  |  | 14.3 |  |  | \u2014 |  |  | \u2014 |  |  | 14.3 |  |  | 14.3 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 90.1 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 137.0 |  |  | $ | 136.8 |  |  | $ | 137.0 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 137.0 | \nCorporate debt securities | 235.3 |  |  | 232.7 |  |  | \u2014 |  |  | 235.3 |  |  | \u2014 |  |  | 235.3 | \nMortgage-backed securities | 109.8 |  |  | 108.1 |  |  | \u2014 |  |  | 109.8 |  |  | \u2014 |  |  | 109.8 | \nAsset-backed securities | 23.1 |  |  | 23.1 |  |  | \u2014 |  |  | 23.1 |  |  | \u2014 |  |  | 23.1 | \nOther securities | 108.1 |  |  | 22.2 |  |  | \u2014 |  |  | \u2014 |  |  | 108.1 |  |  | 108.1 | \nMarketable equity securities | 1,279.7 |  |  | 487.0 |  |  | 1,279.7 |  |  | \u2014 |  |  | \u2014 |  |  | 1,279.7 | \nEquity investments without readily determinable fair values(2) | 548.1 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(2) | 771.5 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 3,212.6 |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nShort-term commercial paper borrowings |  |  |  |  |  |  |  |  | \nJune 30, 2022 | $ | (2,117.1) |  |  | $ | \u2014 |  |  | $ | (2,115.8) |  |  | $ | \u2014 |  |  | $ | (2,115.8) | \nDecember 31, 2021 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nLong-term debt, including current portion |  |  |  |  |  |  |  |  | \nJune 30, 2022 | $ | (14,696.7) |  |  | $ | \u2014 |  |  | $ | (12,929.6) |  |  | $ | \u2014 |  |  | $ | (12,929.6) | \nDecember 31, 2021 | (16,884.7) |  |  | \u2014 |  |  | (18,157.7) |  |  | \u2014 |  |  | (18,157.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  |  |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue |  | \nJune 30, 2022 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | $ | (77.3) |  |  | $ | \u2014 |  |  | $ | (77.3) |  |  | $ | \u2014 |  |  | $ | (77.3) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 297.7 |  |  | \u2014 |  |  | 297.7 |  |  | \u2014 |  |  | 297.7 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 29.3 |  |  | \u2014 |  |  | 29.3 |  |  | \u2014 |  |  | 29.3 |  |  | \nOther noncurrent assets | 77.2 |  |  | \u2014 |  |  | 77.2 |  |  | \u2014 |  |  | 77.2 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 21.7 |  |  | \u2014 |  |  | 21.7 |  |  | \u2014 |  |  | 21.7 |  |  | \nOther noncurrent liabilities | (13.1) |  |  | \u2014 |  |  | (13.1) |  |  | \u2014 |  |  | (13.1) |  |  | \nForeign exchange contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 15.6 |  |  | \u2014 |  |  | 15.6 |  |  | \u2014 |  |  | 15.6 |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 19.1 |  |  | \u2014 |  |  | 19.1 |  |  | \u2014 |  |  | 19.1 |  |  | \nOther current liabilities | (17.0) |  |  | \u2014 |  |  | (17.0) |  |  | \u2014 |  |  | (17.0) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nContingent consideration liability: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (65.1) |  |  | \u2014 |  |  | \u2014 |  |  | (65.1) |  |  | (65.1) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | $ | 4.8 |  |  | $ | \u2014 |  |  | $ | 4.8 |  |  | $ | \u2014 |  |  | $ | 4.8 |  |  | \nOther noncurrent assets | 78.3 |  |  | \u2014 |  |  | 78.3 |  |  | \u2014 |  |  | 78.3 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (7.6) |  |  | \u2014 |  |  | (7.6) |  |  | \u2014 |  |  | (7.6) |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 49.2 |  |  | \u2014 |  |  | 49.2 |  |  | \u2014 |  |  | 49.2 |  |  | \nOther noncurrent liabilities | (31.7) |  |  | \u2014 |  |  | (31.7) |  |  | \u2014 |  |  | (31.7) |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 31.3 |  |  | \u2014 |  |  | 31.3 |  |  | \u2014 |  |  | 31.3 |  |  | \nOther current liabilities | (1.2) |  |  | \u2014 |  |  | (1.2) |  |  | \u2014 |  |  | (1.2) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 33.2 |  |  | \u2014 |  |  | 33.2 |  |  | \u2014 |  |  | 33.2 |  |  | \nOther noncurrent liabilities | (1.3) |  |  | \u2014 |  |  | (1.3) |  |  | \u2014 |  |  | (1.3) |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 9.9 |  |  | \u2014 |  |  | 9.9 |  |  | \u2014 |  |  | 9.9 |  |  | \nOther current liabilities | (35.3) |  |  | \u2014 |  |  | (35.3) |  |  | \u2014 |  |  | (35.3) |  |  | \nContingent consideration liabilities: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (70.5) |  |  | \u2014 |  |  | \u2014 |  |  | (70.5) |  |  | (70.5) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturities by Period\n | Total |  | Less\u00a0Than1 Year |  | 1-5Years |  | 6-10Years |  | More\u00a0Than10 Years\nFair value of debt securities | $ | 553.4 |  |  | $ | 102.1 |  |  | $ | 170.4 |  |  | $ | 109.0 |  |  | $ | 171.9 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2022 |  | December 31, 2021\nUnrealized gross gains | $ | 0.2 |  |  | $ | 9.7 | \nUnrealized gross losses | 36.9 |  |  | 5.2 | \nFair value of securities in an unrealized gain position | 28.8 |  |  | 250.7 | \nFair value of securities in an unrealized loss position | 489.2 |  |  | 290.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nProceeds from sales | $ | 29.9 |  |  | $ | 44.4 |  |  | $ | 65.1 |  |  | $ | 87.7 | \nRealized gross gains on sales | 0.1 |  |  | 0.7 |  |  | 0.2 |  |  | 1.8 | \nRealized gross losses on sales | 0.7 |  |  | 0.4 |  |  | 1.5 |  |  | 0.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Defined Benefit Pension Plans\n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nComponents of net periodic benefit cost: |  |  |  |  |  |  | \nService cost | $ | 88.2 |  |  | $ | 93.3 |  |  | $ | 177.3 |  |  | $ | 185.3 | \nInterest cost | 99.6 |  |  | 84.8 |  |  | 200.1 |  |  | 169.1 | \nExpected return on plan assets | (237.0) |  |  | (237.2) |  |  | (476.5) |  |  | (475.2) | \nAmortization of prior service cost | 0.6 |  |  | 1.1 |  |  | 1.3 |  |  | 2.2 | \nRecognized actuarial loss | 84.5 |  |  | 122.6 |  |  | 171.5 |  |  | 244.4 | \n |  |  |  |  |  |  | \nNet periodic benefit cost | $ | 35.9 |  |  | $ | 64.6 |  |  | $ | 73.7 |  |  | $ | 125.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Retiree Health Benefit Plans\n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nComponents of net periodic benefit income: |  |  |  |  |  |  | \nService cost | $ | 12.1 |  |  | $ | 12.9 |  |  | $ | 23.3 |  |  | $ | 24.6 | \nInterest cost | 9.6 |  |  | 8.2 |  |  | 19.0 |  |  | 16.3 | \nExpected return on plan assets | (38.2) |  |  | (36.5) |  |  | (76.1) |  |  | (73.1) | \nAmortization of prior service benefit | (13.7) |  |  | (14.9) |  |  | (27.4) |  |  | (29.8) | \nRecognized actuarial loss | 0.3 |  |  | 0.8 |  |  | 0.5 |  |  | 1.6 | \n |  |  |  |  |  |  | \nNet periodic benefit income | $ | (29.9) |  |  | $ | (29.5) |  |  | $ | (60.7) |  |  | $ | (60.4) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at April 1, 2022 | $ | (1,575.2) |  |  | $ | (18.1) |  |  | $ | (2,531.6) |  |  | $ | (100.4) |  |  |  |  | $ | (4,225.3) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (269.6) |  |  | (9.3) |  |  | 31.7 |  |  | 124.8 |  |  |  |  | (122.4) | \nNet amount reclassified from accumulated other comprehensive loss | 0.6 |  |  | (0.5) |  |  | 56.7 |  |  | 3.2 |  |  |  |  | 60.0 | \nNet other comprehensive income (loss) | (269.0) |  |  | (9.8) |  |  | 88.4 |  |  | 128.0 |  |  |  |  | (62.4) | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 | $ | (1,844.2) |  |  | $ | (27.9) |  |  | $ | (2,443.2) |  |  | $ | 27.6 |  |  |  |  | $ | (4,287.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at April 1, 2021 | $ | (1,677.2) |  |  | $ | 4.5 |  |  | $ | (4,646.3) |  |  | $ | (76.6) |  |  |  |  | $ | (6,395.6) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | 161.0 |  |  | 4.4 |  |  | (10.2) |  |  | (136.8) |  |  |  |  | 18.4 | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | 0.2 |  |  | 86.6 |  |  | 3.3 |  |  |  |  | 90.1 | \nNet other comprehensive income (loss) | 161.0 |  |  | 4.6 |  |  | 76.4 |  |  | (133.5) |  |  |  |  | 108.5 | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at June 30, 2021 | $ | (1,516.2) |  |  | $ | 9.1 |  |  | $ | (4,569.9) |  |  | $ | (210.1) |  |  |  |  | $ | (6,287.1) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  | Accumulated Other Comprehensive Loss\nBalance at January 1, 2022 | $ | (1,550.2) |  |  | $ | 3.7 |  |  | $ | (2,583.6) |  |  | $ | (213.0) |  |  | $ | (4,343.1) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (294.6) |  |  | (30.6) |  |  | 25.1 |  |  | 234.2 |  |  | (65.9) | \nNet amount reclassified from accumulated other comprehensive loss | 0.6 |  |  | (1.0) |  |  | 115.3 |  |  | 6.4 |  |  | 121.3 | \nNet other comprehensive income (loss) | (294.0) |  |  | (31.6) |  |  | 140.4 |  |  | 240.6 |  |  | 55.4 | \n |  |  |  |  |  |  |  |  | \nBalance at June 30, 2022 | $ | (1,844.2) |  |  | $ | (27.9) |  |  | $ | (2,443.2) |  |  | $ | 27.6 |  |  | $ | (4,287.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  | Accumulated Other Comprehensive Loss\nBalance at January 1, 2021 | $ | (1,427.5) |  |  | $ | 14.8 |  |  | $ | (4,751.0) |  |  | $ | (332.7) |  |  | $ | (6,496.4) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (88.7) |  |  | (6.4) |  |  | 8.6 |  |  | 116.0 |  |  | 29.5 | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | 0.7 |  |  | 172.5 |  |  | 6.6 |  |  | 179.8 | \nNet other comprehensive income (loss) | (88.7) |  |  | (5.7) |  |  | 181.1 |  |  | 122.6 |  |  | 209.3 | \n |  |  |  |  |  |  |  |  | \nBalance at June 30, 2021 | $ | (1,516.2) |  |  | $ | 9.1 |  |  | $ | (4,569.9) |  |  | $ | (210.1) |  |  | $ | (6,287.1) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\nTax benefit (expense) | 2022 |  | 2021 |  | 2022 |  | 2021\nForeign currency translation gains/losses | $ | (87.2) |  |  | $ | (21.9) |  |  | $ | (100.9) |  |  | $ | (53.3) | \nUnrealized net gains/losses on securities | 3.0 |  |  | (1.3) |  |  | 9.7 |  |  | 3.1 | \nDefined benefit pension and retiree health benefit plans | (22.4) |  |  | (20.2) |  |  | (50.8) |  |  | (51.5) | \nEffective portion of cash flow hedges | (34.0) |  |  | 35.5 |  |  | (63.9) |  |  | (32.6) | \nBenefit (expense) for income taxes allocated to other comprehensive income (loss) items | $ | (140.6) |  |  | $ | (7.9) |  |  | $ | (205.9) |  |  | $ | (134.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDetails about Accumulated Other Comprehensive Loss Components |  | Three Months Ended June 30, |  | Six Months Ended June 30, | Affected Line Item in the Consolidated Condensed Statements of Operations\n\n | 2022 |  | 2021 |  | 2022 |  | 2021\nAmortization of retirement benefit items: |  |  |  |  |  |  |  |  | \nPrior service benefits, net |  | $ | (13.1) |  |  | $ | (13.8) |  |  | $ | (26.1) |  |  | $ | (27.6) |  | Other\u2013net, (income) expense\nActuarial losses, net |  | 84.8 |  |  | 123.4 |  |  | 172.0 |  |  | 246.0 |  | Other\u2013net, (income) expense\nTotal before tax |  | 71.7 |  |  | 109.6 |  |  | 145.9 |  |  | 218.4 |  | \nTax benefit |  | (15.0) |  |  | (23.0) |  |  | (30.6) |  |  | (45.9) |  | Income taxes\nNet of tax |  | 56.7 |  |  | 86.6 |  |  | 115.3 |  |  | 172.5 |  | \n |  |  |  |  |  |  |  |  | \nOther, net of tax |  | 3.3 |  |  | 3.5 |  |  | 6.0 |  |  | 7.3 |  | Other\u2013net, (income) expense\n |  |  |  |  |  |  |  |  | \nTotal reclassifications, net of tax |  | $ | 60.0 |  |  | $ | 90.1 |  |  | $ | 121.3 |  |  | $ | 179.8 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nInterest expense | $ | 81.2 |  |  | $ | 86.9 |  |  | $ | 166.1 |  |  | $ | 174.7 | \nInterest income | (10.2) |  |  | (5.4) |  |  | (17.2) |  |  | (10.9) | \nNet investment (gains) losses on equity securities (Note 6) | 118.9 |  |  | (215.4) |  |  | 544.3 |  |  | (517.0) | \nRetirement benefit plans | (94.3) |  |  | (71.1) |  |  | (187.6) |  |  | (144.5) | \n |  |  |  |  |  |  | \nOther (income) expense | 23.6 |  |  | 14.5 |  |  | (35.7) |  |  | (13.9) | \nOther\u2013net, (income) expense | $ | 119.2 |  |  | $ | (190.5) |  |  | $ | 469.9 |  |  | $ | (511.6) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | Percent Change |  | 2022 |  | 2021 |  | Percent Change\nRevenue | $ | 6,488.0 |  |  | $ | 6,740.1 |  |  | (4) |  | $ | 14,298.0 |  |  | $ | 13,545.7 |  |  | 6\nGross margin | 5,057.5 |  |  | 4,786.9 |  |  | 6 |  | 10,795.4 |  |  | 9,713.9 |  |  | 11\nGross margin as a percent of revenue | 78.0 | % |  | 71.0 | % |  |  |  | 75.5 | % |  | 71.7 | % |  | \n |  |  |  |  |  |  |  |  |  |  | \nResearch and development | $ | 1,781.9 |  |  | $ | 1,655.0 |  |  | 8 |  | $ | 3,392.0 |  |  | $ | 3,327.1 |  |  | 2\nMarketing, selling, and administrative | 1,625.1 |  |  | 1,685.7 |  |  | (4) |  | 3,183.0 |  |  | 3,261.7 |  |  | (2)\nAcquired in-process research and development (IPR&D) and development milestones | 440.4 |  |  | 42.8 |  |  | NM |  | 606.0 |  |  | 354.8 |  |  | 71\nAsset impairment, restructuring, and other special charges | \u2014 |  |  | \u2014 |  |  | \u2014 |  | \u2014 |  |  | 211.6 |  |  | NM\nOther\u2013net, (income) expense | 119.2 |  |  | (190.5) |  |  | NM |  | 469.9 |  |  | (511.6) |  |  | NM\n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNet income | 952.5 |  |  | 1,390.2 |  |  | (31) |  | 2,855.4 |  |  | 2,745.5 |  |  | 4\n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nEPS - diluted | 1.05 |  |  | 1.53 |  |  | (31) |  | 3.16 |  |  | 3.01 |  |  | 5  |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nDiabetes | \nTirzepatide (Mounjaro\u00ae) | Type 2 diabetes | Approved | Approved in the U.S. in the second quarter of 2022. Submitted in Europe and Japan in 2021. Received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in July 2022. | \nHeart failure with preserved ejection fraction | Phase III | Phase III trials are ongoing. | \nObesity | Phase III | Announced in the second quarter of 2022 that the initial Phase III trial met co-primary and all key secondary endpoints. Phase III trials are ongoing. | \nObstructive sleep apnea | Phase III | Phase III trial initiated in July 2022. | \nNonalcoholic steatohepatitis | Phase II | Phase II trial is ongoing. | \nBasal Insulin-Fc | Type 1 and 2 diabetes | Phase III | Phase III trials initiated in the first and second quarters of 2022. | \nGLP-1R NPA | Obesity | Phase II | Phase II trials are ongoing. | \nType 2 diabetes | \nRetatrutide (GGG Tri-Agonist) | Obesity | Phase II | Phase II trials are ongoing. | \nType 2 diabetes | \nImmunology | \nMirikizumab | Ulcerative colitis | Submitted | Submitted in the U.S. in first quarter of 2022 and in Europe and Japan in the second quarter of 2022. | \nCrohn's Disease | Phase III | Phase III trials are ongoing. | \nLebrikizumab(1) | Atopic dermatitis | Phase III | Granted FDA Fast Track designation(2). Announced in 2021 and in the second quarter of 2022 that Phase III trials met primary and all key secondary endpoints. Phase III trials are ongoing. | \nBTLA MAB Agonist | Systemic lupus erythematosus | Phase II | Phase II trial initiated in the second quarter of 2022. | \nCXCR1/2 Ligands Monoclonal Antibody | Hidradenitis suppurativa | Phase II | Phase II trial is ongoing. | \nPeresolimab (PD-1 MAB Agonist) | Rheumatoid arthritis | Phase II | Phase II trial is ongoing. | \nRezpegaldesleukin (IL-2 Conjugate) | Systemic lupus erythematosus | Phase II | Phase II trial is ongoing. | \n |  |  |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nNeuroscience | \nDonanemab | Early Alzheimer's disease | Submitted | Granted FDA Breakthrough Therapy designation(3). Submitted in the U.S. in the second quarter of 2022. Received Priority Review designation under the accelerated approval pathway. Phase III trials are ongoing. | \nPreclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nSolanezumab | Preclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nGBA1 Gene Therapy (PR001) | Parkinson's disease | Phase II | Granted FDA Fast Track designation(2). Phase II trials are ongoing. | \nGRN Gene Therapy (PR006) | Frontotemporal dementia | Phase II | \nO-glc-NAcase | Alzheimer's disease | Phase II | Phase II trial is ongoing. | \nPACAP38 Antibody | Migraine | Phase II | Phase II trial is ongoing. | \nSSTR4 Agonist | Pain | Phase II | Phase II trials are ongoing. | \nTRPA1 Antagonist | Pain | Phase II | Phase II trials are ongoing. | \n |  |  |  | \nOncology | \nSelpercatinib (Retevmo\u00ae) | Lung cancer | Approved(4) | Phase III trials are ongoing. | \nThyroid cancer | \nPirtobrutinib (LOXO-305) | Mantle cell lymphoma | Submitted | Submitted in the U.S. in second quarter of 2022. Received Priority Review designation under the accelerated approval pathway. Phase II and Phase III trials are ongoing. | \nChronic lymphocytic leukemia | Phase III | Phase III trials are ongoing. | \nB-cell malignancies | Phase II | Phase II trial is ongoing. | \nImlunestrant | ER+HER2- metastatic breast cancer | Phase III | Phase III trial is ongoing. | \nSintilimab injection(5) | Lung cancer | Not pursuing submission | In the first quarter of 2022 the FDA issued a complete response letter indicating that the FDA did not approve the application in its current form and recommended an additional multiregional clinical study be performed. Lilly does not plan to further pursue submission. |   |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments\nDiabetes\nEmpagliflozin (Jardiance\u00ae)(1) | Heart failure with preserved ejection fraction | Approved | Approved in the U.S. and Europe in the first quarter of 2022 and in Japan in the second quarter of 2022.\nChronic kidney disease | Phase III | Granted FDA Fast Track designation(2). In the first quarter of 2022 the Independent Data Monitoring Committee recommended stopping the Phase III trial early due to clear positive efficacy.\nImmunology\nBaricitinib (Olumiant\u00ae) | Alopecia areata | Approved | Approved in the U.S., Europe and Japan in the second quarter of 2022.\nCOVID-19 | Approved | Approved in the U.S. in the second quarter of 2022.\nOncology\nAbemaciclib (Verzenio\u00ae) | Prostate cancer | Phase III | Phase III trials are ongoing.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  | Six Months Ended June 30, |  | \n | 2022 |  | 2021 |  | Percent Change | 2022 |  | 2021 |  | Percent Change\nU.S. | $ | 3,934.8 |  |  | $ | 3,704.2 |  |  | 6 | $ | 9,109.4 |  |  | $ | 7,645.5 |  |  | 19\nOutside U.S. | 2,553.3 |  |  | 3,035.9 |  |  | (16) | 5,188.7 |  |  | 5,900.2 |  |  | (12)\nRevenue | $ | 6,488.0 |  |  | $ | 6,740.1 |  |  | (4) | $ | 14,298.0 |  |  | $ | 13,545.7 |  |  | 6  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2022 vs. 2021 |  | 2022 vs. 2021\n | U.S. | Outside U.S. | Consolidated |  | U.S. | Outside U.S. | Consolidated\nVolume | 14 | % | 5 | % | 10 | % |  | 23 | % | 5 | % | 15 | %\nPrice | (8) |  | (14) |  | (11) |  |  | (4) |  | (11) |  | (7) | \nForeign exchange rates | \u2014 |  | (6) |  | (3) |  |  | \u2014 |  | (6) |  | (3) | \nPercent change | 6 | % | (16) | % | (4) | % |  | 19 | % | (12) | % | 6 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  |  | \n | 2022 |  | 2021 | \nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | Percent Change | \nTrulicity | $ | 1,430.1 |  |  | $ | 481.7 |  |  | $ | 1,911.9 |  |  | $ | 1,535.6 |  |  | 25 | \nTaltz | 411.6 |  |  | 194.7 |  |  | 606.2 |  |  | 569.1 |  |  | 7 | \nVerzenio | 384.3 |  |  | 204.2 |  |  | 588.5 |  |  | 341.3 |  |  | 72 | \nJardiance(1) | 250.7 |  |  | 210.3 |  |  | 461.0 |  |  | 356.5 |  |  | 29 | \nHumalog(2) | 238.8 |  |  | 208.3 |  |  | 447.1 |  |  | 607.6 |  |  | (26) | \nHumulin\u00ae | 202.3 |  |  | 71.7 |  |  | 274.0 |  |  | 315.3 |  |  | (13) | \nCyramza\u00ae | 92.6 |  |  | 138.6 |  |  | 231.3 |  |  | 268.7 |  |  | (14) | \nAlimta | 171.7 |  |  | 56.1 |  |  | 227.7 |  |  | 610.6 |  |  | (63) | \nOlumiant(3) | 10.4 |  |  | 175.8 |  |  | 186.2 |  |  | 208.4 |  |  | (11) | \nBasaglar | 95.8 |  |  | 78.4 |  |  | 174.2 |  |  | 210.7 |  |  | (17) | \nEmgality\u00ae | 108.6 |  |  | 48.9 |  |  | 157.5 |  |  | 156.3 |  |  | 1 | \nCialis | 10.8 |  |  | 136.2 |  |  | 147.0 |  |  | 281.0 |  |  | (48) | \nErbitux\u00ae | 125.1 |  |  | 15.7 |  |  | 140.8 |  |  | 147.0 |  |  | (4) | \nForteo | 78.5 |  |  | 60.0 |  |  | 138.5 |  |  | 218.4 |  |  | (37) | \nCOVID-19 antibodies(4) | 129.1 |  |  | \u2014 |  |  | 129.1 |  |  | 148.9 |  |  | (13) | \nZyprexa\u00ae | 8.7 |  |  | 78.6 |  |  | 87.3 |  |  | 95.4 |  |  | (8) | \nCymbalta | 8.1 |  |  | 67.4 |  |  | 75.5 |  |  | 175.6 |  |  | (57) | \nTyvyt | \u2014 |  |  | 73.6 |  |  | 73.6 |  |  | 105.0 |  |  | (30) | \nOther products | 177.6 |  |  | 253.1 |  |  | 430.6 |  |  | 388.7 |  |  | 11 | \nRevenue | $ | 3,934.8 |  |  | $ | 2,553.3 |  |  | $ | 6,488.0 |  |  | $ | 6,740.1 |  |  | (4) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30, |  | \n | 2022 |  | 2021\nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | Percent Change\nTrulicity | $ | 2,744.1 |  |  | $ | 909.1 |  |  | $ | 3,653.2 |  |  | $ | 2,988.1 |  |  | 22\nCOVID-19 antibodies(1) | 1,584.3 |  |  | 14.7 |  |  | 1,598.9 |  |  | 959.1 |  |  | 67\nTaltz | 718.8 |  |  | 375.5 |  |  | 1,094.3 |  |  | 972.4 |  |  | 13\nHumalog(2) | 607.7 |  |  | 457.6 |  |  | 1,065.3 |  |  | 1,224.6 |  |  | (13)\nVerzenio | 685.7 |  |  | 372.1 |  |  | 1,057.9 |  |  | 610.3 |  |  | 73\nJardiance(3) | 480.4 |  |  | 400.0 |  |  | 880.4 |  |  | 668.5 |  |  | 32\nAlimta | 425.9 |  |  | 145.8 |  |  | 571.7 |  |  | 1,169.6 |  |  | (51)\nHumulin | 392.8 |  |  | 154.5 |  |  | 547.2 |  |  | 637.0 |  |  | (14)\nCyramza | 171.8 |  |  | 289.7 |  |  | 461.5 |  |  | 509.2 |  |  | (9)\nOlumiant(4) | 81.7 |  |  | 360.1 |  |  | 441.8 |  |  | 402.2 |  |  | 10\nBasaglar | 215.1 |  |  | 150.6 |  |  | 365.7 |  |  | 457.3 |  |  | (20)\nCialis | 17.7 |  |  | 347.0 |  |  | 364.7 |  |  | 407.8 |  |  | (11)\nEmgality | 216.9 |  |  | 89.8 |  |  | 306.7 |  |  | 275.7 |  |  | 11\nForteo | 148.7 |  |  | 127.2 |  |  | 275.9 |  |  | 416.9 |  |  | (34)\nErbitux | 234.7 |  |  | 28.7 |  |  | 263.4 |  |  | 269.4 |  |  | (2)\nZyprexa | 18.3 |  |  | 162.1 |  |  | 180.4 |  |  | 191.1 |  |  | (6)\nTyvyt | \u2014 |  |  | 159.0 |  |  | 159.0 |  |  | 214.6 |  |  | (26)\nCymbalta | 17.2 |  |  | 139.4 |  |  | 156.6 |  |  | 352.3 |  |  | (56)\nOther products | 347.6 |  |  | 505.8 |  |  | 853.4 |  |  | 819.6 |  |  | 4\nRevenue | $ | 9,109.4 |  |  | $ | 5,188.7 |  |  | $ | 14,298.0 |  |  | $ | 13,545.7 |  |  | 6  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | Total Number ofShares Purchased(in thousands) |  | Average\u00a0Price Paidper Share |  | Total\u00a0Number of SharesPurchased\u00a0as Part ofPublicly AnnouncedPlans or Programs(in thousands) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(in millions)\nApril 2022 | \u2014 |  |  | $ | \u2014 |  |  | \u2014 |  |  | $ | 3,250.0 | \nMay 2022 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,250.0 | \nJune 2022 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,250.0 | \nTotal | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nExhibit |  | Description\nEXHIBIT 3.1 |  | Amended Articles of Incorporation are incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \nEXHIBIT 3.2 |  | Bylaws, as amended, are incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \nEXHIBIT\u00a031.1 |  | Rule\u00a013a-14(a) Certification of David A. Ricks, Chair, President, and Chief Executive Officer\n |  | \nEXHIBIT 31.2 |  | Rule\u00a013a-14(a) Certification of Anat Ashkenazi, Senior Vice President and Chief Financial Officer\n | \nEXHIBIT 32. |  | Section 1350 Certification\n |  | \nEXHIBIT 101. |  | Interactive Data Files (embedded within the Inline XBRL document)\n |  | \nEXHIBIT 104. |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)  |  |  |  |  |  |  |  | \n |  | ELI LILLY AND COMPANY\n |  | (Registrant)\n |  | \nDate: | August 4, 2022 | /s/ Anat Ashkenazi\n |  | Anat Ashkenazi\n |  | Senior Vice President and Chief Financial Officer\nDate: | August 4, 2022 | /s/ Donald A. Zakrowski\n |  | Donald A. Zakrowski\n |  | Vice President, Finance, and Chief Accounting Officer"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Eli Lilly, in 2022 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \nIndiana |  | 35-0470950\n(State or other jurisdiction of |  | (I.R.S. Employer\nincorporation or organization) |  | Identification No.)  |  |  |  |  |  |  |  | \nTitle of Each Class | Trading Symbols | Name of Each Exchange On Which Registered\nCommon Stock (no par value) | LLY | New York Stock Exchange\n7 1/8% Notes due 2025 | LLY25 | New York Stock Exchange\n1.625% Notes due 2026 | LLY26 | New York Stock Exchange\n2.125% Notes due 2030 | LLY30 | New York Stock Exchange\n0.625% Notes due 2031 | LLY31 | New York Stock Exchange\n0.500% Notes due 2033 | LLY33 | New York Stock Exchange\n6.77%\u00a0Notes due 2036 | LLY36 | New York Stock Exchange\n1.625% Notes due 2043 | LLY43 | New York Stock Exchange\n1.700% Notes due 2049 | LLY49A | New York Stock Exchange\n1.125% Notes due 2051 | LLY51 | New York Stock Exchange\n1.375% Notes due 2061 | LLY61 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  |  |  |  | Accelerated\u00a0filer | \u2610\nNon-accelerated filer | \u2610 |  |  | Smaller reporting company | \u2610\n |  |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  | \nClass |  | Number of Shares Outstanding\nCommon |  | 950,177,900 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\nPART I. Financial Information |  |  |  | 5\n |  |  |  | \nItem 1. |  | Financial Statements |  | 5\n |  | Consolidated Condensed Statements of Operations |  | 5\n |  | Consolidated Condensed Statements of Comprehensive Income |  | 6\n |  | Consolidated Condensed Balance Sheets |  | 7\n |  | Consolidated Condensed Statements of Equity |  | 8\n |  | Consolidated Condensed Statements of Cash Flows |  | 10\n |  | Notes to Consolidated Condensed Financial Statements |  | 11\nItem 2. |  | Management's Discussion and Analysis of Results of Operations and Financial Condition |  | 37\n |  | Executive Overview |  | 37\n |  | Revenue |  | 45\n |  | Gross Margin, Costs, and Expenses |  | 49\n |  | Financial Condition and Liquidity |  | 50\n |  |  |  | \n |  | Critical Accounting Estimates |  | 51\n |  | Available Information on our Website |  | 51\nItem 4. |  | Controls and Procedures |  | 52\n |  |  |  | \nPART II. Other Information |  |  |  | 53\n |  |  |  | \nItem 1. |  | Legal Proceedings |  | 53\nItem 1A. |  | Risk Factors |  | 53\nItem 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 53\nItem 6. |  | Exhibits |  | 54\n |  |  |  | \nSignatures |  |  |  | 54  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue (Note 2) | $ | 6,941.6 |  |  | $ | 6,772.8 |  |  | $ | 21,239.6 |  |  | $ | 20,318.5 | \nCosts, expenses, and other: |  |  |  |  |  |  | \nCost of sales | 1,579.1 |  |  | 1,430.8 |  |  | 5,081.7 |  |  | 5,262.6 | \nResearch and development | 1,802.9 |  |  | 1,705.3 |  |  | 5,194.9 |  |  | 5,032.4 | \nMarketing, selling, and administrative | 1,614.2 |  |  | 1,577.9 |  |  | 4,797.2 |  |  | 4,839.6 | \nAcquired in-process research and development and development milestones (Note 3) | 62.4 |  |  | 177.6 |  |  | 668.4 |  |  | 532.4 | \nAsset impairment, restructuring, and other special charges (Note 5) | 206.5 |  |  | \u2014 |  |  | 206.5 |  |  | 211.6 | \nOther\u2013net, (income) expense (Note 11) | 111.0 |  |  | 635.9 |  |  | 580.9 |  |  | 124.3 | \n | 5,376.1 |  |  | 5,527.5 |  |  | 16,529.6 |  |  | 16,002.9 | \nIncome before income taxes | 1,565.5 |  |  | 1,245.3 |  |  | 4,710.0 |  |  | 4,315.6 | \nIncome taxes (Note 7) | 113.8 |  |  | 135.2 |  |  | 402.9 |  |  | 460.0 | \nNet income | $ | 1,451.7 |  |  | $ | 1,110.1 |  |  | $ | 4,307.1 |  |  | $ | 3,855.6 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nEarnings per share: |  |  |  |  |  |  | \nBasic | $ | 1.61 |  |  | $ | 1.22 |  |  | $ | 4.78 |  |  | $ | 4.25 | \n |  |  |  |  |  |  | \nDiluted | $ | 1.61 |  |  | $ | 1.22 |  |  | $ | 4.76 |  |  | $ | 4.23 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nShares used in calculation of earnings per share: |  |  |  |  |  |  | \nBasic | 900.7 |  | 906.7 |  | 901.8 |  | 907.7\nDiluted | 903.8 |  | 910.8 |  | 904.5 |  | 911.7  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet income | $ | 1,451.7 |  |  | $ | 1,110.1 |  |  | $ | 4,307.1 |  |  | $ | 3,855.6 | \nOther comprehensive income (loss), net of tax (Note 10) | (8.1) |  |  | 114.4 |  |  | 47.3 |  |  | 323.7 | \nComprehensive income | $ | 1,443.6 |  |  | $ | 1,224.5 |  |  | $ | 4,354.4 |  |  | $ | 4,179.3 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\nAssets | (Unaudited) |  | \nCurrent Assets |  |  | \nCash and cash equivalents (Note 6) | $ | 2,617.4 |  |  | $ | 3,818.5 | \nShort-term investments (Note 6) | 124.7 |  |  | 90.1 | \nAccounts receivable, net of allowances of$17.7(2022)and $22.5(2021) | 6,715.3 |  |  | 6,672.8 | \nOther receivables | 1,609.5 |  |  | 1,454.4 | \nInventories | 3,831.1 |  |  | 3,886.0 | \nPrepaid expenses and other | 2,741.9 |  |  | 2,530.6 | \nTotal current assets | 17,639.9 |  |  | 18,452.4 | \nInvestments (Note 6) | 2,574.6 |  |  | 3,212.6 | \nGoodwill | 3,891.6 |  |  | 3,892.0 | \nOther intangibles, net | 7,124.1 |  |  | 7,691.9 | \nDeferred tax assets | 2,384.3 |  |  | 2,489.3 | \nProperty and equipment, net of accumulated depreciation of$10,074.0(2022)and $9,976.7(2021) | 9,311.3 |  |  | 8,985.1 | \nOther noncurrent assets | 4,535.7 |  |  | 4,082.7 | \nTotal assets | $ | 47,461.5 |  |  | $ | 48,806.0 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nShort-term borrowings and current maturities of long-term debt | $ | 1,744.6 |  |  | $ | 1,538.3 | \nAccounts payable | 1,683.2 |  |  | 1,670.6 | \nEmployee compensation | 984.1 |  |  | 958.1 | \nSales rebates and discounts | 8,568.4 |  |  | 6,845.8 | \nDividends payable | \u2014 |  |  | 885.5 | \nIncome taxes payable | 685.6 |  |  | 126.9 | \nOther current liabilities | 1,986.9 |  |  | 3,027.5 | \nTotal current liabilities | 15,652.8 |  |  | 15,052.7 | \nOther Liabilities |  |  | \nLong-term debt | 14,143.8 |  |  | 15,346.4 | \nAccrued retirement benefits (Note 8) | 1,832.5 |  |  | 1,954.1 | \nLong-term income taxes payable | 3,641.7 |  |  | 3,920.0 | \nDeferred tax liabilities | 171.9 |  |  | 1,733.7 | \nOther noncurrent liabilities | 1,852.9 |  |  | 1,644.3 | \nTotal other liabilities | 21,642.8 |  |  | 24,598.5 | \nCommitments and Contingencies (Note 9) |  |  | \nEli Lilly and Company Shareholders' Equity |  |  | \nCommon stock | 594.1 |  |  | 596.3 | \nAdditional paid-in capital | 6,829.0 |  |  | 6,833.4 | \nRetained earnings | 10,006.5 |  |  | 8,958.5 | \nEmployee benefit trust | (3,013.2) |  |  | (3,013.2) | \nAccumulated other comprehensive loss (Note 10) | (4,295.8) |  |  | (4,343.1) | \nCost of common stock in treasury | (50.5) |  |  | (52.7) | \nTotal Eli Lilly and Company shareholders' equity | 10,070.1 |  |  | 8,979.2 | \nNoncontrolling interests | 95.8 |  |  | 175.6 | \nTotal equity | 10,165.9 |  |  | 9,154.8 | \nTotal liabilities and equity | $ | 47,461.5 |  |  | $ | 48,806.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions, except per-share data, and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at July 1, 2021 | 957,038 |  |  | $ | 598.1 |  |  | $ | 6,669.2 |  |  | $ | 8,530.1 |  |  | $ | (3,013.2) |  |  | $ | (6,287.1) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 219.1 | \nNet income (loss) |  |  |  |  |  |  | 1,110.1 |  |  |  |  |  |  |  |  |  |  | (22.6) | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 114.4 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIssuance of stock under employee stock plans, net | 14 |  |  | 0.1 |  |  | (1.3) |  |  |  |  |  |  |  |  |  |  |  |  | \nStock-based compensation |  |  |  |  | 90.1 |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | (0.8) |  |  |  |  |  |  |  |  |  |  | 0.6 | \nBalance at September\u00a030, 2021 | 957,052 |  |  | $ | 598.2 |  |  | $ | 6,758.0 |  |  | $ | 9,639.4 |  |  | $ | (3,013.2) |  |  | $ | (6,172.7) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 197.1 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at July 1, 2022 | 950,619 |  |  | $ | 594.1 |  |  | $ | 6,746.0 |  |  | $ | 8,556.0 |  |  | $ | (3,013.2) |  |  | $ | (4,287.7) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 114.5 | \nNet income (loss) |  |  |  |  |  |  | 1,451.7 |  |  |  |  |  |  |  |  |  |  | (15.7) | \nOther comprehensive loss, net of tax |  |  |  |  |  |  |  |  |  |  | (8.1) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIssuance of stock under employee stock plans, net | 8 |  |  |  |  | (2.1) |  |  |  |  |  |  |  |  |  |  |  |  | \nStock-based compensation |  |  |  |  | 85.1 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | (1.2) |  |  |  |  |  |  |  |  |  |  | (3.0) | \nBalance at September\u00a030, 2022 | 950,627 |  |  | $ | 594.1 |  |  | $ | 6,829.0 |  |  | $ | 10,006.5 |  |  | $ | (3,013.2) |  |  | $ | (4,295.8) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 95.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions, except per-share data, and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at January 1, 2021 | 957,077 |  |  | $ | 598.2 |  |  | $ | 6,778.5 |  |  | $ | 7,830.2 |  |  | $ | (3,013.2) |  |  | $ | (6,496.4) |  |  | 487 |  |  | $ | (55.7) |  |  | $ | 183.6 | \nNet income |  |  |  |  |  |  | 3,855.6 |  |  |  |  |  |  |  |  |  |  | 25.2 | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 323.7 |  |  |  |  |  |  | \nCash dividends declared per share: $1.70 |  |  |  |  |  |  | (1,542.9) |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (2,467) |  |  | (1.5) |  |  |  |  | (498.5) |  |  |  |  |  |  | (2,467) |  |  | 500.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 2,467 |  |  | (500.0) |  |  | \nIssuance of stock under employee stock plans, net | 2,442 |  |  | 1.5 |  |  | (287.1) |  |  |  |  |  |  |  |  | (24) |  |  | 3.0 |  |  | \nStock-based compensation |  |  |  |  | 267.5 |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  | (0.9) |  |  | (5.0) |  |  |  |  |  |  |  |  |  |  | (11.7) | \nBalance at September\u00a030, 2021 | 957,052 |  |  | $ | 598.2 |  |  | $ | 6,758.0 |  |  | $ | 9,639.4 |  |  | $ | (3,013.2) |  |  | $ | (6,172.7) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 197.1 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January 1, 2022 | 954,116 |  |  | $ | 596.3 |  |  | $ | 6,833.4 |  |  | $ | 8,958.5 |  |  | $ | (3,013.2) |  |  | $ | (4,343.1) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 175.6 | \nNet income (loss) |  |  |  |  |  |  | 4,307.1 |  |  |  |  |  |  |  |  |  |  | (63.7) | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 47.3 |  |  |  |  |  |  | \nCash dividends declared per share: $1.96 |  |  |  |  |  |  | (1,765.9) |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (5,607) |  |  | (3.5) |  |  |  |  | (1,496.5) |  |  |  |  |  |  | (5,607) |  |  | 1,500.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 5,607 |  |  | (1,500.0) |  |  | \nIssuance of stock under employee stock plans, net | 2,118 |  |  | 1.3 |  |  | (282.6) |  |  |  |  |  |  |  |  | (13) |  |  | 2.2 |  |  | \nStock-based compensation |  |  |  |  | 278.2 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | 3.3 |  |  |  |  |  |  |  |  |  |  | (16.1) | \nBalance at September\u00a030, 2022 | 950,627 |  |  | $ | 594.1 |  |  | $ | 6,829.0 |  |  | $ | 10,006.5 |  |  | $ | (3,013.2) |  |  | $ | (4,295.8) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 95.8 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2022 |  | 2021\nCash Flows from Operating Activities | \nNet income | $ | 4,307.1 |  |  | $ | 3,855.6 | \nAdjustments to Reconcile Net Income to Cash Flows from Operating Activities: |  |  | \n |  |  | \nDepreciation and amortization | 1,147.5 |  |  | 1,101.9 | \nChange in deferred income taxes | (2,195.6) |  |  | (709.8) | \nDebt extinguishment loss (Note 6) | \u2014 |  |  | 405.2 | \nStock-based compensation expense | 278.2 |  |  | 267.5 | \n |  |  | \nNet investment (gains) losses | 676.4 |  |  | (271.1) | \nAcquired in-process research and development | 252.0 |  |  | 498.3 | \nOther changes in operating assets and liabilities, net of acquisitions and divestitures | 821.5 |  |  | (548.1) | \nOther non-cash operating activities, net | 217.6 |  |  | 504.7 | \nNet Cash Provided by Operating Activities | 5,504.7 |  |  | 5,104.2 | \nCash Flows from Investing Activities |  |  | \nNet purchases of property and equipment | (1,353.6) |  |  | (1,018.4) | \nProceeds from sales and maturities of short-term investments | 83.1 |  |  | 46.6 | \nPurchases of short-term investments | (65.0) |  |  | (27.9) | \nProceeds from sales of noncurrent investments | 251.6 |  |  | 537.2 | \nPurchases of noncurrent investments | (474.1) |  |  | (710.1) | \nCash paid for acquisitions, net of cash acquired (Note 3) | \u2014 |  |  | (747.4) | \n |  |  | \nPurchases of in-process research and development | (574.8) |  |  | (460.6) | \nOther investing activities, net | (268.3) |  |  | (2.7) | \nNet Cash Used for Investing Activities | (2,401.1) |  |  | (2,383.3) | \nCash Flows from Financing Activities |  |  | \nDividends paid | (2,651.4) |  |  | (2,313.5) | \nNet change in short-term borrowings | 1,741.3 |  |  | (1.5) | \nProceeds from issuance of long-term debt | \u2014 |  |  | 2,410.8 | \nRepayments of long-term debt | (1,560.0) |  |  | (1,905.3) | \nPurchases of common stock | (1,500.0) |  |  | (500.0) | \n |  |  | \nOther financing activities, net | (295.2) |  |  | (295.3) | \nNet Cash Used for Financing Activities | (4,265.3) |  |  | (2,604.8) | \nEffect of exchange rate changes on cash and cash equivalents | (39.4) |  |  | 15.0 | \n |  |  | \nNet decrease in cash and cash equivalents | (1,201.1) |  |  | 131.1 | \nCash and cash equivalents at January\u00a01 | 3,818.5 |  |  | 3,657.1 | \nCash and Cash Equivalents at September 30 | $ | 2,617.4 |  |  | $ | 3,788.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet product revenue | $ | 6,119.2 |  |  | $ | 6,189.0 |  |  | $ | 19,123.0 |  |  | $ | 18,579.5 | \nCollaboration and other revenue(1) | 822.4 |  |  | 583.8 |  |  | 2,116.6 |  |  | 1,739.0 | \nRevenue | $ | 6,941.6 |  |  | $ | 6,772.8 |  |  | $ | 21,239.6 |  |  | $ | 20,318.5 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\nContract liabilities | $ | 232.5 |  |  | $ | 262.6 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30,\n | 2022 |  | 2021\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\nRevenue\u2014to unaffiliated customers: |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity\u00ae | $ | 1,418.3 |  | $ | 432.0 |  | $ | 1,850.4 |  |  | $ | 1,201.4 |  | $ | 398.8 |  | $ | 1,600.1 | \nJardiance(1) | 350.9 |  | 222.4 |  | 573.3 |  |  | 221.2 |  | 169.2 |  | 390.4 | \nHumalog\u00ae (2) | 248.1 |  | 198.8 |  | 447.0 |  |  | 347.3 |  | 279.4 |  | 626.7 | \nHumulin\u00ae | 169.5 |  | 68.7 |  | 238.2 |  |  | 193.4 |  | 93.4 |  | 286.7 | \nBasaglar\u00ae | 124.8 |  | 68.1 |  | 193.0 |  |  | 114.7 |  | 78.1 |  | 192.8 | \nMounjaro\u00ae | 97.3 |  | 90.0 |  | 187.3 |  |  | \u2014 |  | \u2014 |  | \u2014 | \nOther diabetes | 79.7 |  | 94.0 |  | 173.4 |  |  | 65.0 |  | 112.2 |  | 177.4 | \nTotal diabetes | 2,488.6 |  | 1,174.0 |  | 3,662.6 |  |  | 2,143.0 |  | 1,131.1 |  | 3,274.1 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio\u00ae | 414.8 |  | 202.9 |  | 617.7 |  |  | 199.6 |  | 135.9 |  | 335.5 | \nCyramza\u00ae | 87.5 |  | 144.6 |  | 232.1 |  |  | 84.8 |  | 168.6 |  | 253.4 | \nErbitux\u00ae | 126.3 |  | 18.7 |  | 144.9 |  |  | 114.0 |  | 20.3 |  | 134.3 | \nAlimta\u00ae | 64.6 |  | 54.8 |  | 119.4 |  |  | 297.2 |  | 159.8 |  | 457.0 | \nTyvyt\u00ae | \u2014 |  | 76.8 |  | 76.8 |  |  | \u2014 |  | 125.6 |  | 125.6 | \nOther oncology | 39.5 |  | 62.8 |  | 102.4 |  |  | 35.3 |  | 65.1 |  | 100.3 | \nTotal oncology | 732.7 |  | 560.6 |  | 1,293.3 |  |  | 730.9 |  | 675.3 |  | 1,406.1 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz\u00ae | 493.8 |  | 186.1 |  | 679.9 |  |  | 422.2 |  | 170.9 |  | 593.1 | \nOlumiant\u00ae (3) | 22.9 |  | 160.0 |  | 182.9 |  |  | 194.0 |  | 212.9 |  | 406.9 | \nOther immunology | \u2014 |  | 3.6 |  | 3.6 |  |  | \u2014 |  | 4.9 |  | 4.9 | \nTotal immunology | 516.7 |  | 349.7 |  | 866.4 |  |  | 616.2 |  | 388.7 |  | 1,004.9 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nEmgality\u00ae | 114.0 |  | 54.6 |  | 168.5 |  |  | 99.9 |  | 40.1 |  | 140.0 | \nZyprexa\u00ae | 8.0 |  | 73.4 |  | 81.4 |  |  | 13.0 |  | 88.7 |  | 101.7 | \nCymbalta\u00ae | 7.8 |  | 54.9 |  | 62.7 |  |  | 7.0 |  | 125.1 |  | 132.0 | \n |  |  |  |  |  |  | \nOther neuroscience | 16.0 |  | 44.5 |  | 60.6 |  |  | 24.7 |  | 51.6 |  | 76.5 | \nTotal neuroscience | 145.8 |  | 227.4 |  | 373.2 |  |  | 144.6 |  | 305.5 |  | 450.2 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nCOVID-19 antibodies(4) | 386.6 |  | \u2014 |  | 386.6 |  |  | 215.5 |  | 1.6 |  | 217.1 | \nForteo\u00ae | 112.7 |  | 64.4 |  | 177.1 |  |  | 109.6 |  | 91.3 |  | 200.9 | \nCialis\u00ae | 8.1 |  | 107.7 |  | 115.7 |  |  | (6.5) |  | 137.4 |  | 130.9 | \nOther | 30.9 |  | 35.7 |  | 66.6 |  |  | 36.3 |  | 52.4 |  | 88.8 | \nTotal other | 538.3 |  | 207.8 |  | 746.0 |  |  | 354.9 |  | 282.7 |  | 637.7 | \nRevenue | $ | 4,422.1 |  | $ | 2,519.4 |  | $ | 6,941.6 |  |  | $ | 3,989.6 |  | $ | 2,783.3 |  | $ | 6,772.8 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2022 |  | 2021\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\nRevenue\u2014to unaffiliated customers: |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity | $ | 4,162.4 |  | $ | 1,341.1 |  | $ | 5,503.5 |  |  | $ | 3,465.7 |  | $ | 1,122.5 |  | $ | 4,588.2 | \nHumalog(1) | 855.8 |  | 656.4 |  | 1,512.3 |  |  | 1,009.0 |  | 842.3 |  | 1,851.3 | \nJardiance(2) | 831.4 |  | 622.4 |  | 1,453.7 |  |  | 566.8 |  | 492.1 |  | 1,058.9 | \nHumulin | 562.3 |  | 223.1 |  | 785.4 |  |  | 633.5 |  | 290.3 |  | 923.8 | \nBasaglar | 339.9 |  | 218.8 |  | 558.7 |  |  | 423.3 |  | 226.8 |  | 650.1 | \nMounjaro | 109.9 |  | 93.3 |  | 203.2 |  |  | \u2014 |  | \u2014 |  | \u2014 | \nOther diabetes | 195.6 |  | 276.5 |  | 472.2 |  |  | 185.7 |  | 302.6 |  | 488.3 | \nTotal diabetes | 7,057.3 |  | 3,431.6 |  | 10,489.0 |  |  | 6,284.0 |  | 3,276.6 |  | 9,560.6 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio | 1,100.5 |  | 575.1 |  | 1,675.6 |  |  | 582.1 |  | 363.7 |  | 945.8 | \nCyramza | 259.3 |  | 434.3 |  | 693.6 |  |  | 266.3 |  | 496.3 |  | 762.5 | \nAlimta | 490.5 |  | 200.5 |  | 691.1 |  |  | 911.9 |  | 714.7 |  | 1,626.6 | \nErbitux | 361.0 |  | 47.4 |  | 408.3 |  |  | 357.7 |  | 45.9 |  | 403.7 | \nTyvyt | \u2014 |  | 235.8 |  | 235.8 |  |  | \u2014 |  | 340.2 |  | 340.2 | \nOther oncology | 124.1 |  | 186.5 |  | 310.6 |  |  | 83.7 |  | 169.9 |  | 253.6 | \nTotal oncology | 2,335.4 |  | 1,679.6 |  | 4,015.0 |  |  | 2,201.7 |  | 2,130.7 |  | 4,332.4 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz | 1,212.6 |  | 561.6 |  | 1,774.2 |  |  | 1,071.6 |  | 493.8 |  | 1,565.4 | \nOlumiant(3) | 104.6 |  | 520.1 |  | 624.7 |  |  | 236.5 |  | 572.6 |  | 809.1 | \nOther immunology | 0.1 |  | 12.1 |  | 12.1 |  |  | 15.2 |  | 14.5 |  | 29.7 | \nTotal immunology | 1,317.3 |  | 1,093.8 |  | 2,411.0 |  |  | 1,323.3 |  | 1,080.9 |  | 2,404.2 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nEmgality | 330.8 |  | 144.4 |  | 475.2 |  |  | 313.5 |  | 102.2 |  | 415.7 | \nZyprexa | 26.2 |  | 235.5 |  | 261.7 |  |  | 28.3 |  | 264.5 |  | 292.8 | \nCymbalta | 25.0 |  | 194.3 |  | 219.3 |  |  | 30.3 |  | 454.0 |  | 484.3 | \n |  |  |  |  |  |  | \nOther neuroscience | 62.0 |  | 142.7 |  | 204.7 |  |  | 81.0 |  | 154.0 |  | 235.0 | \nTotal neuroscience | 444.0 |  | 716.9 |  | 1,160.9 |  |  | 453.1 |  | 974.7 |  | 1,427.8 | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nCOVID-19 antibodies(4) | 1,970.9 |  | 14.7 |  | 1,985.5 |  |  | 949.5 |  | 226.7 |  | 1,176.2 | \nCialis | 25.8 |  | 454.7 |  | 480.4 |  |  | (3.1) |  | 541.8 |  | 538.7 | \nForteo | 261.4 |  | 191.7 |  | 453.0 |  |  | 330.1 |  | 287.7 |  | 617.8 | \nOther | 119.4 |  | 125.1 |  | 244.8 |  |  | 96.5 |  | 164.3 |  | 260.8 | \nTotal other | 2,377.5 |  | 786.2 |  | 3,163.7 |  |  | 1,373.0 |  | 1,220.5 |  | 2,593.5 | \nRevenue | $ | 13,531.5 |  | $ | 7,708.1 |  | $ | 21,239.6 |  |  | $ | 11,635.1 |  | $ | 8,683.4 |  | $ | 20,318.5 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nRevenue\u2014to unaffiliated customers(1): |  |  |  |  |  |  | \nU.S. | $ | 4,422.1 |  |  | $ | 3,989.6 |  |  | $ | 13,531.5 |  |  | $ | 11,635.1 | \nEurope | 1,056.4 |  |  | 1,098.6 |  |  | 3,224.8 |  |  | 3,629.6 | \nJapan | 487.7 |  |  | 595.0 |  |  | 1,352.3 |  |  | 1,832.2 | \nChina | 343.4 |  |  | 400.3 |  |  | 1,102.0 |  |  | 1,285.0 | \nOther foreign countries | 632.0 |  |  | 689.4 |  |  | 2,029.1 |  |  | 1,936.7 | \nRevenue | $ | 6,941.6 |  |  | $ | 6,772.8 |  |  | $ | 21,239.6 |  |  | $ | 20,318.5 |   |  |  |  |  | \nEstimated Fair Value at January 22, 2021 | \nCash | $ | 90.5 | \nAcquired IPR&D(1) | 824.0\nGoodwill(2) | 126.8\nDeferred tax liabilities | (106.0) | \nOther assets and liabilities, net | (31.5) | \nAcquisition date fair value of consideration transferred | 903.8\nLess: | \nCash acquired | (90.5) | \nFair value of CVR liability(3) | (65.9) | \nCash paid, net of cash acquired | $ | 747.4 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCounterparty | Compound(s), Therapy or Asset | Acquisition Month |  | Phase of Development(1) |  | Acquired IPR&D Expense\nBioMarin Pharmaceutical Inc. | Priority Review Voucher | February 2022 |  | Not applicable |  | $ | 110.0 | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \nRigel Pharmaceuticals, Inc. | R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for the potential treatment of autoimmune and inflammatory diseases | March 2021 |  | Phase I |  | 125.0 | \nPrecision Biosciences, Inc. | Potential in vivo therapies for genetic disorders | January 2021 |  | Pre-clinical |  | 107.8 | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  | \n |  |  |  |  |  |   |  |  |  |  |  |  |  | \n | Net Milestones Capitalized (Deferred)(1)\n | September 30, 2022 | December 31, 2021\nJardiance | $ | 121.2 |  | $ | 136.1 | \nTrajenta | 69.6 |  | 88.5 | \nBasaglar | (135.3) |  | (149.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nJardiance | $ | 573.3 |  |  | $ | 390.4 |  |  | $ | 1,453.7 |  |  | $ | 1,058.9 | \nBasaglar | 193.0 |  |  | 192.8 |  |  | 558.7 |  |  | 650.1 | \nTrajenta | 103.8 |  |  | 96.1 |  |  | 293.0 |  |  | 279.9 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nOlumiant | $ | 182.9 |  |  | $ | 406.9 |  |  | $ | 624.7 |  |  | $ | 809.1 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nTyvyt | $ | 76.8 |  |  | $ | 125.6 |  |  | $ | 235.8 |  |  | $ | 340.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nSeverance | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 11.5 | \nAsset impairment and other special charges | 206.5 |  |  | \u2014 |  |  | 206.5 |  |  | 200.1 | \nTotal asset impairment, restructuring, and other special charges | $ | 206.5 |  |  | $ | \u2014 |  |  | $ | 206.5 |  |  | $ | 211.6 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nFair value hedges: |  |  |  |  |  |  | \nEffect from hedged fixed-rate debt | $ | (62.9) |  |  | $ | (10.1) |  |  | $ | (215.7) |  |  | $ | (60.5) | \nEffect from interest rate contracts | 62.9 |  |  | 10.1 |  |  | 215.7 |  |  | 60.5 | \nCash flow hedges: |  |  |  |  |  |  | \nEffective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss | 4.1 |  |  | 4.2 |  |  | 12.3 |  |  | 12.5 | \nCross-currency interest rate swaps | 33.1 |  |  | 10.0 |  |  | 75.0 |  |  | 58.1 | \nNet (gains) losses on foreign currency exchange contracts not designated as hedging instruments | 129.6 |  |  | 50.8 |  |  | 280.7 |  |  | 110.6 | \nTotal | $ | 166.8 |  |  | $ | 65.0 |  |  | $ | 368.0 |  |  | $ | 181.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nNet investment hedges: |  |  |  |  |  |  | \nForeign currency-denominated notes | $ | 435.1 |  |  | $ | 119.0 |  |  | $ | 822.8 |  |  | $ | 268.8 | \nCross-currency interest rate swaps | 92.1 |  |  | 66.7 |  |  | 171.4 |  |  | 170.8 | \nForeign currency forward contracts | 107.8 |  |  | \u2014 |  |  | 121.4 |  |  | \u2014 | \nCash flow hedges: |  |  |  |  |  |  | \nForward-starting interest rate swaps | 57.5 |  |  | 19.4 |  |  | 337.7 |  |  | 149.3 | \nCross-currency interest rate swaps | 19.9 |  |  | 3.1 |  |  | 38.4 |  |  | 22.5 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Cost(1) |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | Significant OtherObservable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nSeptember 30, 2022 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents | $ | 1,246.8 |  |  | $ | 1,246.8 |  |  | $ | 1,239.2 |  |  | $ | 7.6 |  |  | $ | \u2014 |  |  | $ | 1,246.8 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 43.0 |  |  | $ | 43.5 |  |  | $ | 43.0 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 43.0 | \nCorporate debt securities | 51.7 |  |  | 51.8 |  |  | \u2014 |  |  | 51.7 |  |  | \u2014 |  |  | 51.7 | \n |  |  |  |  |  |  |  |  |  |  | \nAsset-backed securities | 3.0 |  |  | 3.0 |  |  | \u2014 |  |  | 3.0 |  |  | \u2014 |  |  | 3.0 | \nOther securities | 27.0 |  |  | 27.0 |  |  | \u2014 |  |  | 14.8 |  |  | 12.2 |  |  | 27.0 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 124.7 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 131.4 |  |  | $ | 148.3 |  |  | $ | 131.4 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 131.4 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities | 206.4 |  |  | 232.5 |  |  | \u2014 |  |  | 206.4 |  |  | \u2014 |  |  | 206.4 | \nMortgage-backed securities | 143.1 |  |  | 156.1 |  |  | \u2014 |  |  | 143.1 |  |  | \u2014 |  |  | 143.1 | \nAsset-backed securities | 43.6 |  |  | 45.5 |  |  | \u2014 |  |  | 43.6 |  |  | \u2014 |  |  | 43.6 | \nOther securities | 152.5 |  |  | 96.3 |  |  | \u2014 |  |  | 39.5 |  |  | 113.0 |  |  | 152.5 | \nMarketable equity securities | 549.1 |  |  | 416.1 |  |  | 549.1 |  |  | \u2014 |  |  | \u2014 |  |  | 549.1 | \nEquity investments without readily determinable fair values(2) | 583.7 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(2) | 764.8 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 2,574.6 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents | $ | 2,379.5 |  |  | $ | 2,379.5 |  |  | $ | 2,361.0 |  |  | $ | 18.5 |  |  | $ | \u2014 |  |  | $ | 2,379.5 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 25.7 |  |  | $ | 25.6 |  |  | $ | 25.7 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 25.7 | \nCorporate debt securities | 43.7 |  |  | 43.7 |  |  | \u2014 |  |  | 43.7 |  |  | \u2014 |  |  | 43.7 | \nMortgage-backed securities | 0.2 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 |  |  | \u2014 |  |  | 0.2 | \nAsset-backed securities | 6.2 |  |  | 6.2 |  |  | \u2014 |  |  | 6.2 |  |  | \u2014 |  |  | 6.2 | \nOther securities | 14.3 |  |  | 14.3 |  |  | \u2014 |  |  | \u2014 |  |  | 14.3 |  |  | 14.3 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 90.1 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 137.0 |  |  | $ | 136.8 |  |  | $ | 137.0 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 137.0 | \nCorporate debt securities | 235.3 |  |  | 232.7 |  |  | \u2014 |  |  | 235.3 |  |  | \u2014 |  |  | 235.3 | \nMortgage-backed securities | 109.8 |  |  | 108.1 |  |  | \u2014 |  |  | 109.8 |  |  | \u2014 |  |  | 109.8 | \nAsset-backed securities | 23.1 |  |  | 23.1 |  |  | \u2014 |  |  | 23.1 |  |  | \u2014 |  |  | 23.1 | \nOther securities | 108.1 |  |  | 22.2 |  |  | \u2014 |  |  | \u2014 |  |  | 108.1 |  |  | 108.1 | \nMarketable equity securities | 1,279.7 |  |  | 487.0 |  |  | 1,279.7 |  |  | \u2014 |  |  | \u2014 |  |  | 1,279.7 | \nEquity investments without readily determinable fair values(2) | 548.1 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(2) | 771.5 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 3,212.6 |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nShort-term commercial paper borrowings |  |  |  |  |  |  |  |  | \nSeptember 30, 2022 | $ | (1,741.3) |  |  | $ | \u2014 |  |  | $ | (1,738.0) |  |  | $ | \u2014 |  |  | $ | (1,738.0) | \nDecember 31, 2021 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | \u2014 | \nLong-term debt, including current portion |  |  |  |  |  |  |  |  | \nSeptember 30, 2022 | $ | (14,147.1) |  |  | $ | \u2014 |  |  | $ | (11,848.6) |  |  | $ | \u2014 |  |  | $ | (11,848.6) | \nDecember 31, 2021 | (16,884.7) |  |  | \u2014 |  |  | (18,157.7) |  |  | \u2014 |  |  | (18,157.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  |  |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue |  | \nSeptember 30, 2022 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | $ | (140.2) |  |  | $ | \u2014 |  |  | $ | (140.2) |  |  | $ | \u2014 |  |  | $ | (140.2) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 355.2 |  |  | \u2014 |  |  | 355.2 |  |  | \u2014 |  |  | 355.2 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 81.6 |  |  | \u2014 |  |  | 81.6 |  |  | \u2014 |  |  | 81.6 |  |  | \nOther noncurrent assets | 116.9 |  |  | \u2014 |  |  | 116.9 |  |  | \u2014 |  |  | 116.9 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 8.3 |  |  | \u2014 |  |  | 8.3 |  |  | \u2014 |  |  | 8.3 |  |  | \nOther noncurrent liabilities | (12.9) |  |  | \u2014 |  |  | (12.9) |  |  | \u2014 |  |  | (12.9) |  |  | \nForeign exchange contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 108.2 |  |  | \u2014 |  |  | 108.2 |  |  | \u2014 |  |  | 108.2 |  |  | \nOther current liabilities | (2.9) |  |  | \u2014 |  |  | (2.9) |  |  | \u2014 |  |  | (2.9) |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 48.1 |  |  | \u2014 |  |  | 48.1 |  |  | \u2014 |  |  | 48.1 |  |  | \nOther current liabilities | (93.5) |  |  | \u2014 |  |  | (93.5) |  |  | \u2014 |  |  | (93.5) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nContingent consideration liability: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (42.1) |  |  | \u2014 |  |  | \u2014 |  |  | (42.1) |  |  | (42.1) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nDecember 31, 2021 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | $ | 4.8 |  |  | $ | \u2014 |  |  | $ | 4.8 |  |  | $ | \u2014 |  |  | $ | 4.8 |  |  | \nOther noncurrent assets | 78.3 |  |  | \u2014 |  |  | 78.3 |  |  | \u2014 |  |  | 78.3 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (7.6) |  |  | \u2014 |  |  | (7.6) |  |  | \u2014 |  |  | (7.6) |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 49.2 |  |  | \u2014 |  |  | 49.2 |  |  | \u2014 |  |  | 49.2 |  |  | \nOther noncurrent liabilities | (31.7) |  |  | \u2014 |  |  | (31.7) |  |  | \u2014 |  |  | (31.7) |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 31.3 |  |  | \u2014 |  |  | 31.3 |  |  | \u2014 |  |  | 31.3 |  |  | \nOther current liabilities | (1.2) |  |  | \u2014 |  |  | (1.2) |  |  | \u2014 |  |  | (1.2) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 33.2 |  |  | \u2014 |  |  | 33.2 |  |  | \u2014 |  |  | 33.2 |  |  | \nOther noncurrent liabilities | (1.3) |  |  | \u2014 |  |  | (1.3) |  |  | \u2014 |  |  | (1.3) |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 9.9 |  |  | \u2014 |  |  | 9.9 |  |  | \u2014 |  |  | 9.9 |  |  | \nOther current liabilities | (35.3) |  |  | \u2014 |  |  | (35.3) |  |  | \u2014 |  |  | (35.3) |  |  | \nContingent consideration liabilities: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | (70.5) |  |  | \u2014 |  |  | \u2014 |  |  | (70.5) |  |  | (70.5) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturities by Period\n | Total |  | Less\u00a0Than1 Year |  | 1-5Years |  | 6-10Years |  | More\u00a0Than10 Years\nFair value of debt securities | $ | 622.2 |  |  | $ | 97.7 |  |  | $ | 197.8 |  |  | $ | 121.0 |  |  | $ | 205.7 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2022 |  | December 31, 2021\nUnrealized gross gains | $ | 0.1 |  |  | $ | 9.7 | \nUnrealized gross losses | 51.6 |  |  | 5.2 | \nFair value of securities in an unrealized gain position | 13.8 |  |  | 250.7 | \nFair value of securities in an unrealized loss position | 578.8 |  |  | 290.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nProceeds from sales | $ | 50.5 |  |  | $ | 49.6 |  |  | $ | 115.6 |  |  | $ | 137.3 | \nRealized gross gains on sales | \u2014 |  |  | 0.4 |  |  | 0.2 |  |  | 2.2 | \nRealized gross losses on sales | 7.5 |  |  | 0.3 |  |  | 9.0 |  |  | 1.1 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Defined Benefit Pension Plans\n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nComponents of net periodic benefit cost: |  |  |  |  |  |  | \nService cost | $ | 87.1 |  |  | $ | 92.5 |  |  | $ | 264.4 |  |  | $ | 277.8 | \nInterest cost | 98.9 |  |  | 84.5 |  |  | 299.0 |  |  | 253.6 | \nExpected return on plan assets | (235.1) |  |  | (237.5) |  |  | (711.6) |  |  | (712.7) | \nAmortization of prior service cost | 0.6 |  |  | 1.0 |  |  | 1.9 |  |  | 3.2 | \nRecognized actuarial loss | 85.3 |  |  | 121.9 |  |  | 256.8 |  |  | 366.3 | \n |  |  |  |  |  |  | \nNet periodic benefit cost | $ | 36.8 |  |  | $ | 62.4 |  |  | $ | 110.5 |  |  | $ | 188.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Retiree Health Benefit Plans\n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nComponents of net periodic benefit income: |  |  |  |  |  |  | \nService cost | $ | 11.7 |  |  | $ | 12.4 |  |  | $ | 35.0 |  |  | $ | 37.0 | \nInterest cost | 9.4 |  |  | 8.1 |  |  | 28.4 |  |  | 24.4 | \nExpected return on plan assets | (38.0) |  |  | (36.5) |  |  | (114.1) |  |  | (109.6) | \nAmortization of prior service benefit | (13.7) |  |  | (14.9) |  |  | (41.1) |  |  | (44.7) | \nRecognized actuarial loss | 0.2 |  |  | 0.8 |  |  | 0.7 |  |  | 2.4 | \n |  |  |  |  |  |  | \nNet periodic benefit income | $ | (30.4) |  |  | $ | (30.1) |  |  | $ | (91.1) |  |  | $ | (90.5) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at July 1, 2022 | $ | (1,844.2) |  |  | $ | (27.9) |  |  | $ | (2,443.2) |  |  | $ | 27.6 |  |  |  |  | $ | (4,287.7) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (165.1) |  |  | (24.9) |  |  | 47.8 |  |  | 63.0 |  |  |  |  | (79.2) | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | 13.5 |  |  | 57.2 |  |  | 0.4 |  |  |  |  | 71.1 | \nNet other comprehensive income (loss) | (165.1) |  |  | (11.4) |  |  | 105.0 |  |  | 63.4 |  |  |  |  | (8.1) | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at September\u00a030, 2022 | $ | (2,009.3) |  |  | $ | (39.3) |  |  | $ | (2,338.2) |  |  | $ | 91.0 |  |  |  |  | $ | (4,295.8) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at July 1, 2021 | $ | (1,516.2) |  |  | $ | 9.1 |  |  | $ | (4,569.9) |  |  | $ | (210.1) |  |  |  |  | $ | (6,287.1) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (8.0) |  |  | (2.4) |  |  | 18.6 |  |  | 16.8 |  |  |  |  | 25.0 | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | 0.1 |  |  | 86.0 |  |  | 3.3 |  |  |  |  | 89.4 | \nNet other comprehensive income (loss) | (8.0) |  |  | (2.3) |  |  | 104.6 |  |  | 20.1 |  |  |  |  | 114.4 | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at September\u00a030, 2021 | $ | (1,524.2) |  |  | $ | 6.8 |  |  | $ | (4,465.3) |  |  | $ | (190.0) |  |  |  |  | $ | (6,172.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  | Accumulated Other Comprehensive Loss\nBalance at January 1, 2022 | $ | (1,550.2) |  |  | $ | 3.7 |  |  | $ | (2,583.6) |  |  | $ | (213.0) |  |  | $ | (4,343.1) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (459.7) |  |  | (55.5) |  |  | 72.9 |  |  | 297.2 |  |  | (145.1) | \nNet amount reclassified from accumulated other comprehensive loss | 0.6 |  |  | 12.5 |  |  | 172.5 |  |  | 6.8 |  |  | 192.4 | \nNet other comprehensive income (loss) | (459.1) |  |  | (43.0) |  |  | 245.4 |  |  | 304.0 |  |  | 47.3 | \n |  |  |  |  |  |  |  |  | \nBalance at September\u00a030, 2022 | $ | (2,009.3) |  |  | $ | (39.3) |  |  | $ | (2,338.2) |  |  | $ | 91.0 |  |  | $ | (4,295.8) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Unrealized Net Gains (Losses) on\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Effective Portion of Cash\u00a0Flow Hedges |  | Accumulated Other Comprehensive Loss\nBalance at January 1, 2021 | $ | (1,427.5) |  |  | $ | 14.8 |  |  | $ | (4,751.0) |  |  | $ | (332.7) |  |  | $ | (6,496.4) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (96.7) |  |  | (8.8) |  |  | 27.2 |  |  | 132.8 |  |  | 54.5 | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | 0.8 |  |  | 258.5 |  |  | 9.9 |  |  | 269.2 | \nNet other comprehensive income (loss) | (96.7) |  |  | (8.0) |  |  | 285.7 |  |  | 142.7 |  |  | 323.7 | \n |  |  |  |  |  |  |  |  | \nBalance at September\u00a030, 2021 | $ | (1,524.2) |  |  | $ | 6.8 |  |  | $ | (4,465.3) |  |  | $ | (190.0) |  |  | $ | (6,172.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\nTax benefit (expense) | 2022 |  | 2021 |  | 2022 |  | 2021\nForeign currency translation gains/losses | $ | (133.3) |  |  | $ | (39.0) |  |  | $ | (234.2) |  |  | $ | (92.3) | \nUnrealized net gains/losses on securities | 3.4 |  |  | 0.8 |  |  | 13.1 |  |  | 3.8 | \nDefined benefit pension and retiree health benefit plans | (22.4) |  |  | (28.2) |  |  | (73.2) |  |  | (79.7) | \nEffective portion of cash flow hedges | (16.9) |  |  | (5.4) |  |  | (80.8) |  |  | (37.9) | \nBenefit (expense) for income taxes allocated to other comprehensive income (loss) items | $ | (169.2) |  |  | $ | (71.8) |  |  | $ | (375.1) |  |  | $ | (206.1) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDetails about Accumulated Other Comprehensive Loss Components |  | Three Months Ended September 30, |  | Nine Months Ended September 30, | Affected Line Item in the Consolidated Condensed Statements of Operations\n\n | 2022 |  | 2021 |  | 2022 |  | 2021\nAmortization of retirement benefit items: |  |  |  |  |  |  |  |  | \nPrior service benefits, net |  | $ | (13.1) |  |  | $ | (13.9) |  |  | $ | (39.2) |  |  | $ | (41.5) |  | Other\u2013net, (income) expense\nActuarial losses, net |  | 85.5 |  |  | 122.7 |  |  | 257.5 |  |  | 368.7 |  | Other\u2013net, (income) expense\nTotal before tax |  | 72.4 |  |  | 108.8 |  |  | 218.3 |  |  | 327.2 |  | \nTax benefit |  | (15.2) |  |  | (22.8) |  |  | (45.8) |  |  | (68.7) |  | Income taxes\nNet of tax |  | 57.2 |  |  | 86.0 |  |  | 172.5 |  |  | 258.5 |  | \n |  |  |  |  |  |  |  |  | \nOther, net of tax |  | 13.9 |  |  | 3.4 |  |  | 19.9 |  |  | 10.7 |  | Other\u2013net, (income) expense\n |  |  |  |  |  |  |  |  | \nTotal reclassifications, net of tax |  | $ | 71.1 |  |  | $ | 89.4 |  |  | $ | 192.4 |  |  | $ | 269.2 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 |  | 2021 |  | 2022 |  | 2021\nInterest expense | $ | 81.5 |  |  | $ | 83.6 |  |  | $ | 247.6 |  |  | $ | 258.4 | \nInterest income | (20.1) |  |  | (7.0) |  |  | (37.3) |  |  | (18.0) | \nNet investment (gains) losses on equity securities (Note 6) | 123.3 |  |  | 246.8 |  |  | 667.6 |  |  | (270.1) | \nRetirement benefit plans | (92.4) |  |  | (72.6) |  |  | (280.0) |  |  | (217.1) | \nDebt extinguishment loss (Note 6) | \u2014 |  |  | 405.2 |  |  | \u2014 |  |  | 405.2 | \nOther (income) expense | 18.7 |  |  | (20.1) |  |  | (17.0) |  |  | (34.1) | \nOther\u2013net, (income) expense | $ | 111.0 |  |  | $ | 635.9 |  |  | $ | 580.9 |  |  | $ | 124.3 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  |  | Nine Months EndedSeptember 30, |  | \n | 2022 |  | 2021 |  | Percent Change |  | 2022 |  | 2021 |  | Percent Change\nRevenue | $ | 6,941.6 |  |  | $ | 6,772.8 |  |  | 2 |  | $ | 21,239.6 |  |  | $ | 20,318.5 |  |  | 5\nGross margin | 5,362.5 |  |  | 5,342.0 |  |  | \u2014 |  | 16,157.9 |  |  | 15,055.9 |  |  | 7\nGross margin as a percent of revenue | 77.3 | % |  | 78.9 | % |  |  |  | 76.1 | % |  | 74.1 | % |  | \n |  |  |  |  |  |  |  |  |  |  | \nResearch and development | $ | 1,802.9 |  |  | $ | 1,705.3 |  |  | 6 |  | $ | 5,194.9 |  |  | $ | 5,032.4 |  |  | 3\nMarketing, selling, and administrative | 1,614.2 |  |  | 1,577.9 |  |  | 2 |  | 4,797.2 |  |  | 4,839.6 |  |  | (1)\nAcquired in-process research and development (IPR&D) and development milestones | 62.4 |  |  | 177.6 |  |  | (65) |  | 668.4 |  |  | 532.4 |  |  | 26\nAsset impairment, restructuring, and other special charges | 206.5 |  |  | \u2014 |  |  | NM |  | 206.5 |  |  | 211.6 |  |  | (2)\nOther\u2013net, (income) expense | 111.0 |  |  | 635.9 |  |  | (83) |  | 580.9 |  |  | 124.3 |  |  | NM\n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNet income | 1,451.7 |  |  | 1,110.1 |  |  | 31 |  | 4,307.1 |  |  | 3,855.6 |  |  | 12\n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nEPS - diluted | 1.61 |  |  | 1.22 |  |  | 32 |  | 4.76 |  |  | 4.23 |  |  | 13  |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nDiabetes | \nTirzepatide (Mounjaro) | Type 2 diabetes | Approved | Approved in the U.S. in the second quarter of 2022 and in Europe and Japan in the third quarter of 2022. | \nHeart failure with preserved ejection fraction | Phase III | Phase III trials are ongoing. | \nObesity | Phase III | Granted FDA Fast Track designation(1)in October 2022. Announced in the second quarter of 2022 that the initial Phase III trial met co-primary and all key secondary endpoints. Phase III trials are ongoing. | \nObstructive sleep apnea | Phase III | Phase III trial initiated in the third quarter of 2022. | \nNonalcoholic steatohepatitis | Phase II | Phase II trial is ongoing. | \nBasal Insulin-Fc | Type 1 and 2 diabetes | Phase III | Phase III trials initiated in the first, second, and third quarters of 2022. | \nOrforglipron (GLP-1R NPA) | Obesity | Phase II | Phase II trials are ongoing. | \nType 2 diabetes | \nRetatrutide (GGG Tri-Agonist) | Obesity | Phase II | Phase II trials are ongoing. | \nType 2 diabetes | \nImmunology | \nLebrikizumab(2) | Atopic dermatitis | Submitted | Granted FDA Fast Track designation(1). Submitted in the U.S. in the third quarter of 2022 and in Europe in October 2022. Phase III trials are ongoing. | \nMirikizumab | Ulcerative colitis | Submitted | Submitted in the U.S. in first quarter of 2022 and in Europe and Japan in the second quarter of 2022. | \nCrohn's Disease | Phase III | Phase III trials are ongoing. | \nANGPTL3 siRNA | Cardiovascular disease | Phase II | Phase II trial initiated in the third quarter of 2022. | \nBTLA MAB Agonist | Systemic lupus erythematosus | Phase II | Phase II trial initiated in the second quarter of 2022. | \nCXCR1/2 Ligands Monoclonal Antibody | Hidradenitis suppurativa | Phase II | Phase II trial is ongoing. | \nPeresolimab (PD-1 MAB Agonist) | Rheumatoid arthritis | Phase II | Phase II trial is ongoing. | \nRezpegaldesleukin (IL-2 Conjugate) | Systemic lupus erythematosus | Phase II | Phase II trial is ongoing. | \n |  |  |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nNeuroscience | \nDonanemab | Early Alzheimer's disease | Submitted | Granted FDA Breakthrough Therapy designation(3). Submitted in the U.S. in the second quarter of 2022. Received Priority Review designation under the accelerated approval pathway. Phase III trials are ongoing. | \nPreclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nRemternetug | Early Alzheimer's disease | Phase III | Phase III trial initiated in the third quarter of 2022. | \nSolanezumab | Preclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nGBA1 Gene Therapy (PR001) | Parkinson's disease | Phase II | Granted FDA Fast Track designation(1). Phase II trial is ongoing. | \nGRN Gene Therapy (PR006) | Frontotemporal dementia | Phase II | Granted FDA Fast Track designation(1). Phase II trial is ongoing. | \nO-GlcNAcase Inh | Alzheimer's disease | Phase II | Phase II trial is ongoing. | \nSSTR4 Agonist | Pain | Phase II | Phase II trials are ongoing. | \nTRPA1 Antagonist | Pain | Phase II | Phase II trials are ongoing. | \nPACAP38 Antibody | Migraine | Discontinued | In the third quarter of 2022 based on the results of the Phase II trial, we discontinued development. | \nOncology | \nSelpercatinib (Retevmo\u00ae) | Lung cancer | Approved(4) | Phase III trials are ongoing. In the third quarter of 2022, the FDA granted accelerated approval in tumor-agnostic RET fusion-positive advanced or metastatic solid tumors and traditional approval in locally advanced or metastatic RET fusion-positive non-small cell lung cancer. | \nThyroid cancer | Approved(4) | Phase III trial is ongoing. | \nPirtobrutinib (LOXO-305) | Mantle cell lymphoma | Submitted | Submitted in the U.S. in second quarter of 2022. Received Priority Review designation under the accelerated approval pathway. Phase III trial is ongoing. | \nChronic lymphocytic leukemia | Phase III | Phase III trials are ongoing. | \nB-cell malignancies | Phase II | Phase II trial is ongoing. | \nImlunestrant | ER+HER2- metastatic breast cancer | Phase III | Phase III trial is ongoing. |   |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments\nDiabetes\nEmpagliflozin (Jardiance\u00ae)(1) | Heart failure with preserved ejection fraction | Approved | Approved in the U.S. and Europe in the first quarter of 2022 and in Japan in the second quarter of 2022.\nChronic kidney disease | Phase III | Granted FDA Fast Track designation(2). In the first quarter of 2022 the Independent Data Monitoring Committee recommended stopping the Phase III trial early due to clear positive efficacy.\nImmunology\nBaricitinib (Olumiant\u00ae) | Alopecia areata | Approved | Approved in the U.S., Europe, and Japan in the second quarter of 2022.\nCOVID-19 | Approved | Approved in the U.S. in the second quarter of 2022.\nOncology\nAbemaciclib (Verzenio\u00ae) | Prostate cancer | Phase III | Phase III trials are ongoing.  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |  | \n | 2022 |  | 2021 |  | Percent Change | 2022 |  | 2021 |  | Percent Change\nU.S. | $ | 4,422.1 |  |  | $ | 3,989.6 |  |  | 11 | $ | 13,531.5 |  |  | $ | 11,635.1 |  |  | 16\nOutside U.S. | 2,519.4 |  |  | 2,783.3 |  |  | (9) | 7,708.1 |  |  | 8,683.4 |  |  | (11)\nRevenue | $ | 6,941.6 |  |  | $ | 6,772.8 |  |  | 2 | $ | 21,239.6 |  |  | $ | 20,318.5 |  |  | 5  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2022 vs. 2021 |  | 2022 vs. 2021\n | U.S. | Outside U.S. | Consolidated |  | U.S. | Outside U.S. | Consolidated\nVolume | 15 | % | 13 | % | 14 | % |  | 20 | % | 7 | % | 15 | %\nPrice | (4) |  | (12) |  | (7) |  |  | (4) |  | (11) |  | (7) | \nForeign exchange rates | \u2014 |  | (11) |  | (4) |  |  | \u2014 |  | (7) |  | (3) | \nPercent change | 11 | % | (9) | % | 2 | % |  | 16 | % | (11) | % | 5 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  |  | \n | 2022 |  | 2021 | \nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | Percent Change | \nTrulicity | $ | 1,418.3 |  |  | $ | 432.0 |  |  | $ | 1,850.4 |  |  | $ | 1,600.1 |  |  | 16 | \nTaltz | 493.8 |  |  | 186.1 |  |  | 679.9 |  |  | 593.1 |  |  | 15 | \nVerzenio | 414.8 |  |  | 202.9 |  |  | 617.7 |  |  | 335.5 |  |  | 84 | \nJardiance(1) | 350.9 |  |  | 222.4 |  |  | 573.3 |  |  | 390.4 |  |  | 47 | \nHumalog(2) | 248.1 |  |  | 198.8 |  |  | 447.0 |  |  | 626.7 |  |  | (29) | \nCOVID-19 antibodies(3) | 386.6 |  |  | \u2014 |  |  | 386.6 |  |  | 217.1 |  |  | 78 | \nHumulin\u00ae | 169.5 |  |  | 68.7 |  |  | 238.2 |  |  | 286.7 |  |  | (17) | \nCyramza\u00ae | 87.5 |  |  | 144.6 |  |  | 232.1 |  |  | 253.4 |  |  | (8) | \nBasaglar\u00ae | 124.8 |  |  | 68.1 |  |  | 193.0 |  |  | 192.8 |  |  | \u2014 | \nMounjaro | 97.3 |  |  | 90.0 |  |  | 187.3 |  |  | \u2014 |  |  | NM | \nOlumiant(4) | 22.9 |  |  | 160.0 |  |  | 182.9 |  |  | 406.9 |  |  | (55) | \nForteo | 112.7 |  |  | 64.4 |  |  | 177.1 |  |  | 200.9 |  |  | (12) | \nEmgality\u00ae | 114.0 |  |  | 54.6 |  |  | 168.5 |  |  | 140.0 |  |  | 20 | \nErbitux\u00ae | 126.3 |  |  | 18.7 |  |  | 144.9 |  |  | 134.3 |  |  | 8 | \nAlimta | 64.6 |  |  | 54.8 |  |  | 119.4 |  |  | 457.0 |  |  | (74) | \nCialis | 8.1 |  |  | 107.7 |  |  | 115.7 |  |  | 130.9 |  |  | (12) | \nZyprexa\u00ae | 8.0 |  |  | 73.4 |  |  | 81.4 |  |  | 101.7 |  |  | (20) | \nTyvyt | \u2014 |  |  | 76.8 |  |  | 76.8 |  |  | 125.6 |  |  | (39) | \nCymbalta | 7.8 |  |  | 54.9 |  |  | 62.7 |  |  | 132.0 |  |  | (53) | \nOther products | 166.1 |  |  | 240.5 |  |  | 406.7 |  |  | 447.7 |  |  | (9) | \nRevenue | $ | 4,422.1 |  |  | $ | 2,519.4 |  |  | $ | 6,941.6 |  |  | $ | 6,772.8 |  |  | 2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30, |  | \n | 2022 |  | 2021\nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | Percent Change\nTrulicity | $ | 4,162.4 |  |  | $ | 1,341.1 |  |  | $ | 5,503.5 |  |  | $ | 4,588.2 |  |  | 20\nCOVID-19 antibodies(1) | 1,970.9 |  |  | 14.7 |  |  | 1,985.5 |  |  | 1,176.2 |  |  | 69\nTaltz | 1,212.6 |  |  | 561.6 |  |  | 1,774.2 |  |  | 1,565.4 |  |  | 13\nVerzenio | 1,100.5 |  |  | 575.1 |  |  | 1,675.6 |  |  | 945.8 |  |  | 77\nHumalog(2) | 855.8 |  |  | 656.4 |  |  | 1,512.3 |  |  | 1,851.3 |  |  | (18)\nJardiance(3) | 831.4 |  |  | 622.4 |  |  | 1,453.7 |  |  | 1,058.9 |  |  | 37\nHumulin | 562.3 |  |  | 223.1 |  |  | 785.4 |  |  | 923.8 |  |  | (15)\nCyramza | 259.3 |  |  | 434.3 |  |  | 693.6 |  |  | 762.5 |  |  | (9)\nAlimta | 490.5 |  |  | 200.5 |  |  | 691.1 |  |  | 1,626.6 |  |  | (58)\nOlumiant(4) | 104.6 |  |  | 520.1 |  |  | 624.7 |  |  | 809.1 |  |  | (23)\nBasaglar | 339.9 |  |  | 218.8 |  |  | 558.7 |  |  | 650.1 |  |  | (14)\nCialis | 25.8 |  |  | 454.7 |  |  | 480.4 |  |  | 538.7 |  |  | (11)\nEmgality | 330.8 |  |  | 144.4 |  |  | 475.2 |  |  | 415.7 |  |  | 14\nForteo | 261.4 |  |  | 191.7 |  |  | 453.0 |  |  | 617.8 |  |  | (27)\nErbitux | 361.0 |  |  | 47.4 |  |  | 408.3 |  |  | 403.7 |  |  | 1\nZyprexa | 26.2 |  |  | 235.5 |  |  | 261.7 |  |  | 292.8 |  |  | (11)\nTyvyt | \u2014 |  |  | 235.8 |  |  | 235.8 |  |  | 340.2 |  |  | (31)\nCymbalta | 25.0 |  |  | 194.3 |  |  | 219.3 |  |  | 484.3 |  |  | (55)\nMounjaro | 109.9 |  |  | 93.3 |  |  | 203.2 |  |  | \u2014 |  |  | NM\nOther products | 501.1 |  |  | 743.0 |  |  | 1,244.2 |  |  | 1,267.3 |  |  | (2)\nRevenue | $ | 13,531.5 |  |  | $ | 7,708.1 |  |  | $ | 21,239.6 |  |  | $ | 20,318.5 |  |  | 5  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | Total Number ofShares Purchased(in thousands) |  | Average\u00a0Price Paidper Share |  | Total\u00a0Number of SharesPurchased\u00a0as Part ofPublicly AnnouncedPlans or Programs(in thousands) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(in millions)\nJuly 2022 | \u2014 |  |  | $ | \u2014 |  |  | \u2014 |  |  | $ | 3,250.0 | \nAugust 2022 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,250.0 | \nSeptember 2022 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 3,250.0 | \nTotal | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nExhibit |  | Description\nEXHIBIT 3.1 |  | Amended Articles of Incorporation are incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \nEXHIBIT 3.2 |  | Bylaws, as amended, are incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \nEXHIBIT 10.1 |  | Form of Performance Award under the 2002 Lilly Stock Plan (with non-compete)(1)\n |  | \nEXHIBIT 10.2 |  | Form of Shareholder Value Award under the 2002 Lilly Stock Plan (with non-compete)(1)\n |  | \nEXHIBIT 10.3 |  | Form of Relative Value Award under the 2002 Lilly Stock Plan (with non-compete)(1)\n |  | \nEXHIBIT\u00a031.1 |  | Rule\u00a013a-14(a) Certification of David A. Ricks, Chair, President, and Chief Executive Officer\n |  | \nEXHIBIT 31.2 |  | Rule\u00a013a-14(a) Certification of Anat Ashkenazi,ExecutiveVice President and Chief Financial Officer\n | \nEXHIBIT 32. |  | Section 1350 Certification\n |  | \nEXHIBIT 101. |  | Interactive Data Files (embedded within the Inline XBRL document)\n |  | \nEXHIBIT 104. |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)  |  |  |  |  |  |  |  | \n |  | ELI LILLY AND COMPANY\n |  | (Registrant)\n |  | \nDate: | November 1, 2022 | /s/ Anat Ashkenazi\n |  | Anat Ashkenazi\n |  | Executive Vice President and Chief Financial Officer\nDate: | November 1, 2022 | /s/ Donald A. Zakrowski\n |  | Donald A. Zakrowski\n |  | Senior Vice President, Finance, and Chief Accounting Officer"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Eli Lilly, in 2023 Q1, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \nIndiana |  | 35-0470950\n(State or other jurisdiction of |  | (I.R.S. Employer\nincorporation or organization) |  | Identification No.)  |  |  |  |  |  |  |  | \nTitle of Each Class | Trading Symbols | Name of Each Exchange On Which Registered\nCommon Stock (no par value) | LLY | New York Stock Exchange\n7 1/8% Notes due 2025 | LLY25 | New York Stock Exchange\n1.625% Notes due 2026 | LLY26 | New York Stock Exchange\n2.125% Notes due 2030 | LLY30 | New York Stock Exchange\n0.625% Notes due 2031 | LLY31 | New York Stock Exchange\n0.500% Notes due 2033 | LLY33 | New York Stock Exchange\n6.77%\u00a0Notes due 2036 | LLY36 | New York Stock Exchange\n1.625% Notes due 2043 | LLY43 | New York Stock Exchange\n1.700% Notes due 2049 | LLY49A | New York Stock Exchange\n1.125% Notes due 2051 | LLY51 | New York Stock Exchange\n1.375% Notes due 2061 | LLY61 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  |  |  |  | Accelerated\u00a0filer | \u2610\nNon-accelerated filer | \u2610 |  |  | Smaller reporting company | \u2610\n |  |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  | \nClass |  | Number of Shares Outstanding\nCommon |  | 949,272,933 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\nPART I. Financial Information |  |  |  | 5\n |  |  |  | \nItem 1. |  | Financial Statements |  | 5\n |  | Consolidated Condensed Statements of Operations |  | 5\n |  | Consolidated Condensed Statements of Comprehensive Income |  | 6\n |  | Consolidated Condensed Balance Sheets |  | 7\n |  | Consolidated Condensed Statements of Equity |  | 8\n |  | Consolidated Condensed Statements of Cash Flows |  | 9\n |  | Notes to Consolidated Condensed Financial Statements |  | 10\nItem 2. |  | Management's Discussion and Analysis of Results of Operations and Financial Condition |  | 32\n |  | Executive Overview |  | 32\n |  | Results of Operations |  | 38\n |  | Financial Condition and Liquidity |  | 41\n |  |  |  | \n |  | Critical Accounting Estimates |  | 41\n |  | Available Information on our Website |  | 42\nItem 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  | 43\nItem 4. |  | Controls and Procedures |  | 43\n |  |  |  | \nPART II. Other Information |  |  |  | 44\n |  |  |  | \nItem 1. |  | Legal Proceedings |  | 44\nItem 1A. |  | Risk Factors |  | 44\nItem 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 44\nItem 6. |  | Exhibits |  | 45\n |  |  |  | \nSignatures |  |  |  | 45  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nRevenue (Note 2) | $ | 6,960.0 |  |  | $ | 7,810.0 |  |  |  |  | \nCosts, expenses, and other: |  |  |  |  |  |  | \nCost of sales | 1,626.7 |  |  | 2,072.1 |  |  |  |  | \nResearch and development | 1,985.1 |  |  | 1,610.1 |  |  |  |  | \nMarketing, selling, and administrative | 1,749.2 |  |  | 1,557.9 |  |  |  |  | \nAcquired in-process research and development (Note 3) | 105.0 |  |  | 165.6 |  |  |  |  | \n |  |  |  |  |  |  | \nOther\u2013net, (income) expense (Note 10) | (35.7) |  |  | 350.7 |  |  |  |  | \n | 5,430.3 |  |  | 5,756.4 |  |  |  |  | \nIncome before income taxes | 1,529.7 |  |  | 2,053.6 |  |  |  |  | \nIncome taxes (Note 6) | 184.8 |  |  | 150.7 |  |  |  |  | \nNet income | $ | 1,344.9 |  |  | $ | 1,902.9 |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nEarnings per share: |  |  |  |  |  |  | \nBasic | $ | 1.49 |  |  | $ | 2.11 |  |  |  |  | \n |  |  |  |  |  |  | \nDiluted | $ | 1.49 |  |  | $ | 2.10 |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nShares used in calculation of earnings per share: |  |  |  |  |  |  | \nBasic | 901.0 |  | 903.7 |  |  |  | \nDiluted | 903.3 |  | 906.4 |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nNet income | $ | 1,344.9 |  |  | $ | 1,902.9 |  |  |  |  | \nOther comprehensive income, net of tax (Note 9) | 67.3 |  |  | 117.8 |  |  |  |  | \nComprehensive income | $ | 1,412.2 |  |  | $ | 2,020.7 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nAssets | (Unaudited) |  | \nCurrent Assets |  |  | \nCash and cash equivalents (Note 5) | $ | 3,545.9 |  |  | $ | 2,067.0 | \nShort-term investments (Note 5) | 123.4 |  |  | 144.8 | \nAccounts receivable, net of allowances of$14.0(2023)and $16.0(2022) | 7,526.2 |  |  | 6,896.0 | \nOther receivables | 1,495.9 |  |  | 1,662.9 | \nInventories | 4,544.8 |  |  | 4,309.7 | \nPrepaid expenses and other current assets | 3,575.2 |  |  | 2,954.1 | \nTotal current assets | 20,811.4 |  |  | 18,034.5 | \nInvestments (Note 5) | 2,750.4 |  |  | 2,901.8 | \nGoodwill | 4,073.1 |  |  | 4,073.0 | \nOther intangibles, net | 7,087.1 |  |  | 7,206.6 | \nDeferred tax assets | 3,406.7 |  |  | 2,792.9 | \nProperty and equipment, net of accumulated depreciation of$10,486.0(2023)and $10,233.4(2022) | 10,546.2 |  |  | 10,144.0 | \nOther noncurrent assets | 4,488.1 |  |  | 4,337.0 | \nTotal assets | $ | 53,163.0 |  |  | $ | 49,489.8 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nShort-term borrowings and current maturities of long-term debt | $ | 3.1 |  |  | $ | 1,501.1 | \nAccounts payable | 2,015.9 |  |  | 1,930.6 | \nEmployee compensation | 739.7 |  |  | 1,059.8 | \nSales rebates and discounts | 9,529.5 |  |  | 8,784.1 | \nDividends payable | \u2014 |  |  | 1,017.2 | \nIncome taxes payable | 1,528.3 |  |  | 475.1 | \nOther current liabilities | 2,193.5 |  |  | 2,370.3 | \nTotal current liabilities | 16,010.0 |  |  | 17,138.2 | \nOther Liabilities |  |  | \nLong-term debt | 18,880.5 |  |  | 14,737.5 | \nAccrued retirement benefits (Note 7) | 1,313.0 |  |  | 1,305.1 | \nLong-term income taxes payable | 3,842.1 |  |  | 3,709.6 | \nOther noncurrent liabilities | 1,822.5 |  |  | 1,824.0 | \nTotal other liabilities | 25,858.1 |  |  | 21,576.2 | \nCommitments and Contingencies (Note 8) |  |  | \nEli Lilly and Company Shareholders' Equity |  |  | \nCommon stock | 593.5 |  |  | 594.1 | \nAdditional paid-in capital | 6,793.1 |  |  | 6,921.4 | \nRetained earnings | 10,639.3 |  |  | 10,042.6 | \nEmployee benefit trust | (3,013.2) |  |  | (3,013.2) | \nAccumulated other comprehensive loss (Note 9) | (3,777.3) |  |  | (3,844.6) | \nCost of common stock in treasury | (45.0) |  |  | (50.5) | \nTotal Eli Lilly and Company shareholders' equity | 11,190.4 |  |  | 10,649.8 | \nNoncontrolling interests | 104.5 |  |  | 125.6 | \nTotal equity | 11,294.9 |  |  | 10,775.4 | \nTotal liabilities and equity | $ | 53,163.0 |  |  | $ | 49,489.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions, except per-share data, and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at January\u00a01, 2022 | 954,116 |  |  | $ | 596.3 |  |  | $ | 6,833.4 |  |  | $ | 8,958.5 |  |  | $ | (3,013.2) |  |  | $ | (4,343.1) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 175.6 | \nNet income (loss) |  |  |  |  |  |  | 1,902.9 |  |  |  |  |  |  |  |  |  |  | (36.6) | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 117.8 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (5,607) |  |  | (3.5) |  |  |  |  | (1,496.5) |  |  |  |  |  |  | (5,607) |  |  | 1,500.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 5,607 |  |  | (1,500.0) |  |  | \nIssuance of stock under employee stock plans, net | 2,096 |  |  | 1.3 |  |  | (278.1) |  |  |  |  |  |  |  |  | (13) |  |  | 2.2 |  |  | \nStock-based compensation |  |  |  |  | 101.0 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | 4.5 |  |  |  |  |  |  |  |  |  |  | (7.8) | \nBalance at March\u00a031, 2022 | 950,605 |  |  | $ | 594.1 |  |  | $ | 6,656.3 |  |  | $ | 9,369.4 |  |  | $ | (3,013.2) |  |  | $ | (4,225.3) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 131.2 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January\u00a01, 2023 | 950,632 |  |  | $ | 594.1 |  |  | $ | 6,921.4 |  |  | $ | 10,042.6 |  |  | $ | (3,013.2) |  |  | $ | (3,844.6) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 125.6 | \nNet income |  |  |  |  |  |  | 1,344.9 |  |  |  |  |  |  |  |  |  |  | 10.0 | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 67.3 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (2,299) |  |  | (1.4) |  |  |  |  | (748.6) |  |  |  |  |  |  | (2,299) |  |  | 750.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 2,299 |  |  | (750.0) |  |  | \nIssuance of stock under employee stock plans, net | 1,336 |  |  | 0.8 |  |  | (259.5) |  |  |  |  |  |  |  |  | (48) |  |  | 8.8 |  |  | \nStock-based compensation |  |  |  |  | 131.2 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | 0.4 |  |  |  |  |  |  |  |  | (3.3) |  |  | (31.1) | \nBalance at March\u00a031, 2023 | 949,669 |  |  | $ | 593.5 |  |  | $ | 6,793.1 |  |  | $ | 10,639.3 |  |  | $ | (3,013.2) |  |  | $ | (3,777.3) |  |  | 402 |  |  | $ | (45.0) |  |  | $ | 104.5 |   |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2023 |  | 2022\nCash Flows from Operating Activities | \nNet income | $ | 1,344.9 |  |  | $ | 1,902.9 | \nAdjustments to Reconcile Net Income to Cash Flows from Operating Activities: |  |  | \n |  |  | \nDepreciation and amortization | 362.3 |  |  | 435.7 | \nChange in deferred income taxes | (559.4) |  |  | (506.6) | \n |  |  | \nStock-based compensation expense | 131.2 |  |  | 101.0 | \n |  |  | \nNet investment losses | 14.2 |  |  | 426.1 | \nAcquired in-process research and development | 105.0 |  |  | 165.6 | \nOther changes in operating assets and liabilities, net of acquisitions and divestitures | 164.1 |  |  | (34.3) | \nOther operating activities, net | 168.3 |  |  | 32.6 | \nNet Cash Provided by Operating Activities | 1,730.6 |  |  | 2,523.0 | \nCash Flows from Investing Activities |  |  | \nPurchases of property and equipment | (668.5) |  |  | (365.4) | \nProceeds from sales and maturities of short-term investments | 61.5 |  |  | 26.7 | \nPurchases of short-term investments | (23.0) |  |  | (14.6) | \nProceeds from sales of and distributions from noncurrent investments | 281.9 |  |  | 81.4 | \nPurchases of noncurrent investments | (146.0) |  |  | (116.7) | \n |  |  | \n |  |  | \nPurchases of in-process research and development | (235.0) |  |  | (515.6) | \nOther investing activities, net | 40.3 |  |  | (133.4) | \nNet Cash Used for Investing Activities | (688.8) |  |  | (1,037.6) | \nCash Flows from Financing Activities |  |  | \nDividends paid | (1,017.2) |  |  | (885.5) | \nNet change in short-term borrowings | (1,498.0) |  |  | 499.7 | \nProceeds from issuance of long-term debt | 3,958.5 |  |  | \u2014 | \nRepayments of long-term debt | \u2014 |  |  | (710.1) | \nPurchases of common stock | (750.0) |  |  | (1,500.0) | \n |  |  | \nOther financing activities, net | (281.0) |  |  | (282.4) | \nNet Cash Provided by (Used for) Financing Activities | 412.3 |  |  | (2,878.3) | \nEffect of exchange rate changes on cash and cash equivalents | 24.8 |  |  | 33.6 | \n |  |  | \nNet increase (decrease) in cash and cash equivalents | 1,478.9 |  |  | (1,359.3) | \nCash and cash equivalents at January\u00a01 | 2,067.0 |  |  | 3,818.5 | \nCash and Cash Equivalents at March 31 | $ | 3,545.9 |  |  | $ | 2,459.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nNet product revenue | $ | 6,238.2 |  |  | $ | 7,132.9 |  |  |  |  | \nCollaboration and other revenue(1) | 721.8 |  |  | 677.1 |  |  |  |  | \nRevenue | $ | 6,960.0 |  |  | $ | 7,810.0 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nContract liabilities | $ | 220.3 |  |  | $ | 219.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31,\n | 2023 |  | 2022\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\nRevenue\u2014to unaffiliated customers: |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity\u00ae | $ | 1,547.4 |  | $ | 429.7 |  | $ | 1,977.1 |  |  | $ | 1,313.9 |  | $ | 427.4 |  | $ | 1,741.3 | \nJardiance(1) | 329.4 |  | 248.1 |  | 577.5 |  |  | 229.8 |  | 189.7 |  | 419.4 | \nMounjaro\u00ae | 536.4 |  | 32.0 |  | 568.5 |  |  | \u2014 |  | \u2014 |  | \u2014 | \nHumalog\u00ae (2) | 271.6 |  | 189.3 |  | 460.9 |  |  | 368.9 |  | 249.3 |  | 618.2 | \nHumulin\u00ae | 198.8 |  | 53.2 |  | 252.0 |  |  | 190.4 |  | 82.8 |  | 273.2 | \nBasaglar\u00ae | 135.4 |  | 73.9 |  | 209.3 |  |  | 119.3 |  | 72.2 |  | 191.5 | \nOther diabetes | 56.0 |  | 89.2 |  | 145.1 |  |  | 54.3 |  | 90.2 |  | 144.6 | \nTotal diabetes | 3,075.0 |  | 1,115.4 |  | 4,190.4 |  |  | 2,276.6 |  | 1,111.6 |  | 3,388.2 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio\u00ae | 461.1 |  | 289.8 |  | 750.9 |  |  | 301.5 |  | 167.9 |  | 469.4 | \nCyramza\u00ae | 100.6 |  | 136.1 |  | 236.8 |  |  | 79.2 |  | 151.1 |  | 230.3 | \nErbitux\u00ae | 118.8 |  | 11.1 |  | 129.9 |  |  | 109.7 |  | 13.0 |  | 122.7 | \nAlimta\u00ae | 20.1 |  | 38.1 |  | 58.2 |  |  | 254.3 |  | 89.7 |  | 343.9 | \nOther oncology | 52.8 |  | 127.5 |  | 180.2 |  |  | 39.0 |  | 147.5 |  | 186.7 | \nTotal oncology | 753.4 |  | 602.6 |  | 1,356.0 |  |  | 783.7 |  | 569.2 |  | 1,353.0 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz\u00ae | 312.2 |  | 214.8 |  | 527.0 |  |  | 307.2 |  | 180.8 |  | 488.1 | \nOlumiant\u00ae (3) | 42.3 |  | 186.5 |  | 228.9 |  |  | 71.3 |  | 184.3 |  | 255.6 | \nOther immunology | \u2014 |  | 22.0 |  | 22.0 |  |  | \u2014 |  | 4.5 |  | 4.5 | \nTotal immunology | 354.5 |  | 423.3 |  | 777.8 |  |  | 378.5 |  | 369.6 |  | 748.1 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nEmgality\u00ae | 108.7 |  | 45.6 |  | 154.3 |  |  | 108.3 |  | 41.0 |  | 149.3 | \n |  |  |  |  |  |  | \nOther neuroscience | 35.8 |  | 170.4 |  | 206.2 |  |  | 45.1 |  | 203.4 |  | 248.4 | \nTotal neuroscience | 144.5 |  | 216.0 |  | 360.5 |  |  | 153.4 |  | 244.4 |  | 397.7 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nForteo\u00ae | 70.7 |  | 51.7 |  | 122.3 |  |  | 70.2 |  | 67.3 |  | 137.4 | \nCialis\u00ae | 7.6 |  | 92.7 |  | 100.3 |  |  | 6.9 |  | 210.8 |  | 217.7 | \nCOVID-19 antibodies(4) | \u2014 |  | \u2014 |  | \u2014 |  |  | 1,455.2 |  | 14.7 |  | 1,469.8 | \nOther | 30.5 |  | 22.2 |  | 52.8 |  |  | 50.1 |  | 47.8 |  | 98.1 | \nTotal other | 108.7 |  | 166.6 |  | 275.3 |  |  | 1,582.4 |  | 340.6 |  | 1,923.0 | \nRevenue | $ | 4,436.2 |  | $ | 2,523.9 |  | $ | 6,960.0 |  |  | $ | 5,174.6 |  | $ | 2,635.4 |  | $ | 7,810.0 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nRevenue\u2014to unaffiliated customers(1): |  |  |  |  |  |  | \nU.S. | $ | 4,436.2 |  |  | $ | 5,174.6 |  |  |  |  | \nEurope | 1,090.9 |  |  | 1,067.3 |  |  |  |  | \nJapan | 387.2 |  |  | 410.2 |  |  |  |  | \nChina | 372.7 |  |  | 406.5 |  |  |  |  | \nOther foreign countries | 673.1 |  |  | 751.5 |  |  |  |  | \nRevenue | $ | 6,960.0 |  |  | $ | 7,810.0 |  |  |  |  |   |  |  |  |  | \nEstimated Fair Value at December 1, 2022 | \nCash | $ | 153.2 | \nAcquired IPR&D(1) | 184.0\nGoodwill(2) | 181.2\n | \nOther assets and liabilities, net | 28.9 | \nAcquisition date fair value of consideration transferred | 547.3\nLess: | \nCash acquired | (153.2) | \nFair value of CVR liability(3) | (66.9) | \nCash paid, net of cash acquired | $ | 327.2 |   |  |  |  |  |  |  |  | \n | Net Milestones Capitalized (Deferred)(1)\n | March 31, 2023 | December 31, 2022\nJardiance | $ | 111.2 |  | $ | 116.2 | \nTrajenta | 57.3 |  | 63.5 | \nBasaglar | (126.0) |  | (130.6) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nJardiance | $ | 577.5 |  |  | $ | 419.4 |  |  |  |  | \nBasaglar | 209.3 |  |  | 191.5 |  |  |  |  | \nTrajenta | 85.8 |  |  | 92.0 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nOlumiant | $ | 228.9 |  |  | $ | 255.6 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturities by Period\n | Total |  | Less\u00a0Than1 Year |  | 1-5Years |  | 6-10Years |  | More\u00a0Than10 Years\nFair value of debt securities | $ | 648.1 |  |  | $ | 76.0 |  |  | $ | 219.4 |  |  | $ | 115.5 |  |  | $ | 237.2 |   |  |  |  |  |  |  |  |  |  |  | \n | March 31, 2023 |  | December 31, 2022\nUnrealized gross gains | $ | 1.8 |  |  | $ | 0.6 | \nUnrealized gross losses | 39.0 |  |  | 49.2 | \nFair value of securities in an unrealized gain position | 120.5 |  |  | 46.8 | \nFair value of securities in an unrealized loss position | 512.4 |  |  | 568.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nProceeds from sales | $ | 27.6 |  |  | $ | 35.2 |  |  |  |  | \nRealized gross gains on sales | 0.2 |  |  | 0.1 |  |  |  |  | \nRealized gross losses on sales | 0.7 |  |  | 0.8 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Cost(1) |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | Significant OtherObservable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nMarch 31, 2023 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents(2) | $ | 2,343.1 |  |  | $ | 2,343.1 |  |  | $ | 2,330.2 |  |  | $ | 12.9 |  |  | $ | \u2014 |  |  | $ | 2,343.1 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 23.1 |  |  | $ | 23.5 |  |  | $ | 23.1 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 23.1 | \nCorporate debt securities | 50.1 |  |  | 50.2 |  |  | \u2014 |  |  | 50.1 |  |  | \u2014 |  |  | 50.1 | \n |  |  |  |  |  |  |  |  |  |  | \nAsset-backed securities | 2.8 |  |  | 2.8 |  |  | \u2014 |  |  | 2.8 |  |  | \u2014 |  |  | 2.8 | \nOther securities | 47.4 |  |  | 47.4 |  |  | \u2014 |  |  | 28.0 |  |  | 19.4 |  |  | 47.4 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 123.4 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 145.2 |  |  | $ | 157.5 |  |  | $ | 145.2 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 145.2 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities | 214.8 |  |  | 232.5 |  |  | \u2014 |  |  | 214.8 |  |  | \u2014 |  |  | 214.8 | \nMortgage-backed securities | 155.3 |  |  | 165.2 |  |  | \u2014 |  |  | 155.3 |  |  | \u2014 |  |  | 155.3 | \nAsset-backed securities | 56.8 |  |  | 58.2 |  |  | \u2014 |  |  | 56.8 |  |  | \u2014 |  |  | 56.8 | \nOther securities | 204.0 |  |  | 22.7 |  |  | \u2014 |  |  | 113.8 |  |  | 90.2 |  |  | 204.0 | \nMarketable equity securities | 624.0 |  |  | 475.6 |  |  | 624.0 |  |  | \u2014 |  |  | \u2014 |  |  | 624.0 | \nEquity investments without readily determinable fair values(3) | 516.6 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(3) | 833.7 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 2,750.4 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents(2) | $ | 657.4 |  |  | $ | 657.4 |  |  | $ | 650.4 |  |  | $ | 7.0 |  |  | $ | \u2014 |  |  | $ | 657.4 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 30.8 |  |  | $ | 31.1 |  |  | $ | 30.8 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 30.8 | \nCorporate debt securities | 53.4 |  |  | 53.5 |  |  | \u2014 |  |  | 53.4 |  |  | \u2014 |  |  | 53.4 | \n |  |  |  |  |  |  |  |  |  |  | \nAsset-backed securities | 2.0 |  |  | 2.0 |  |  | \u2014 |  |  | 2.0 |  |  | \u2014 |  |  | 2.0 | \nOther securities | 58.6 |  |  | 58.6 |  |  | \u2014 |  |  | 39.1 |  |  | 19.5 |  |  | 58.6 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 144.8 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 146.4 |  |  | $ | 163.2 |  |  | $ | 146.4 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 146.4 | \nCorporate debt securities | 213.9 |  |  | 235.8 |  |  | \u2014 |  |  | 213.9 |  |  | \u2014 |  |  | 213.9 | \nMortgage-backed securities | 149.2 |  |  | 161.5 |  |  | \u2014 |  |  | 149.2 |  |  | \u2014 |  |  | 149.2 | \nAsset-backed securities | 50.6 |  |  | 52.5 |  |  | \u2014 |  |  | 50.6 |  |  | \u2014 |  |  | 50.6 | \nOther securities | 398.6 |  |  | 34.5 |  |  | \u2014 |  |  | 311.0 |  |  | 87.6 |  |  | 398.6 | \nMarketable equity securities | 683.6 |  |  | 484.7 |  |  | 683.6 |  |  | \u2014 |  |  | \u2014 |  |  | 683.6 | \nEquity investments without readily determinable fair values(3) | 478.4 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(3) | 781.1 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 2,901.8 |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nShort-term commercial paper borrowings |  |  |  |  |  |  |  |  | \nMarch 31, 2023 | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nDecember 31, 2022 | (1,498.0) |  |  | \u2014 |  |  | (1,492.0) |  |  | \u2014 |  |  | (1,492.0) | \nLong-term debt, including current portion |  |  |  |  |  |  |  |  | \nMarch 31, 2023 | $ | (18,883.6) |  |  | $ | \u2014 |  |  | $ | (16,654.6) |  |  | $ | \u2014 |  |  | $ | (16,654.6) | \nDecember 31, 2022 | (14,740.6) |  |  | \u2014 |  |  | (12,329.3) |  |  | \u2014 |  |  | (12,329.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nMarch 31, 2023\nPurchase |  | Sell\nCurrency | Amount(in millions) |  | Currency | Amount(in millions)\nU.S. dollars | 2,410.5 |  | Euro | 2,231.4\nEuro | 3,667.4 |  | U.S. dollars | 3,948.6\nU.S. dollars | 229.8 |  | Chinese yuan | 1,574.7\n |  |  |  | \n |  |  |  | \nBritish pounds | 216.7 |  | U.S. dollars | 265.8\n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nFair value hedges: |  |  |  |  |  |  | \nEffect from hedged fixed-rate debt | $ | 35.3 |  |  | $ | (94.6) |  |  |  |  | \nEffect from interest rate contracts | (35.3) |  |  | 94.6 |  |  |  |  | \nCash flow hedges: |  |  |  |  |  |  | \nEffective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss | 3.8 |  |  | 4.1 |  |  |  |  | \nCross-currency interest rate swaps | (12.9) |  |  | 8.3 |  |  |  |  | \nNet gains on foreign currency exchange contracts not designated as hedging instruments | (52.8) |  |  | (6.1) |  |  |  |  | \nTotal | $ | (61.9) |  |  | $ | 6.3 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nNet investment hedges: |  |  |  |  |  |  | \nForeign currency-denominated notes | $ | (131.8) |  |  | $ | 54.4 |  |  |  |  | \nCross-currency interest rate swaps | (11.8) |  |  | 10.8 |  |  |  |  | \nForeign currency forward contracts | (46.1) |  |  | \u2014 |  |  |  |  | \nCash flow hedges: |  |  |  |  |  |  | \nForward-starting interest rate swaps | 23.8 |  |  | 122.5 |  |  |  |  | \nCross-currency interest rate swaps | (7.8) |  |  | 17.1 |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  |  |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue |  | \nMarch 31, 2023 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | $ | 2.7 |  |  | $ | \u2014 |  |  | $ | 2.7 |  |  | $ | \u2014 |  |  | $ | 2.7 |  |  | \nOther current liabilities | (9.9) |  |  | \u2014 |  |  | (9.9) |  |  | \u2014 |  |  | (9.9) |  |  | \nOther noncurrent liabilities | (91.8) |  |  | \u2014 |  |  | (91.8) |  |  | \u2014 |  |  | (91.8) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 228.6 |  |  | \u2014 |  |  | 228.6 |  |  | \u2014 |  |  | 228.6 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 55.6 |  |  | \u2014 |  |  | 55.6 |  |  | \u2014 |  |  | 55.6 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 58.2 |  |  | \u2014 |  |  | 58.2 |  |  | \u2014 |  |  | 58.2 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 0.9 |  |  | \u2014 |  |  | 0.9 |  |  | \u2014 |  |  | 0.9 |  |  | \nOther current liabilities | (13.1) |  |  | \u2014 |  |  | (13.1) |  |  | \u2014 |  |  | (13.1) |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 63.7 |  |  | \u2014 |  |  | 63.7 |  |  | \u2014 |  |  | 63.7 |  |  | \nOther current liabilities | (32.0) |  |  | \u2014 |  |  | (32.0) |  |  | \u2014 |  |  | (32.0) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nContingent consideration liabilities: |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | (40.1) |  |  | \u2014 |  |  | \u2014 |  |  | (40.1) |  |  | (40.1) |  |  | \nOther noncurrent liabilities | (71.8) |  |  | \u2014 |  |  | \u2014 |  |  | (71.8) |  |  | (71.8) |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  |  |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue |  | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | $ | (134.3) |  |  | $ | \u2014 |  |  | $ | (134.3) |  |  | $ | \u2014 |  |  | $ | (134.3) |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 162.9 |  |  | \u2014 |  |  | 162.9 |  |  | \u2014 |  |  | 162.9 |  |  | \nOther noncurrent assets | 246.0 |  |  | \u2014 |  |  | 246.0 |  |  | \u2014 |  |  | 246.0 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 67.6 |  |  | \u2014 |  |  | 67.6 |  |  | \u2014 |  |  | 67.6 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 53.1 |  |  | \u2014 |  |  | 53.1 |  |  | \u2014 |  |  | 53.1 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | (38.3) |  |  | \u2014 |  |  | (38.3) |  |  | \u2014 |  |  | (38.3) |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 26.6 |  |  | \u2014 |  |  | 26.6 |  |  | \u2014 |  |  | 26.6 |  |  | \nOther current liabilities | (21.5) |  |  | \u2014 |  |  | (21.5) |  |  | \u2014 |  |  | (21.5) |  |  | \nContingent consideration liabilities: |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | (39.5) |  |  | \u2014 |  |  | \u2014 |  |  | (39.5) |  |  | (39.5) |  |  | \nOther noncurrent liabilities | (70.6) |  |  | \u2014 |  |  | \u2014 |  |  | (70.6) |  |  | (70.6) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Defined Benefit Pension Plans\n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nComponents of net periodic (benefit) cost: |  |  |  |  |  |  | \nService cost | $ | 70.4 |  |  | $ | 89.1 |  |  |  |  | \nInterest cost | 161.1 |  |  | 100.5 |  |  |  |  | \nExpected return on plan assets | (263.3) |  |  | (239.5) |  |  |  |  | \nAmortization of prior service cost | 0.6 |  |  | 0.7 |  |  |  |  | \nRecognized actuarial loss | 30.0 |  |  | 87.0 |  |  |  |  | \n |  |  |  |  |  |  | \nNet periodic (benefit) cost | $ | (1.2) |  |  | $ | 37.8 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Retiree Health Benefit Plans\n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nComponents of net periodic benefit: |  |  |  |  |  |  | \nService cost | $ | 7.7 |  |  | $ | 11.2 |  |  |  |  | \nInterest cost | 15.4 |  |  | 9.4 |  |  |  |  | \nExpected return on plan assets | (45.5) |  |  | (37.9) |  |  |  |  | \nAmortization of prior service benefit | (13.2) |  |  | (13.7) |  |  |  |  | \nRecognized actuarial (gain) loss | (0.9) |  |  | 0.2 |  |  |  |  | \n |  |  |  |  |  |  | \nNet periodic benefit | $ | (36.5) |  |  | $ | (30.8) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at January\u00a01, 2023 | $ | (1,874.2) |  |  | $ | (37.1) |  |  | $ | (2,062.3) |  |  | $ | 129.0 |  |  |  |  | $ | (3,844.6) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | 72.8 |  |  | 8.1 |  |  | (16.8) |  |  | 12.7 |  |  |  |  | 76.8 | \nNet amount reclassified from accumulated other comprehensive loss | (25.2) |  |  | 0.7 |  |  | 13.0 |  |  | 2.0 |  |  |  |  | (9.5) | \nNet other comprehensive income (loss) | 47.6 |  |  | 8.8 |  |  | (3.8) |  |  | 14.7 |  |  |  |  | 67.3 | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at March\u00a031, 2023 | $ | (1,826.6) |  |  | $ | (28.3) |  |  | $ | (2,066.1) |  |  | $ | 143.7 |  |  |  |  | $ | (3,777.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at January\u00a01, 2022 | $ | (1,550.2) |  |  | $ | 3.7 |  |  | $ | (2,583.6) |  |  | $ | (213.0) |  |  |  |  | $ | (4,343.1) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (25.0) |  |  | (21.3) |  |  | (6.6) |  |  | 109.4 |  |  |  |  | 56.5 | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | (0.5) |  |  | 58.6 |  |  | 3.2 |  |  |  |  | 61.3 | \nNet other comprehensive income (loss) | (25.0) |  |  | (21.8) |  |  | 52.0 |  |  | 112.6 |  |  |  |  | 117.8 | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at March\u00a031, 2022 | $ | (1,575.2) |  |  | $ | (18.1) |  |  | $ | (2,531.6) |  |  | $ | (100.4) |  |  |  |  | $ | (4,225.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \nTax benefit (expense) | 2023 |  | 2022 |  |  |  | \nForeign currency translation gains/losses | $ | 46.5 |  |  | $ | (13.7) |  |  |  |  | \nNet unrealized gains/losses on available-for-sale securities | (2.6) |  |  | 6.7 |  |  |  |  | \nDefined benefit pension and retiree health benefit plans | (4.0) |  |  | (28.4) |  |  |  |  | \nNet unrealized gains/losses on cash flow hedges | (3.9) |  |  | (29.9) |  |  |  |  | \nBenefit (expense) for income taxes allocated to other comprehensive income (loss) items | $ | 36.0 |  |  | $ | (65.3) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDetails about Accumulated Other Comprehensive Loss Components |  | Three Months Ended March 31, |  |  | Affected Line Item in the Consolidated Condensed Statements of Operations\n\n | 2023 |  | 2022 |  |  |  | \nAmortization of retirement benefit items: |  |  |  |  |  |  |  |  | \nPrior service benefits, net |  | $ | (12.6) |  |  | $ | (13.0) |  |  |  |  |  | Other\u2013net, (income) expense\nActuarial losses, net |  | 29.1 |  |  | 87.2 |  |  |  |  |  | Other\u2013net, (income) expense\nTotal before tax |  | 16.5 |  |  | 74.2 |  |  |  |  |  | \nTax benefit |  | (3.5) |  |  | (15.6) |  |  |  |  |  | Income taxes\nNet of tax |  | 13.0 |  |  | 58.6 |  |  |  |  |  | \n |  |  |  |  |  |  |  |  | \nOther, net of tax |  | (22.5) |  |  | 2.7 |  |  |  |  |  | Other\u2013net, (income) expense\n |  |  |  |  |  |  |  |  | \nTotal reclassifications, net of tax |  | $ | (9.5) |  |  | $ | 61.3 |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 |  | 2022 |  |  |  | \nInterest expense | $ | 102.8 |  |  | $ | 84.9 |  |  |  |  | \nInterest income | (34.2) |  |  | (7.0) |  |  |  |  | \nNet investment losses on equity securities (Note 5) | 13.7 |  |  | 425.4 |  |  |  |  | \nRetirement benefit plans | (115.8) |  |  | (93.3) |  |  |  |  | \n |  |  |  |  |  |  | \nOther (income) expense | (2.2) |  |  | (59.3) |  |  |  |  | \nOther\u2013net, (income) expense | $ | (35.7) |  |  | $ | 350.7 |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | Percent Change |  |  |  |  |  | \nRevenue | $ | 6,960.0 |  |  | $ | 7,810.0 |  |  | (11) |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNet income | 1,344.9 |  |  | 1,902.9 |  |  | (29) |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nEarnings per share - diluted | 1.49 |  |  | 2.10 |  |  | (29) |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nDiabetes and Obesity | \n |  |  |  | \nEmpagliflozin (Jardiance\u00ae)(1) | Chronic kidney disease | Submitted | Granted U.S. Food and Drug Administration (FDA) Fast Track designation(2). Submitted in Japan in 2022 and in the U.S. and Europe in the first quarter of 2023. | \nTirzepatide (Mounjaro) | Obesity | Submitted | Submitted in Europe in the first quarter of 2023. Granted FDA Fast Track designation(2). Initiated a rolling submission in the U.S. in 2022. Announced in April 2023 that a Phase III trial met co-primary and all key secondary endpoints. Phase III trials are ongoing. | \nHeart failure with preserved ejection fraction | Phase III | Phase III trials are ongoing. | \nObstructive sleep apnea | Phase III | Granted FDA Fast Track designation(2). Phase III trial is ongoing. | \nNonalcoholic steatohepatitis | Phase II | Phase II trial is ongoing. | \nInsulin Efsitora Alfa(Basal Insulin-Fc) | Type 1 and 2 diabetes | Phase III | Phase III trials are ongoing. | \nLP(a) siRNA | Cardiovascular disease | Phase II | Phase II trial is ongoing. | \nMuvalaplin(LP(a) Inhibitor) | Cardiovascular disease | Phase II | Phase II trial is ongoing. | \nOrforglipron | Obesity | Phase II | Phase II trials were completed. | \nType 2 diabetes | \nRelaxin-LA | Heart failure | Phase II | Phase II trial initiated in the first quarter of 2023. | \nRetatrutide | Obesity | Phase II | Phase II trials were completed. | \nType 2 diabetes | \nSolbinsiran(ANGPTL3 siRNA) | Cardiovascular disease | Phase II | Phase II trial is ongoing. |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nImmunology | \nMirikizumab(Omvoh\u00ae) | Ulcerative colitis | Approved | Approved in Japan in the first quarter of 2023. Submitted in the U.S. and Europe in 2022. Received a complete response letter from the FDA in April 2023. Received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe in the first quarter of 2023. | \nCrohn's Disease | Phase III | Phase III trials are ongoing. | \nLebrikizumab(3) | Atopic dermatitis | Submitted | Submitted in the U.S. and Europe in 2022 and in Japan in the first quarter of 2023. Phase III trials are ongoing. | \nBTLA MAB Agonist | Systemic lupus erythematosus | Phase II | Phase II trial is ongoing. | \nEltrekibart(CXCR1/2 Ligands Monoclonal Antibody) | Hidradenitis suppurativa | Phase II | Phase II trial is ongoing. | \nPeresolimab | Rheumatoid arthritis | Phase II | Phase II trial is ongoing. | \nRezpegaldesleukin | Systemic lupus erythematosus | Discontinued | Phase II trial failed to meet primary endpoint in the first quarter of 2023. | \n |  |  | \nNeuroscience | \nDonanemab | Early Alzheimer's disease | Complete Response Letter | Granted FDA Breakthrough Therapy designation(4). Submitted in the U.S. in 2022 under the accelerated approval pathway. Received a complete response letter from the FDA in the first quarter of 2023 for the accelerated approval submission. Phase III trials are ongoing. | \nPreclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nRemternetug | Early Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nGBA1 Gene Therapy (PR001) | Gaucher disease Type 1 | Phase II | Phase II trial initiated in April 2023. | \nParkinson's disease | Phase II | Granted FDA Fast Track designation(2). Phase II trial is ongoing. | \nGRN Gene Therapy (PR006) | Frontotemporal dementia | Phase II | Granted FDA Fast Track designation(2). Phase II trial is ongoing. | \nO-GlcNAcase Inh | Alzheimer's disease | Phase II | Phase II trial is ongoing. | \nP2X7 Inhibitor | Pain | Phase II | Phase II trials are ongoing. | \nSSTR4 Agonist | Pain | Phase II | Phase II trials are ongoing. | \nSolanezumab | Preclinical Alzheimer's disease | Discontinued | Phase III trial failed to meet primary and secondary endpoints in the first quarter of 2023. | \nTRPA1 Antagonist | Pain | Discontinued | Phase II trials discontinued in the first quarter of 2023. |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nOncology | \nPirtobrutinib(Jaypirca\u00ae) | Mantle cell lymphoma | Approved(5) | FDA granted accelerated approval(5)in the U.S. in the first quarter of 2023. Submitted in Europe in 2022. Received a positive opinion from the CHMP in Europe in April 2023. Phase III trial is ongoing. | \nChronic lymphocytic leukemia | Phase III | Phase III trials are ongoing. | \nB-cell malignancies | Phase II | Phase II trial is ongoing. | \nSelpercatinib (Retevmo\u00ae) | Lung cancer | Approved(5) | Phase III trials are ongoing. | \nThyroid cancer | Approved(5) | Phase III trial is ongoing. | \nAbemaciclib (Verzenio\u00ae) | Prostate cancer | Phase III | Phase III trials are ongoing. | \nImlunestrant | Adjuvant breast cancer | Phase III | Phase III trial is ongoing. | \nER+HER2- metastatic breast cancer | Phase III | Phase III trial is ongoing. |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  | \n | 2023 |  | 2022 |  | Percent Change |  |  |  |  | \nU.S. | $ | 4,436.2 |  |  | $ | 5,174.6 |  |  | (14) |  |  |  |  | \nOutside U.S. | 2,523.9 |  |  | 2,635.4 |  |  | (4) |  |  |  |  | \nRevenue | $ | 6,960.0 |  |  | $ | 7,810.0 |  |  | (11) |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | \n | 2023 vs. 2022 |  | \n | U.S. | Outside U.S. | Consolidated |  |  |  | \nVolume | (10) | % | 7 | % | (4) | % |  |  |  | \nPrice | (5) |  | (5) |  | (5) |  |  |  |  | \nForeign exchange rates | \u2014 |  | (6) |  | (2) |  |  |  |  | \nPercent change | (14) | % | (4) | % | (11) | % |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  | Percent Change | \n | 2023 |  | 2022 | \nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | \nTrulicity | $ | 1,547.4 |  |  | $ | 429.7 |  |  | $ | 1,977.1 |  |  | $ | 1,741.3 |  |  | 14 | \nVerzenio | 461.1 |  |  | 289.8 |  |  | 750.9 |  |  | 469.4 |  |  | 60 | \nJardiance(1) | 329.4 |  |  | 248.1 |  |  | 577.5 |  |  | 419.4 |  |  | 38 | \nMounjaro | 536.4 |  |  | 32.0 |  |  | 568.5 |  |  | \u2014 |  |  | NM | \nTaltz | 312.2 |  |  | 214.8 |  |  | 527.0 |  |  | 488.1 |  |  | 8 | \nHumalog(2) | 271.6 |  |  | 189.3 |  |  | 460.9 |  |  | 618.2 |  |  | (25) | \nHumulin\u00ae | 198.8 |  |  | 53.2 |  |  | 252.0 |  |  | 273.2 |  |  | (8) | \nCyramza\u00ae | 100.6 |  |  | 136.1 |  |  | 236.8 |  |  | 230.3 |  |  | 3 | \nOlumiant\u00ae (3) | 42.3 |  |  | 186.5 |  |  | 228.9 |  |  | 255.6 |  |  | (10) | \nBasaglar\u00ae | 135.4 |  |  | 73.9 |  |  | 209.3 |  |  | 191.5 |  |  | 9 | \nEmgality\u00ae | 108.7 |  |  | 45.6 |  |  | 154.3 |  |  | 149.3 |  |  | 3 | \nErbitux\u00ae | 118.8 |  |  | 11.1 |  |  | 129.9 |  |  | 122.7 |  |  | 6 | \nForteo\u00ae | 70.7 |  |  | 51.7 |  |  | 122.3 |  |  | 137.4 |  |  | (11) | \nCialis | 7.6 |  |  | 92.7 |  |  | 100.3 |  |  | 217.7 |  |  | (54) | \nAlimta | 20.1 |  |  | 38.1 |  |  | 58.2 |  |  | 343.9 |  |  | (83) | \nCOVID-19 antibodies(4) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1,469.8 |  |  | (100) | \nOther products | 175.1 |  |  | 431.3 |  |  | 606.1 |  |  | 682.2 |  |  | (11) | \nRevenue | $ | 4,436.2 |  |  | $ | 2,523.9 |  |  | $ | 6,960.0 |  |  | $ | 7,810.0 |  |  | (11) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended March 31, |  |  |  |  |  | \n | 2023 |  | 2022 |  | Percent Change |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nGross margin | $ | 5,333.3 |  |  | $ | 5,737.9 |  |  | (7) |  |  |  |  |  | \nGross margin as a percent of revenue | 76.6 | % |  | 73.5 | % |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nResearch and development | $ | 1,985.1 |  |  | $ | 1,610.1 |  |  | 23 |  |  |  |  |  | \nMarketing, selling, and administrative | 1,749.2 |  |  | 1,557.9 |  |  | 12 |  |  |  |  |  | \nAcquired in-process research and development (IPR&D) | 105.0 |  |  | 165.6 |  |  | (37) |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther\u2013net, (income) expense | (35.7) |  |  | 350.7 |  |  | NM |  |  |  |  |  | \nIncome taxes | 184.8 |  |  | 150.7 |  |  | 23 |  |  |  |  |  | \nEffective tax rate | 12.1 | % |  | 7.3 | % |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | Total Number ofShares Purchased(in thousands) |  | Average\u00a0Price Paidper Share |  | Total\u00a0Number of SharesPurchased\u00a0as Part ofPublicly AnnouncedPlans or Programs(in thousands) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(in millions)\nJanuary 2023 | \u2014 |  |  | $ | \u2014 |  |  | \u2014 |  |  | $ | 3,250.0 | \nFebruary 2023 | 1,210 |  |  | 326.24 |  |  | 1,210 |  |  | 2,855.4 | \nMarch 2023 | 1,089 |  |  | 326.34 |  |  | 1,089 |  |  | 2,500.0 | \nTotal | 2,299 |  |  | 326.29 |  |  | 2,299 |  |  |   |  |  |  |  |  |  |  | \nExhibit |  | Description\n3.1 |  | Amended Articles of Incorporation,incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \n3.2 |  | Bylaws, as amended,incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \n31.1 |  | Rule\u00a013a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer*\n |  | \n31.2 |  | Rule\u00a013a-14(a) Certification of Anat Ashkenazi, Executive Vice President and Chief Financial Officer*\n | \n32 |  | Section 1350 Certification*\n |  | \n101 |  | Interactive Data Files (embedded within the Inline XBRL document)*\n |  | \n104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*\n\n* Filed herewith.  |  |  |  |  |  |  |  | \n |  | ELI LILLY AND COMPANY\n |  | (Registrant)\n |  | \nDate: | April 27, 2023 | /s/ Anat Ashkenazi\n |  | Anat Ashkenazi\n |  | Executive Vice President and Chief Financial Officer\nDate: | April 27, 2023 | /s/ Donald Zakrowski\n |  | Donald Zakrowski\n |  | Senior Vice President, Finance, and Chief Accounting Officer"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Eli Lilly, in 2023 Q2, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \nIndiana |  | 35-0470950\n(State or other jurisdiction of |  | (I.R.S. Employer\nincorporation or organization) |  | Identification No.)  |  |  |  |  |  |  |  | \nTitle of Each Class | Trading Symbols | Name of Each Exchange On Which Registered\nCommon Stock (no par value) | LLY | New York Stock Exchange\n7 1/8% Notes due 2025 | LLY25 | New York Stock Exchange\n1.625% Notes due 2026 | LLY26 | New York Stock Exchange\n2.125% Notes due 2030 | LLY30 | New York Stock Exchange\n0.625% Notes due 2031 | LLY31 | New York Stock Exchange\n0.500% Notes due 2033 | LLY33 | New York Stock Exchange\n6.77%\u00a0Notes due 2036 | LLY36 | New York Stock Exchange\n1.625% Notes due 2043 | LLY43 | New York Stock Exchange\n1.700% Notes due 2049 | LLY49A | New York Stock Exchange\n1.125% Notes due 2051 | LLY51 | New York Stock Exchange\n1.375% Notes due 2061 | LLY61 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  |  |  |  | Accelerated\u00a0filer | \u2610\nNon-accelerated filer | \u2610 |  |  | Smaller reporting company | \u2610\n |  |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  | \nClass |  | Number of Shares Outstanding\nCommon |  | 949,295,173 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\nPART I. Financial Information |  |  |  | 5\n |  |  |  | \nItem 1. |  | Financial Statements |  | 5\n |  | Consolidated Condensed Statements of Operations |  | 5\n |  | Consolidated Condensed Statements of Comprehensive Income |  | 6\n |  | Consolidated Condensed Balance Sheets |  | 7\n |  | Consolidated Condensed Statements of Equity |  | 8\n |  | Consolidated Condensed Statements of Cash Flows |  | 10\n |  | Notes to Consolidated Condensed Financial Statements |  | 11\nItem 2. |  | Management's Discussion and Analysis of Results of Operations and Financial Condition |  | 36\n |  | Executive Overview |  | 36\n |  | Results of Operations |  | 42\n |  | Financial Condition and Liquidity |  | 46\n |  |  |  | \n |  | Critical Accounting Estimates |  | 47\n |  | Available Information on our Website |  | 47\nItem 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  | 48\nItem 4. |  | Controls and Procedures |  | 48\n |  |  |  | \nPART II. Other Information |  |  |  | 49\n |  |  |  | \nItem 1. |  | Legal Proceedings |  | 49\nItem 1A. |  | Risk Factors |  | 49\nItem 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 49\nItem 5. |  | Other Information |  | 49\nItem 6. |  | Exhibits |  | 50\n |  |  |  | \nSignatures |  |  |  | 50  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue (Note 2) | $ | 8,312.1 |  |  | $ | 6,488.0 |  |  | $ | 15,272.1 |  |  | $ | 14,298.0 | \nCosts, expenses, and other: |  |  |  |  |  |  | \nCost of sales | 1,807.4 |  |  | 1,430.5 |  |  | 3,434.1 |  |  | 3,502.6 | \nResearch and development | 2,356.5 |  |  | 1,781.9 |  |  | 4,341.6 |  |  | 3,392.0 | \nMarketing, selling, and administrative | 1,925.4 |  |  | 1,625.1 |  |  | 3,674.6 |  |  | 3,183.0 | \nAcquired in-process research and development (Note 3) | 97.1 |  |  | 440.4 |  |  | 202.1 |  |  | 606.0 | \n |  |  |  |  |  |  | \nOther\u2013net, (income) expense (Note 10) | 36.8 |  |  | 119.2 |  |  | 1.1 |  |  | 469.9 | \n | 6,223.2 |  |  | 5,397.1 |  |  | 11,653.5 |  |  | 11,153.5 | \nIncome before income taxes | 2,088.9 |  |  | 1,090.9 |  |  | 3,618.6 |  |  | 3,144.5 | \nIncome taxes (Note 6) | 325.7 |  |  | 138.4 |  |  | 510.5 |  |  | 289.1 | \nNet income | $ | 1,763.2 |  |  | $ | 952.5 |  |  | $ | 3,108.1 |  |  | $ | 2,855.4 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nEarnings per share: |  |  |  |  |  |  | \nBasic | $ | 1.96 |  |  | $ | 1.06 |  |  | $ | 3.45 |  |  | $ | 3.17 | \n |  |  |  |  |  |  | \nDiluted | $ | 1.95 |  |  | $ | 1.05 |  |  | $ | 3.44 |  |  | $ | 3.16 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nShares used in calculation of earnings per share: |  |  |  |  |  |  | \nBasic | 899.7 |  | 900.3 |  | 900.3 |  | 902.0\nDiluted | 902.7 |  | 902.9 |  | 903.0 |  | 904.4  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet income | $ | 1,763.2 |  |  | $ | 952.5 |  |  | $ | 3,108.1 |  |  | $ | 2,855.4 | \nOther comprehensive income (loss), net of tax (Note 9) | (11.4) |  |  | (62.4) |  |  | 55.9 |  |  | 55.4 | \nComprehensive income | $ | 1,751.8 |  |  | $ | 890.1 |  |  | $ | 3,164.0 |  |  | $ | 2,910.8 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nAssets | (Unaudited) |  | \nCurrent Assets |  |  | \nCash and cash equivalents (Note 5) | $ | 2,694.5 |  |  | $ | 2,067.0 | \nShort-term investments (Note 5) | 134.6 |  |  | 144.8 | \nAccounts receivable, net of allowances of$13.8(2023)and $16.0(2022) | 7,516.1 |  |  | 6,896.0 | \nOther receivables | 1,655.3 |  |  | 1,662.9 | \nInventories | 4,798.7 |  |  | 4,309.7 | \nPrepaid expenses and other current assets | 4,532.4 |  |  | 2,954.1 | \nTotal current assets | 21,331.6 |  |  | 18,034.5 | \nInvestments (Note 5) | 2,745.1 |  |  | 2,901.8 | \nGoodwill | 4,078.9 |  |  | 4,073.0 | \nOther intangibles, net | 6,903.5 |  |  | 7,206.6 | \nDeferred tax assets | 3,805.9 |  |  | 2,792.9 | \nProperty and equipment, net of accumulated depreciation of$10,631.6(2023)and $10,233.4(2022) | 11,277.4 |  |  | 10,144.0 | \nOther noncurrent assets | 4,671.6 |  |  | 4,337.0 | \nTotal assets | $ | 54,814.0 |  |  | $ | 49,489.8 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nShort-term borrowings and current maturities of long-term debt | $ | 661.6 |  |  | $ | 1,501.1 | \nAccounts payable | 2,474.2 |  |  | 1,930.6 | \nEmployee compensation | 867.7 |  |  | 1,059.8 | \nSales rebates and discounts | 10,389.9 |  |  | 8,784.1 | \nDividends payable | 1,016.2 |  |  | 1,017.2 | \nIncome taxes payable | 1,233.8 |  |  | 475.1 | \nOther current liabilities | 2,271.6 |  |  | 2,370.3 | \nTotal current liabilities | 18,915.0 |  |  | 17,138.2 | \nOther Liabilities |  |  | \nLong-term debt | 18,158.4 |  |  | 14,737.5 | \nAccrued retirement benefits (Note 7) | 1,308.8 |  |  | 1,305.1 | \nLong-term income taxes payable | 3,330.7 |  |  | 3,709.6 | \nOther noncurrent liabilities | 1,951.8 |  |  | 1,824.0 | \nTotal other liabilities | 24,749.7 |  |  | 21,576.2 | \nCommitments and Contingencies (Note 8) |  |  | \nEli Lilly and Company Shareholders' Equity |  |  | \nCommon stock | 593.6 |  |  | 594.1 | \nAdditional paid-in capital | 6,948.6 |  |  | 6,921.4 | \nRetained earnings | 10,368.5 |  |  | 10,042.6 | \nEmployee benefit trust | (3,013.2) |  |  | (3,013.2) | \nAccumulated other comprehensive loss (Note 9) | (3,788.7) |  |  | (3,844.6) | \nCost of common stock in treasury | (45.0) |  |  | (50.5) | \nTotal Eli Lilly and Company shareholders' equity | 11,063.8 |  |  | 10,649.8 | \nNoncontrolling interests | 85.5 |  |  | 125.6 | \nTotal equity | 11,149.3 |  |  | 10,775.4 | \nTotal liabilities and equity | $ | 54,814.0 |  |  | $ | 49,489.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions, except per-share data, and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at April\u00a01, 2022 | 950,605 |  |  | $ | 594.1 |  |  | $ | 6,656.3 |  |  | $ | 9,369.4 |  |  | $ | (3,013.2) |  |  | $ | (4,225.3) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 131.2 | \nNet income (loss) |  |  |  |  |  |  | 952.5 |  |  |  |  |  |  |  |  |  |  | (11.4) | \nOther comprehensive loss, net of tax |  |  |  |  |  |  |  |  |  |  | (62.4) |  |  |  |  |  |  | \nCash dividends declared per share: $1.96 |  |  |  |  |  |  | (1,765.9) |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIssuance of stock under employee stock plans, net | 14 |  |  |  |  | (2.4) |  |  |  |  |  |  |  |  |  |  |  |  | \nStock-based compensation |  |  |  |  | 92.1 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (5.3) | \nBalance at June\u00a030, 2022 | 950,619 |  |  | $ | 594.1 |  |  | $ | 6,746.0 |  |  | $ | 8,556.0 |  |  | $ | (3,013.2) |  |  | $ | (4,287.7) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 114.5 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at April\u00a01, 2023 | 949,669 |  |  | $ | 593.5 |  |  | $ | 6,793.1 |  |  | $ | 10,639.3 |  |  | $ | (3,013.2) |  |  | $ | (3,777.3) |  |  | 402 |  |  | $ | (45.0) |  |  | $ | 104.5 | \nNet income (loss) |  |  |  |  |  |  | 1,763.2 |  |  |  |  |  |  |  |  |  |  | (9.5) | \nOther comprehensive loss, net of tax |  |  |  |  |  |  |  |  |  |  | (11.4) |  |  |  |  |  |  | \nCash dividends declared per share: $2.26 |  |  |  |  |  |  | (2,034.0) |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIssuance of stock under employee stock plans, net | 19 |  |  | 0.1 |  |  | (6.0) |  |  |  |  |  |  |  |  |  |  |  |  | \nStock-based compensation |  |  |  |  | 161.5 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (9.5) | \nBalance at June\u00a030, 2023 | 949,688 |  |  | $ | 593.6 |  |  | $ | 6,948.6 |  |  | $ | 10,368.5 |  |  | $ | (3,013.2) |  |  | $ | (3,788.7) |  |  | 402 |  |  | $ | (45.0) |  |  | $ | 85.5 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions, except per-share data, and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at January\u00a01, 2022 | 954,116 |  |  | $ | 596.3 |  |  | $ | 6,833.4 |  |  | $ | 8,958.5 |  |  | $ | (3,013.2) |  |  | $ | (4,343.1) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 175.6 | \nNet income (loss) |  |  |  |  |  |  | 2,855.4 |  |  |  |  |  |  |  |  |  |  | (48.0) | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 55.4 |  |  |  |  |  |  | \nCash dividends declared per share: $1.96 |  |  |  |  |  |  | (1,765.9) |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (5,607) |  |  | (3.5) |  |  |  |  | (1,496.5) |  |  |  |  |  |  | (5,607) |  |  | 1,500.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 5,607 |  |  | (1,500.0) |  |  | \nIssuance of stock under employee stock plans, net | 2,110 |  |  | 1.3 |  |  | (280.5) |  |  |  |  |  |  |  |  | (13) |  |  | 2.2 |  |  | \nStock-based compensation |  |  |  |  | 193.1 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | 4.5 |  |  |  |  |  |  |  |  |  |  | (13.1) | \nBalance at June\u00a030, 2022 | 950,619 |  |  | $ | 594.1 |  |  | $ | 6,746.0 |  |  | $ | 8,556.0 |  |  | $ | (3,013.2) |  |  | $ | (4,287.7) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 114.5 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January\u00a01, 2023 | 950,632 |  |  | $ | 594.1 |  |  | $ | 6,921.4 |  |  | $ | 10,042.6 |  |  | $ | (3,013.2) |  |  | $ | (3,844.6) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 125.6 | \nNet income |  |  |  |  |  |  | 3,108.1 |  |  |  |  |  |  |  |  |  |  | 0.5 | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 55.9 |  |  |  |  |  |  | \nCash dividends declared per share: $2.26 |  |  |  |  |  |  | (2,034.0) |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (2,299) |  |  | (1.4) |  |  |  |  | (748.6) |  |  |  |  |  |  | (2,299) |  |  | 750.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 2,299 |  |  | (750.0) |  |  | \nIssuance of stock under employee stock plans, net | 1,355 |  |  | 0.9 |  |  | (265.5) |  |  |  |  |  |  |  |  | (48) |  |  | 8.8 |  |  | \nStock-based compensation |  |  |  |  | 292.7 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | 0.4 |  |  |  |  |  |  |  |  | (3.3) |  |  | (40.6) | \nBalance at June\u00a030, 2023 | 949,688 |  |  | $ | 593.6 |  |  | $ | 6,948.6 |  |  | $ | 10,368.5 |  |  | $ | (3,013.2) |  |  | $ | (3,788.7) |  |  | 402 |  |  | $ | (45.0) |  |  | $ | 85.5 |   |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2023 |  | 2022\nCash Flows from Operating Activities | \nNet income | $ | 3,108.1 |  |  | $ | 2,855.4 | \nAdjustments to Reconcile Net Income to Cash Flows from Operating Activities: |  |  | \n |  |  | \nDepreciation and amortization | 728.6 |  |  | 784.6 | \nChange in deferred income taxes | (990.5) |  |  | (1,125.0) | \n |  |  | \nStock-based compensation expense | 292.7 |  |  | 193.1 | \n |  |  | \nNet investment losses | 80.0 |  |  | 545.6 | \nAcquired in-process research and development | 202.1 |  |  | 606.0 | \nOther changes in operating assets and liabilities, net of acquisitions and divestitures | (676.1) |  |  | (104.2) | \nOther operating activities, net | (382.4) |  |  | (49.2) | \nNet Cash Provided by Operating Activities | 2,362.5 |  |  | 3,706.3 | \nCash Flows from Investing Activities |  |  | \nPurchases of property and equipment | (1,406.7) |  |  | (736.4) | \nProceeds from sales and maturities of short-term investments | 109.6 |  |  | 57.6 | \nPurchases of short-term investments | (59.8) |  |  | (32.9) | \nProceeds from sales of and distributions from noncurrent investments | 388.4 |  |  | 168.5 | \nPurchases of noncurrent investments | (343.4) |  |  | (251.4) | \n |  |  | \n |  |  | \nPurchases of in-process research and development | (333.1) |  |  | (958.2) | \nOther investing activities, net | 497.1 |  |  | (111.3) | \nNet Cash Used for Investing Activities | (1,147.9) |  |  | (1,864.1) | \nCash Flows from Financing Activities |  |  | \nDividends paid | (2,035.0) |  |  | (1,769.2) | \nNet change in short-term borrowings | (1,498.0) |  |  | 2,117.2 | \nProceeds from issuance of long-term debt | 3,958.5 |  |  | \u2014 | \nRepayments of long-term debt | \u2014 |  |  | (1,560.0) | \nPurchases of common stock | (750.0) |  |  | (1,500.0) | \n |  |  | \nOther financing activities, net | (296.6) |  |  | (290.0) | \nNet Cash Used for Financing Activities | (621.1) |  |  | (3,002.0) | \nEffect of exchange rate changes on cash and cash equivalents | 34.0 |  |  | (35.8) | \n |  |  | \nNet increase (decrease) in cash and cash equivalents | 627.5 |  |  | (1,195.6) | \nCash and cash equivalents at January\u00a01 | 2,067.0 |  |  | 3,818.5 | \nCash and Cash Equivalents at June 30 | $ | 2,694.5 |  |  | $ | 2,622.9 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet product revenue | $ | 6,979.8 |  |  | $ | 5,870.9 |  |  | $ | 13,218.0 |  |  | $ | 13,003.8 | \nCollaboration and other revenue(1) | 1,332.3 |  |  | 617.1 |  |  | 2,054.1 |  |  | 1,294.2 | \nRevenue | $ | 8,312.1 |  |  | $ | 6,488.0 |  |  | $ | 15,272.1 |  |  | $ | 14,298.0 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nContract liabilities | $ | 211.1 |  |  | $ | 219.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30,\n | 2023 |  | 2022\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\n |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity\u00ae | $ | 1,371.3 |  | $ | 441.2 |  | $ | 1,812.5 |  |  | $ | 1,430.1 |  | $ | 481.7 |  | $ | 1,911.9 | \nMounjaro\u00ae | 915.7 |  | 64.0 |  | 979.7 |  |  | 12.6 |  | 3.4 |  | 16.0 | \nJardiance(1) | 386.1 |  | 282.2 |  | 668.3 |  |  | 250.7 |  | 210.3 |  | 461.0 | \nBaqsimi | 606.2 |  | 7.7 |  | 613.9 |  |  | 21.8 |  | 7.2 |  | 29.0 | \nHumalog\u00ae (2) | 229.8 |  | 210.6 |  | 440.4 |  |  | 238.8 |  | 208.3 |  | 447.1 | \nHumulin\u00ae | 144.3 |  | 61.0 |  | 205.3 |  |  | 202.3 |  | 71.7 |  | 274.0 | \nBasaglar\u00ae (3) | 83.0 |  | 71.2 |  | 154.2 |  |  | 95.8 |  | 78.4 |  | 174.2 | \nOther diabetes | 45.0 |  | 91.6 |  | 136.6 |  |  | 40.1 |  | 85.0 |  | 125.0 | \nTotal diabetes | 3,781.4 |  | 1,229.5 |  | 5,010.9 |  |  | 2,292.2 |  | 1,146.0 |  | 3,438.2 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio\u00ae | 588.6 |  | 338.2 |  | 926.8 |  |  | 384.3 |  | 204.2 |  | 588.5 | \nCyramza\u00ae | 115.0 |  | 145.3 |  | 260.3 |  |  | 92.6 |  | 138.6 |  | 231.3 | \nErbitux\u00ae | 145.5 |  | 17.0 |  | 162.5 |  |  | 125.1 |  | 15.7 |  | 140.8 | \nAlimta\u00ae | 17.9 |  | 43.1 |  | 60.9 |  |  | 171.7 |  | 56.1 |  | 227.7 | \nOther oncology | 68.0 |  | 192.4 |  | 260.5 |  |  | 45.3 |  | 135.2 |  | 180.4 | \nTotal oncology | 935.0 |  | 736.0 |  | 1,671.0 |  |  | 819.0 |  | 549.8 |  | 1,368.7 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz\u00ae | 472.3 |  | 231.6 |  | 703.9 |  |  | 411.6 |  | 194.7 |  | 606.2 | \nOlumiant\u00ae (4) | 50.8 |  | 168.1 |  | 218.9 |  |  | 10.4 |  | 175.8 |  | 186.2 | \nOther immunology | \u2014 |  | 5.7 |  | 5.7 |  |  | \u2014 |  | 4.0 |  | 4.0 | \nTotal immunology | 523.1 |  | 405.4 |  | 928.5 |  |  | 422.0 |  | 374.5 |  | 796.5 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nEmgality\u00ae | 118.8 |  | 50.5 |  | 169.3 |  |  | 108.6 |  | 48.9 |  | 157.5 | \n |  |  |  |  |  |  | \nOther neuroscience | 42.1 |  | 175.8 |  | 217.9 |  |  | 36.2 |  | 196.3 |  | 232.4 | \nTotal neuroscience | 160.9 |  | 226.3 |  | 387.2 |  |  | 144.8 |  | 245.2 |  | 389.9 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nForteo\u00ae | 97.4 |  | 50.6 |  | 148.0 |  |  | 78.5 |  | 60.0 |  | 138.5 | \nCialis\u00ae | 9.2 |  | 106.4 |  | 115.6 |  |  | 10.8 |  | 136.2 |  | 147.0 | \nCOVID-19 antibodies(5) | \u2014 |  | \u2014 |  | \u2014 |  |  | 129.1 |  | \u2014 |  | 129.1 | \nOther | 24.4 |  | 26.5 |  | 51.0 |  |  | 38.5 |  | 41.7 |  | 80.1 | \nTotal other | 131.0 |  | 183.5 |  | 314.6 |  |  | 256.9 |  | 237.9 |  | 494.7 | \nRevenue | $ | 5,531.4 |  | $ | 2,780.7 |  | $ | 8,312.1 |  |  | $ | 3,934.8 |  | $ | 2,553.3 |  | $ | 6,488.0 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30,\n | 2023 |  | 2022\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\n |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity | $ | 2,918.7 |  | $ | 871.0 |  | $ | 3,789.6 |  |  | $ | 2,744.1 |  | $ | 909.1 |  | $ | 3,653.2 | \nMounjaro | 1,452.2 |  | 96.0 |  | 1,548.2 |  |  | 12.6 |  | 3.4 |  | 16.0 | \nJardiance(1) | 715.6 |  | 530.2 |  | 1,245.8 |  |  | 480.4 |  | 400.0 |  | 880.4 | \nHumalog(2) | 501.4 |  | 400.0 |  | 901.4 |  |  | 607.7 |  | 457.6 |  | 1,065.3 | \nBaqsimi | 629.3 |  | 16.1 |  | 645.4 |  |  | 44.3 |  | 13.9 |  | 58.2 | \nHumulin | 343.1 |  | 114.2 |  | 457.3 |  |  | 392.8 |  | 154.5 |  | 547.2 | \nBasaglar(3) | 218.4 |  | 145.2 |  | 363.5 |  |  | 215.1 |  | 150.6 |  | 365.7 | \nOther diabetes | 77.7 |  | 172.2 |  | 250.1 |  |  | 71.7 |  | 168.5 |  | 240.3 | \nTotal diabetes | 6,856.4 |  | 2,344.9 |  | 9,201.3 |  |  | 4,568.7 |  | 2,257.6 |  | 6,826.3 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio | 1,049.6 |  | 628.0 |  | 1,677.7 |  |  | 685.7 |  | 372.1 |  | 1,057.9 | \nCyramza | 215.6 |  | 281.4 |  | 497.0 |  |  | 171.8 |  | 289.7 |  | 461.5 | \nErbitux | 264.2 |  | 28.1 |  | 292.4 |  |  | 234.7 |  | 28.7 |  | 263.4 | \nAlimta | 38.0 |  | 81.2 |  | 119.1 |  |  | 425.9 |  | 145.8 |  | 571.7 | \nOther oncology | 121.0 |  | 319.9 |  | 440.8 |  |  | 84.6 |  | 282.7 |  | 367.2 | \nTotal oncology | 1,688.4 |  | 1,338.6 |  | 3,027.0 |  |  | 1,602.7 |  | 1,119.0 |  | 2,721.7 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz | 784.5 |  | 446.3 |  | 1,230.8 |  |  | 718.8 |  | 375.5 |  | 1,094.3 | \nOlumiant(4) | 93.1 |  | 354.6 |  | 447.8 |  |  | 81.7 |  | 360.1 |  | 441.8 | \nOther immunology | \u2014 |  | 27.7 |  | 27.7 |  |  | \u2014 |  | 8.5 |  | 8.5 | \nTotal immunology | 877.6 |  | 828.6 |  | 1,706.3 |  |  | 800.5 |  | 744.1 |  | 1,544.6 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nEmgality | 227.5 |  | 96.1 |  | 323.6 |  |  | 216.9 |  | 89.8 |  | 306.7 | \n |  |  |  |  |  |  | \nOther neuroscience | 77.9 |  | 346.2 |  | 424.1 |  |  | 81.2 |  | 399.7 |  | 481.0 | \nTotal neuroscience | 305.4 |  | 442.3 |  | 747.7 |  |  | 298.1 |  | 489.5 |  | 787.7 | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nForteo | 168.0 |  | 102.3 |  | 270.3 |  |  | 148.7 |  | 127.2 |  | 275.9 | \nCialis | 16.8 |  | 199.1 |  | 215.9 |  |  | 17.7 |  | 347.0 |  | 364.7 | \nCOVID-19 antibodies(5) | \u2014 |  | \u2014 |  | \u2014 |  |  | 1,584.3 |  | 14.7 |  | 1,598.9 | \nOther | 55.0 |  | 48.7 |  | 103.7 |  |  | 88.5 |  | 89.6 |  | 178.2 | \nTotal other | 239.8 |  | 350.1 |  | 589.9 |  |  | 1,839.2 |  | 578.5 |  | 2,417.7 | \nRevenue | $ | 9,967.6 |  | $ | 5,304.6 |  | $ | 15,272.1 |  |  | $ | 9,109.4 |  | $ | 5,188.7 |  | $ | 14,298.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue(1): |  |  |  |  |  |  | \nU.S. | $ | 5,531.4 |  |  | $ | 3,934.8 |  |  | $ | 9,967.6 |  |  | $ | 9,109.4 | \nEurope | 1,177.6 |  |  | 1,101.1 |  |  | 2,268.5 |  |  | 2,168.4 | \nJapan | 455.6 |  |  | 454.4 |  |  | 842.8 |  |  | 864.6 | \nChina | 399.0 |  |  | 352.1 |  |  | 771.7 |  |  | 758.5 | \nOther foreign countries | 748.5 |  |  | 645.7 |  |  | 1,421.5 |  |  | 1,397.2 | \nRevenue | $ | 8,312.1 |  |  | $ | 6,488.0 |  |  | $ | 15,272.1 |  |  | $ | 14,298.0 |   |  |  |  |  | \nEstimated Fair Value at December 1, 2022 | \nCash | $ | 153.2 | \nAcquired IPR&D(1) | 184.0\nGoodwill(2) | 187.1\n | \nOther assets and liabilities, net | 23.0 | \nAcquisition date fair value of consideration transferred | 547.3\nLess: | \nCash acquired | (153.2) | \nFair value of CVR liability(3) | (66.9) | \nCash paid, net of cash acquired | $ | 327.2 |   |  |  |  |  |  |  |  | \n | Net Milestones Capitalized (Deferred)(1)\n | June 30, 2023 | December 31, 2022\nJardiance | $ | 106.3 |  | $ | 116.2 | \nTrajenta | 51.2 |  | 63.5 | \nBasaglar | (121.3) |  | (130.6) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nJardiance | $ | 668.3 |  |  | $ | 461.0 |  |  | $ | 1,245.8 |  |  | $ | 880.4 | \nBasaglar | 154.2 |  |  | 174.2 |  |  | 363.5 |  |  | 365.7 | \nTrajenta | 103.6 |  |  | 97.1 |  |  | 189.5 |  |  | 189.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nOlumiant | $ | 218.9 |  |  | $ | 186.2 |  |  | $ | 447.8 |  |  | $ | 441.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturities by Period\n | Total |  | Less\u00a0Than1 Year |  | 1-5Years |  | 6-10Years |  | More\u00a0Than10 Years\nFair value of debt securities | $ | 663.6 |  |  | $ | 86.1 |  |  | $ | 213.2 |  |  | $ | 117.0 |  |  | $ | 247.3 |   |  |  |  |  |  |  |  |  |  |  | \n | June 30, 2023 |  | December 31, 2022\nUnrealized gross gains | $ | 0.6 |  |  | $ | 0.6 | \nUnrealized gross losses | 44.6 |  |  | 49.2 | \nFair value of securities in an unrealized gain position | 54.6 |  |  | 46.8 | \nFair value of securities in an unrealized loss position | 570.6 |  |  | 568.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nProceeds from sales | $ | 34.2 |  |  | $ | 29.9 |  |  | $ | 61.8 |  |  | $ | 65.1 | \nRealized gross gains on sales | 0.1 |  |  | 0.1 |  |  | 0.3 |  |  | 0.2 | \nRealized gross losses on sales | 1.0 |  |  | 0.7 |  |  | 1.7 |  |  | 1.5 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Cost(1) |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | Significant OtherObservable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nJune 30, 2023 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents(2) | $ | 1,340.9 |  |  | $ | 1,340.9 |  |  | $ | 1,333.7 |  |  | $ | 7.2 |  |  | $ | \u2014 |  |  | $ | 1,340.9 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 19.5 |  |  | $ | 19.9 |  |  | $ | 19.5 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 19.5 | \nCorporate debt securities | 65.3 |  |  | 65.6 |  |  | \u2014 |  |  | 65.3 |  |  | \u2014 |  |  | 65.3 | \n |  |  |  |  |  |  |  |  |  |  | \nAsset-backed securities | 1.3 |  |  | 1.3 |  |  | \u2014 |  |  | 1.3 |  |  | \u2014 |  |  | 1.3 | \nOther securities | 48.5 |  |  | 48.5 |  |  | \u2014 |  |  | 23.5 |  |  | 25.0 |  |  | 48.5 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 134.6 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 150.2 |  |  | $ | 164.7 |  |  | $ | 150.2 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 150.2 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities | 211.5 |  |  | 230.7 |  |  | \u2014 |  |  | 211.5 |  |  | \u2014 |  |  | 211.5 | \nMortgage-backed securities | 158.3 |  |  | 170.8 |  |  | \u2014 |  |  | 158.3 |  |  | \u2014 |  |  | 158.3 | \nAsset-backed securities | 57.5 |  |  | 59.2 |  |  | \u2014 |  |  | 57.5 |  |  | \u2014 |  |  | 57.5 | \nOther securities | 166.2 |  |  | 69.5 |  |  | \u2014 |  |  | 6.2 |  |  | 160.0 |  |  | 166.2 | \nMarketable equity securities | 577.6 |  |  | 460.6 |  |  | 577.6 |  |  | \u2014 |  |  | \u2014 |  |  | 577.6 | \nEquity investments without readily determinable fair values(3) | 535.4 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(3) | 888.4 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 2,745.1 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents(2) | $ | 657.4 |  |  | $ | 657.4 |  |  | $ | 650.4 |  |  | $ | 7.0 |  |  | $ | \u2014 |  |  | $ | 657.4 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 30.8 |  |  | $ | 31.1 |  |  | $ | 30.8 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 30.8 | \nCorporate debt securities | 53.4 |  |  | 53.5 |  |  | \u2014 |  |  | 53.4 |  |  | \u2014 |  |  | 53.4 | \n |  |  |  |  |  |  |  |  |  |  | \nAsset-backed securities | 2.0 |  |  | 2.0 |  |  | \u2014 |  |  | 2.0 |  |  | \u2014 |  |  | 2.0 | \nOther securities | 58.6 |  |  | 58.6 |  |  | \u2014 |  |  | 39.1 |  |  | 19.5 |  |  | 58.6 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 144.8 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 146.4 |  |  | $ | 163.2 |  |  | $ | 146.4 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 146.4 | \nCorporate debt securities | 213.9 |  |  | 235.8 |  |  | \u2014 |  |  | 213.9 |  |  | \u2014 |  |  | 213.9 | \nMortgage-backed securities | 149.2 |  |  | 161.5 |  |  | \u2014 |  |  | 149.2 |  |  | \u2014 |  |  | 149.2 | \nAsset-backed securities | 50.6 |  |  | 52.5 |  |  | \u2014 |  |  | 50.6 |  |  | \u2014 |  |  | 50.6 | \nOther securities | 398.6 |  |  | 34.5 |  |  | \u2014 |  |  | 311.0 |  |  | 87.6 |  |  | 398.6 | \nMarketable equity securities | 683.6 |  |  | 484.7 |  |  | 683.6 |  |  | \u2014 |  |  | \u2014 |  |  | 683.6 | \nEquity investments without readily determinable fair values(3) | 478.4 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(3) | 781.1 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 2,901.8 |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nShort-term commercial paper borrowings |  |  |  |  |  |  |  |  | \nJune 30, 2023 | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | \u2014 | \nDecember 31, 2022 | (1,498.0) |  |  | \u2014 |  |  | (1,492.0) |  |  | \u2014 |  |  | (1,492.0) | \nLong-term debt, including current portion |  |  |  |  |  |  |  |  | \nJune 30, 2023 | $ | (18,820.0) |  |  | $ | \u2014 |  |  | $ | (16,589.9) |  |  | $ | \u2014 |  |  | $ | (16,589.9) | \nDecember 31, 2022 | (14,740.6) |  |  | \u2014 |  |  | (12,329.3) |  |  | \u2014 |  |  | (12,329.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nJune 30, 2023\nPurchase |  | Sell\nCurrency | Amount(in millions) |  | Currency | Amount(in millions)\nEuro | 3,373.9 |  | U.S. dollars | 3,683.6\nU.S. dollars | 2,617.8 |  | Euro | 2,394.7\nBritish pounds | 182.9 |  | U.S. dollars | 234.4\n |  |  |  | \n |  |  |  | \n |  |  |  | \nU.S. dollars | 151.4 |  | Chinese yuan | 1,084.8\n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nFair value hedges: |  |  |  |  |  |  | \nEffect from hedged fixed-rate debt | $ | (34.4) |  |  | $ | (58.2) |  |  | $ | 0.9 |  |  | $ | (152.8) | \nEffect from interest rate contracts | 34.4 |  |  | 58.2 |  |  | (0.9) |  |  | 152.8 | \nCash flow hedges: |  |  |  |  |  |  | \nEffective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss | 3.3 |  |  | 4.1 |  |  | 7.1 |  |  | 8.2 | \nCross-currency interest rate swaps | (17.1) |  |  | 33.6 |  |  | (30.0) |  |  | 41.9 | \nNet (gains) losses on foreign currency exchange contracts not designated as hedging instruments | 29.6 |  |  | 151.1 |  |  | (23.2) |  |  | 145.0 | \nTotal | $ | 15.8 |  |  | $ | 188.8 |  |  | $ | (46.1) |  |  | $ | 195.1 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet investment hedges: |  |  |  |  |  |  | \nForeign currency-denominated notes | $ | 10.6 |  |  | $ | 333.3 |  |  | $ | (121.2) |  |  | $ | 387.7 | \nCross-currency interest rate swaps | (7.8) |  |  | 68.5 |  |  | (19.6) |  |  | 79.3 | \nForeign currency forward contracts | 27.7 |  |  | 13.6 |  |  | (18.4) |  |  | 13.6 | \nCash flow hedges: |  |  |  |  |  |  | \nForward-starting interest rate swaps | 33.3 |  |  | 157.7 |  |  | 57.1 |  |  | 280.2 | \nCross-currency interest rate swaps | 21.9 |  |  | 1.4 |  |  | 14.1 |  |  | 18.5 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  |  |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue |  | \nJune 30, 2023 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | $ | (8.7) |  |  | $ | \u2014 |  |  | $ | (8.7) |  |  | $ | \u2014 |  |  | $ | (8.7) |  |  | \nOther noncurrent liabilities | (124.8) |  |  | \u2014 |  |  | (124.8) |  |  | \u2014 |  |  | (124.8) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 261.9 |  |  | \u2014 |  |  | 261.9 |  |  | \u2014 |  |  | 261.9 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 42.7 |  |  | \u2014 |  |  | 42.7 |  |  | \u2014 |  |  | 42.7 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 69.5 |  |  | \u2014 |  |  | 69.5 |  |  | \u2014 |  |  | 69.5 |  |  | \nOther noncurrent assets | 27.6 |  |  | \u2014 |  |  | 27.6 |  |  | \u2014 |  |  | 27.6 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 17.3 |  |  | \u2014 |  |  | 17.3 |  |  | \u2014 |  |  | 17.3 |  |  | \nOther current liabilities | (15.2) |  |  | \u2014 |  |  | (15.2) |  |  | \u2014 |  |  | (15.2) |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 15.3 |  |  | \u2014 |  |  | 15.3 |  |  | \u2014 |  |  | 15.3 |  |  | \nOther current liabilities | (17.8) |  |  | \u2014 |  |  | (17.8) |  |  | \u2014 |  |  | (17.8) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nContingent consideration liabilities: |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | (38.9) |  |  | \u2014 |  |  | \u2014 |  |  | (38.9) |  |  | (38.9) |  |  | \nOther noncurrent liabilities | (72.3) |  |  | \u2014 |  |  | \u2014 |  |  | (72.3) |  |  | (72.3) |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  |  |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue |  | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | $ | (134.3) |  |  | $ | \u2014 |  |  | $ | (134.3) |  |  | $ | \u2014 |  |  | $ | (134.3) |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 162.9 |  |  | \u2014 |  |  | 162.9 |  |  | \u2014 |  |  | 162.9 |  |  | \nOther noncurrent assets | 246.0 |  |  | \u2014 |  |  | 246.0 |  |  | \u2014 |  |  | 246.0 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 67.6 |  |  | \u2014 |  |  | 67.6 |  |  | \u2014 |  |  | 67.6 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 53.1 |  |  | \u2014 |  |  | 53.1 |  |  | \u2014 |  |  | 53.1 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | (38.3) |  |  | \u2014 |  |  | (38.3) |  |  | \u2014 |  |  | (38.3) |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 26.6 |  |  | \u2014 |  |  | 26.6 |  |  | \u2014 |  |  | 26.6 |  |  | \nOther current liabilities | (21.5) |  |  | \u2014 |  |  | (21.5) |  |  | \u2014 |  |  | (21.5) |  |  | \nContingent consideration liabilities: |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | (39.5) |  |  | \u2014 |  |  | \u2014 |  |  | (39.5) |  |  | (39.5) |  |  | \nOther noncurrent liabilities | (70.6) |  |  | \u2014 |  |  | \u2014 |  |  | (70.6) |  |  | (70.6) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Defined Benefit Pension Plans\n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nComponents of net periodic cost: |  |  |  |  |  |  | \nService cost | $ | 74.9 |  |  | $ | 88.2 |  |  | $ | 145.3 |  |  | $ | 177.3 | \nInterest cost | 162.6 |  |  | 99.6 |  |  | 323.7 |  |  | 200.1 | \nExpected return on plan assets | (264.2) |  |  | (237.0) |  |  | (527.5) |  |  | (476.5) | \nAmortization of prior service cost | 0.6 |  |  | 0.6 |  |  | 1.2 |  |  | 1.3 | \nRecognized actuarial loss | 30.9 |  |  | 84.5 |  |  | 60.9 |  |  | 171.5 | \n |  |  |  |  |  |  | \nNet periodic cost | $ | 4.8 |  |  | $ | 35.9 |  |  | $ | 3.6 |  |  | $ | 73.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Retiree Health Benefit Plans\n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nComponents of net periodic benefit: |  |  |  |  |  |  | \nService cost | $ | 8.2 |  |  | $ | 12.1 |  |  | $ | 15.9 |  |  | $ | 23.3 | \nInterest cost | 15.3 |  |  | 9.6 |  |  | 30.7 |  |  | 19.0 | \nExpected return on plan assets | (45.6) |  |  | (38.2) |  |  | (91.1) |  |  | (76.1) | \nAmortization of prior service benefit | (13.2) |  |  | (13.7) |  |  | (26.4) |  |  | (27.4) | \nRecognized actuarial (gain) loss | (2.0) |  |  | 0.3 |  |  | (2.9) |  |  | 0.5 | \n |  |  |  |  |  |  | \nNet periodic benefit | $ | (37.3) |  |  | $ | (29.9) |  |  | $ | (73.8) |  |  | $ | (60.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at April\u00a01, 2023 | $ | (1,826.6) |  |  | $ | (28.3) |  |  | $ | (2,066.1) |  |  | $ | 143.7 |  |  |  |  | $ | (3,777.3) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (58.7) |  |  | (5.9) |  |  | (5.6) |  |  | 43.5 |  |  |  |  | (26.7) | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | 0.7 |  |  | 12.9 |  |  | 1.7 |  |  |  |  | 15.3 | \nNet other comprehensive income (loss) | (58.7) |  |  | (5.2) |  |  | 7.3 |  |  | 45.2 |  |  |  |  | (11.4) | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at June\u00a030, 2023 | $ | (1,885.3) |  |  | $ | (33.5) |  |  | $ | (2,058.8) |  |  | $ | 188.9 |  |  |  |  | $ | (3,788.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at April\u00a01, 2022 | $ | (1,575.2) |  |  | $ | (18.1) |  |  | $ | (2,531.6) |  |  | $ | (100.4) |  |  |  |  | $ | (4,225.3) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (269.6) |  |  | (9.3) |  |  | 31.7 |  |  | 124.8 |  |  |  |  | (122.4) | \nNet amount reclassified from accumulated other comprehensive loss | 0.6 |  |  | (0.5) |  |  | 56.7 |  |  | 3.2 |  |  |  |  | 60.0 | \nNet other comprehensive income (loss) | (269.0) |  |  | (9.8) |  |  | 88.4 |  |  | 128.0 |  |  |  |  | (62.4) | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at June\u00a030, 2022 | $ | (1,844.2) |  |  | $ | (27.9) |  |  | $ | (2,443.2) |  |  | $ | 27.6 |  |  |  |  | $ | (4,287.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  | Accumulated Other Comprehensive Loss\nBalance at January\u00a01, 2023 | $ | (1,874.2) |  |  | $ | (37.1) |  |  | $ | (2,062.3) |  |  | $ | 129.0 |  |  | $ | (3,844.6) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | 14.1 |  |  | 2.2 |  |  | (22.4) |  |  | 56.2 |  |  | 50.1 | \nNet amount reclassified from accumulated other comprehensive loss | (25.2) |  |  | 1.4 |  |  | 25.9 |  |  | 3.7 |  |  | 5.8 | \nNet other comprehensive income (loss) | (11.1) |  |  | 3.6 |  |  | 3.5 |  |  | 59.9 |  |  | 55.9 | \n |  |  |  |  |  |  |  |  | \nBalance at June\u00a030, 2023 | $ | (1,885.3) |  |  | $ | (33.5) |  |  | $ | (2,058.8) |  |  | $ | 188.9 |  |  | $ | (3,788.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  | Accumulated Other Comprehensive Loss\nBalance at January\u00a01, 2022 | $ | (1,550.2) |  |  | $ | 3.7 |  |  | $ | (2,583.6) |  |  | $ | (213.0) |  |  | $ | (4,343.1) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (294.6) |  |  | (30.6) |  |  | 25.1 |  |  | 234.2 |  |  | (65.9) | \nNet amount reclassified from accumulated other comprehensive loss | 0.6 |  |  | (1.0) |  |  | 115.3 |  |  | 6.4 |  |  | 121.3 | \nNet other comprehensive income (loss) | (294.0) |  |  | (31.6) |  |  | 140.4 |  |  | 240.6 |  |  | 55.4 | \n |  |  |  |  |  |  |  |  | \nBalance at June\u00a030, 2022 | $ | (1,844.2) |  |  | $ | (27.9) |  |  | $ | (2,443.2) |  |  | $ | 27.6 |  |  | $ | (4,287.7) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\nTax benefit (expense) | 2023 |  | 2022 |  | 2023 |  | 2022\nForeign currency translation gains/losses | $ | (6.4) |  |  | $ | (87.2) |  |  | $ | 40.1 |  |  | $ | (100.9) | \nNet unrealized gains/losses on available-for-sale securities | 1.6 |  |  | 3.0 |  |  | (1.0) |  |  | 9.7 | \nDefined benefit pension and retiree health benefit plans | (3.0) |  |  | (22.4) |  |  | (7.0) |  |  | (50.8) | \nNet unrealized gains/losses on cash flow hedges | (12.0) |  |  | (34.0) |  |  | (15.9) |  |  | (63.9) | \nBenefit (expense) for income taxes allocated to other comprehensive income (loss) items | $ | (19.8) |  |  | $ | (140.6) |  |  | $ | 16.2 |  |  | $ | (205.9) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDetails about Accumulated Other Comprehensive Loss Components | Three Months Ended June 30, |  | Six Months Ended June 30, | Affected Line Item in the Consolidated Condensed Statements of Operations\n\n2023 |  | 2022 |  | 2023 |  | 2022\nAmortization of retirement benefit items: |  |  |  |  |  |  |  | \nPrior service benefits, net | $ | (12.6) |  |  | $ | (13.1) |  |  | $ | (25.2) |  |  | $ | (26.1) |  | Other\u2013net, (income) expense\nActuarial losses, net | 28.9 |  |  | 84.8 |  |  | 58.0 |  |  | 172.0 |  | Other\u2013net, (income) expense\nTotal before tax | 16.3 |  |  | 71.7 |  |  | 32.8 |  |  | 145.9 |  | \nTax benefit | (3.4) |  |  | (15.0) |  |  | (6.9) |  |  | (30.6) |  | Income taxes\nNet of tax | 12.9 |  |  | 56.7 |  |  | 25.9 |  |  | 115.3 |  | \n |  |  |  |  |  |  |  | \nOther, net of tax | 2.4 |  |  | 3.3 |  |  | (20.1) |  |  | 6.0 |  | Other\u2013net, (income) expense\n |  |  |  |  |  |  |  | \nTotal reclassifications, net of tax | $ | 15.3 |  |  | $ | 60.0 |  |  | $ | 5.8 |  |  | $ | 121.3 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest expense | $ | 120.3 |  |  | $ | 81.2 |  |  | $ | 223.1 |  |  | $ | 166.1 | \nInterest income | (46.0) |  |  | (10.2) |  |  | (80.2) |  |  | (17.2) | \nNet investment losses on equity securities (Note 5) | 64.9 |  |  | 118.9 |  |  | 78.6 |  |  | 544.3 | \nRetirement benefit plans | (115.6) |  |  | (94.3) |  |  | (231.4) |  |  | (187.6) | \n |  |  |  |  |  |  | \nOther (income) expense | 13.2 |  |  | 23.6 |  |  | 11.0 |  |  | (35.7) | \nOther\u2013net, (income) expense | $ | 36.8 |  |  | $ | 119.2 |  |  | $ | 1.1 |  |  | $ | 469.9 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Percent Change |  | Six Months Ended June 30, |  | Percent Change\n | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \nRevenue | $ | 8,312.1 |  |  | $ | 6,488.0 |  |  | 28 |  | $ | 15,272.1 |  |  | $ | 14,298.0 |  |  | 7\n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNet income | 1,763.2 |  |  | 952.5 |  |  | 85 |  | 3,108.1 |  |  | 2,855.4 |  |  | 9\nEarnings per share - diluted | 1.95 |  |  | 1.05 |  |  | 86 |  | 3.44 |  |  | 3.16 |  |  | 9  |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nDiabetes and Obesity | \n |  |  |  | \nEmpagliflozin (Jardiance)(1) | Chronic kidney disease | Approved | Approved in Europe in July 2023. Submitted in Japan in 2022 and in the U.S. in the first quarter of 2023. Granted U.S. Food and Drug Administration (FDA) Fast Track designation(2). | \nTirzepatide (Mounjaro) | Obesity | Submitted | Submitted in Europe in the first quarter of 2023 and in the U.S. in the second quarter of 2023. Received Priority Review designation from the FDA. Announced in the second quarter of 2023 and in July 2023 that Phase III trials met all primary and key secondary endpoints. Phase III trials are ongoing. | \nHeart failure with preserved ejection fraction | Phase III | Phase III trials are ongoing. | \nObstructive sleep apnea | Phase III | Granted FDA Fast Track designation(2). Phase III trial is ongoing. | \nNonalcoholic steatohepatitis | Phase II | Phase II trial is ongoing. | \nInsulin Efsitora Alfa | Type 1 and 2 diabetes | Phase III | Phase III trials are ongoing. | \nOrforglipron | Obesity | Phase III | Phase III trials initiated in the second quarter of 2023. | \nType 2 diabetes | Phase III | Phase III trial initiated in the second quarter of 2023. | \nRetatrutide | Obesity | Phase III | Phase III trials initiated in the second quarter of 2023. | \nType 2 diabetes | Phase II | Phase II trial was completed. | \nLepodisiran(LP(a) siRNA) | Cardiovascular disease | Phase II | Phase II trial is ongoing. | \nMuvalaplin | Cardiovascular disease | Phase II | Phase II trial is ongoing. | \nRelaxin-LA | Heart failure | Phase II | Phase II trial initiated in the first quarter of 2023. | \nSolbinsiran | Cardiovascular disease | Phase II | Phase II trial is ongoing. |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nImmunology | \nMirikizumab(Omvoh\u00ae) | Ulcerative colitis | Approved | Approved in Japan in the first quarter of 2023 and in Europe in the second quarter of 2023. Following the receipt of a complete response letter from the FDA, re-submitted in the U.S. in the second quarter of 2023. | \nCrohn's Disease | Phase III | Phase III trials are ongoing. | \nLebrikizumab(3) | Atopic dermatitis | Submitted | Submitted in the U.S. and Europe in 2022 and in Japan in the first quarter of 2023. Phase III trials are ongoing. | \nBTLA MAB Agonist | Systemic lupus erythematosus | Phase II | Phase II trial is ongoing. | \nEltrekibart | Hidradenitis suppurativa | Phase II | Phase II trial is ongoing. | \nPeresolimab | Rheumatoid arthritis | Phase II | Phase II trial is ongoing. | \nNeuroscience | \nDonanemab | Early Alzheimer's disease | Submitted | Submitted for traditional approval in the U.S. in the second quarter of 2023 and in Europe in July 2023. Granted FDA Breakthrough Therapy designation(4). Announced in the second quarter of 2023 that a Phase III trial met primary and all secondary endpoints. Phase III trials are ongoing. | \nPreclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nRemternetug | Early Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nGBA1 Gene Therapy (PR001) | Gaucher disease Type 1 | Phase II | Phase II trial initiated in the second quarter of 2023. | \nParkinson's disease | Phase II | Granted FDA Fast Track designation(2). Phase II trial is ongoing. | \nGRN Gene Therapy (PR006) | Frontotemporal dementia | Phase II | Granted FDA Fast Track designation(2). Phase II trial is ongoing. | \nO-GlcNAcase Inh | Alzheimer's disease | Phase II | Phase II trial is ongoing. | \nP2X7 Inhibitor | Pain | Phase II | Phase II trials are ongoing. | \nSSTR4 Agonist | Pain | Phase II | Phase II trials are ongoing. |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication | Status | Developments | \nOncology | \nPirtobrutinib(Jaypirca\u00ae) | Mantle cell lymphoma | Approved(5) | FDA granted accelerated approval(5)in the U.S. in the first quarter of 2023. Submitted in Europe in 2022 and in Japan in the second quarter of 2023. Received a positive opinion from the Committee for Medicinal Products for Human Use in Europe in the second quarter of 2023. Phase III trial is ongoing. | \nChronic lymphocytic leukemia | Submitted | Submitted in the U.S. in August 2023 under the accelerated approval pathway. Phase III trials are ongoing. | \nB-cell malignancies | Phase II | Phase II trial is ongoing. | \nSelpercatinib (Retevmo\u00ae) | Lung cancer | Approved(5) | Phase III trials are ongoing. | \nThyroid cancer | Approved(5) | Phase III trial is ongoing. | \nAbemaciclib (Verzenio) | Prostate cancer | Phase III | Phase III trials are ongoing. | \nImlunestrant | Adjuvant breast cancer | Phase III | Phase III trial is ongoing. | \nER+HER2- metastatic breast cancer | Phase III | Phase III trial is ongoing. |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Percent Change | Six Months Ended June 30, |  | Percent Change\n | 2023 |  | 2022 |  | 2023 |  | 2022 | \nU.S. | $ | 5,531.4 |  |  | $ | 3,934.8 |  |  | 41 | $ | 9,967.6 |  |  | $ | 9,109.4 |  |  | 9\nOutside U.S. | 2,780.7 |  |  | 2,553.3 |  |  | 9 | 5,304.6 |  |  | 5,188.7 |  |  | 2\nRevenue | $ | 8,312.1 |  |  | $ | 6,488.0 |  |  | 28 | $ | 15,272.1 |  |  | $ | 14,298.0 |  |  | 7  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Six Months Ended June 30,\n | 2023 vs. 2022 |  | 2023 vs. 2022\n | U.S. | Outside U.S. | Consolidated |  | U.S. | Outside U.S. | Consolidated\nVolume | 39 | % | 14 | % | 29 | % |  | 11 | % | 10 | % | 11 | %\nPrice | 2 |  | (3) |  | \u2014 |  |  | (2) |  | (4) |  | (3) | \nForeign exchange rates | \u2014 |  | (3) |  | (1) |  |  | \u2014 |  | (4) |  | (2) | \nPercent change | 41 | % | 9 | % | 28 | % |  | 9 | % | 2 | % | 7 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Percent Change | \n | 2023 |  | 2022 | \nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | \nTrulicity | $ | 1,371.3 |  |  | $ | 441.2 |  |  | $ | 1,812.5 |  |  | $ | 1,911.9 |  |  | (5) | \nMounjaro | 915.7 |  |  | 64.0 |  |  | 979.7 |  |  | 16.0 |  |  | NM | \nVerzenio | 588.6 |  |  | 338.2 |  |  | 926.8 |  |  | 588.5 |  |  | 57 | \nTaltz | 472.3 |  |  | 231.6 |  |  | 703.9 |  |  | 606.2 |  |  | 16 | \nJardiance(1) | 386.1 |  |  | 282.2 |  |  | 668.3 |  |  | 461.0 |  |  | 45 | \nBaqsimi | 606.2 |  |  | 7.7 |  |  | 613.9 |  |  | 29.0 |  |  | NM | \nHumalog(2) | 229.8 |  |  | 210.6 |  |  | 440.4 |  |  | 447.1 |  |  | (1) | \nCyramza\u00ae | 115.0 |  |  | 145.3 |  |  | 260.3 |  |  | 231.3 |  |  | 13 | \nOlumiant(3) | 50.8 |  |  | 168.1 |  |  | 218.9 |  |  | 186.2 |  |  | 18 | \nHumulin\u00ae | 144.3 |  |  | 61.0 |  |  | 205.3 |  |  | 274.0 |  |  | (25) | \nEmgality\u00ae | 118.8 |  |  | 50.5 |  |  | 169.3 |  |  | 157.5 |  |  | 8 | \nErbitux\u00ae | 145.5 |  |  | 17.0 |  |  | 162.5 |  |  | 140.8 |  |  | 15 | \nBasaglar\u00ae (4) | 83.0 |  |  | 71.2 |  |  | 154.2 |  |  | 174.2 |  |  | (11) | \nForteo\u00ae | 97.4 |  |  | 50.6 |  |  | 148.0 |  |  | 138.5 |  |  | 7 | \nCialis | 9.2 |  |  | 106.4 |  |  | 115.6 |  |  | 147.0 |  |  | (21) | \nAlimta | 17.9 |  |  | 43.1 |  |  | 60.9 |  |  | 227.7 |  |  | (73) | \nCOVID-19 antibodies(5) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 129.1 |  |  | (100) | \nOther products | 179.5 |  |  | 492.0 |  |  | 671.6 |  |  | 622.0 |  |  | 8 | \nRevenue | $ | 5,531.4 |  |  | $ | 2,780.7 |  |  | $ | 8,312.1 |  |  | $ | 6,488.0 |  |  | 28 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Six Months Ended June 30, |  | \n | 2023 |  | 2022\nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | Percent Change\nTrulicity | $ | 2,918.7 |  |  | $ | 871.0 |  |  | $ | 3,789.6 |  |  | $ | 3,653.2 |  |  | 4\nVerzenio | 1,049.6 |  |  | 628.0 |  |  | 1,677.7 |  |  | 1,057.9 |  |  | 59\nMounjaro | 1,452.2 |  |  | 96.0 |  |  | 1,548.2 |  |  | 16.0 |  |  | NM\nJardiance(1) | 715.6 |  |  | 530.2 |  |  | 1,245.8 |  |  | 880.4 |  |  | 42\nTaltz | 784.5 |  |  | 446.3 |  |  | 1,230.8 |  |  | 1,094.3 |  |  | 12\nHumalog(2) | 501.4 |  |  | 400.0 |  |  | 901.4 |  |  | 1,065.3 |  |  | (15)\nBaqsimi | 629.3 |  |  | 16.1 |  |  | 645.4 |  |  | 58.2 |  |  | NM\nCyramza | 215.6 |  |  | 281.4 |  |  | 497.0 |  |  | 461.5 |  |  | 8\nHumulin | 343.1 |  |  | 114.2 |  |  | 457.3 |  |  | 547.2 |  |  | (16)\nOlumiant(3) | 93.1 |  |  | 354.6 |  |  | 447.8 |  |  | 441.8 |  |  | 1\nBasaglar(4) | 218.4 |  |  | 145.2 |  |  | 363.5 |  |  | 365.7 |  |  | (1)\nEmgality | 227.5 |  |  | 96.1 |  |  | 323.6 |  |  | 306.7 |  |  | 6\nErbitux | 264.2 |  |  | 28.1 |  |  | 292.4 |  |  | 263.4 |  |  | 11\nForteo | 168.0 |  |  | 102.3 |  |  | 270.3 |  |  | 275.9 |  |  | (2)\nCialis | 16.8 |  |  | 199.1 |  |  | 215.9 |  |  | 364.7 |  |  | (41)\nAlimta | 38.0 |  |  | 81.2 |  |  | 119.1 |  |  | 571.7 |  |  | (79)\nCOVID-19 antibodies(5) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1,598.9 |  |  | (100)\nOther products | 331.6 |  |  | 914.8 |  |  | 1,246.3 |  |  | 1,275.2 |  |  | 71\nRevenue | $ | 9,967.6 |  |  | $ | 5,304.6 |  |  | $ | 15,272.1 |  |  | $ | 14,298.0 |  |  | 7  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended June 30, |  | Percent Change |  | Six Months Ended June 30, |  | Percent Change\n | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  |  |  |  |  |  |  |  |  |  | \nGross margin | $ | 6,504.7 |  |  | $ | 5,057.5 |  |  | 29 |  | $ | 11,838.0 |  |  | $ | 10,795.4 |  |  | 10\nGross margin as a percent of revenue | 78.3 | % |  | 78.0 | % |  |  |  | 77.5 | % |  | 75.5 | % |  | \n |  |  |  |  |  |  |  |  |  |  | \nResearch and development | $ | 2,356.5 |  |  | $ | 1,781.9 |  |  | 32 |  | $ | 4,341.6 |  |  | $ | 3,392.0 |  |  | 28\nMarketing, selling, and administrative | 1,925.4 |  |  | 1,625.1 |  |  | 18 |  | 3,674.6 |  |  | 3,183.0 |  |  | 15\nAcquired IPR&D | 97.1 |  |  | 440.4 |  |  | (78) |  | 202.1 |  |  | 606.0 |  |  | (67)\n |  |  |  |  |  |  |  |  |  |  | \nOther\u2013net, (income) expense | 36.8 |  |  | 119.2 |  |  | (69) |  | 1.1 |  |  | 469.9 |  |  | (100)\nIncome taxes | 325.7 |  |  | 138.4 |  |  | NM |  | 510.5 |  |  | 289.1 |  |  | 77\nEffective tax rate | 15.6 | % |  | 12.7 | % |  |  |  | 14.1 | % |  | 9.2 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | Total Number ofShares Purchased(in thousands) |  | Average\u00a0Price Paidper Share |  | Total\u00a0Number of SharesPurchased\u00a0as Part ofPublicly AnnouncedPlans or Programs(in thousands) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(in millions)\nApril 2023 | \u2014 |  |  | $ | \u2014 |  |  | \u2014 |  |  | $ | 2,500.0 | \nMay 2023 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,500.0 | \nJune 2023 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,500.0 | \nTotal | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nExhibit |  | Description\n3.1 |  | Amended Articles of Incorporation, incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \n3.2 |  | Bylaws, as amended, incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \n31.1 |  | Rule\u00a013a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer*\n |  | \n31.2 |  | Rule\u00a013a-14(a) Certification of Anat Ashkenazi, Executive Vice President and Chief Financial Officer*\n | \n32 |  | Section 1350 Certification*\n |  | \n101 |  | Interactive Data Files (embedded within the Inline XBRL document)*\n |  | \n104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*\n\n* Filed herewith.  |  |  |  |  |  |  |  | \n |  | ELI LILLY AND COMPANY\n |  | (Registrant)\n |  | \nDate: | August 8, 2023 | /s/ Anat Ashkenazi\n |  | Anat Ashkenazi\n |  | Executive Vice President and Chief Financial Officer\nDate: | August 8, 2023 | /s/ Donald Zakrowski\n |  | Donald Zakrowski\n |  | Senior Vice President, Finance, and Chief Accounting Officer"}]}
{"messages": [{"role": "system", "content": "You are a financial AI that is trained on the top 30 companies in the S&P500, specially their 10Q forms."}, {"role": "user", "content": "For Eli Lilly, in 2023 Q3, what is its Quarterly Report?"}, {"role": "assistant", "content": " |  | \n  |  |  |  |  |  |  |  | \nIndiana |  | 35-0470950\n(State or other jurisdiction of |  | (I.R.S. Employer\nincorporation or organization) |  | Identification No.)  |  |  |  |  |  |  |  | \nTitle of Each Class | Trading Symbols | Name of Each Exchange On Which Registered\nCommon Stock (no par value) | LLY | New York Stock Exchange\n7 1/8% Notes due 2025 | LLY25 | New York Stock Exchange\n1.625% Notes due 2026 | LLY26 | New York Stock Exchange\n2.125% Notes due 2030 | LLY30 | New York Stock Exchange\n0.625% Notes due 2031 | LLY31 | New York Stock Exchange\n0.500% Notes due 2033 | LLY33 | New York Stock Exchange\n6.77%\u00a0Notes due 2036 | LLY36 | New York Stock Exchange\n1.625% Notes due 2043 | LLY43 | New York Stock Exchange\n1.700% Notes due 2049 | LLY49A | New York Stock Exchange\n1.125% Notes due 2051 | LLY51 | New York Stock Exchange\n1.375% Notes due 2061 | LLY61 | New York Stock Exchange  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nLarge accelerated filer | \u2612 |  |  |  |  | Accelerated\u00a0filer | \u2610\nNon-accelerated filer | \u2610 |  |  | Smaller reporting company | \u2610\n |  |  |  |  |  | Emerging growth company | \u2610  |  |  |  |  |  |  |  | \nClass |  | Number of Shares Outstanding\nCommon |  | 949,307,237 |   |  | \n  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  | Page\nPART I. Financial Information |  |  |  | 5\n |  |  |  | \nItem 1. |  | Financial Statements |  | 5\n |  | Consolidated Condensed Statements of Operations |  | 5\n |  | Consolidated Condensed Statements of Comprehensive Income (Loss) |  | 6\n |  | Consolidated Condensed Balance Sheets |  | 7\n |  | Consolidated Condensed Statements of Equity |  | 8\n |  | Consolidated Condensed Statements of Cash Flows |  | 10\n |  | Notes to Consolidated Condensed Financial Statements |  | 11\nItem 2. |  | Management's Discussion and Analysis of Results of Operations and Financial Condition |  | 35\n |  | Executive Overview |  | 35\n |  | Results of Operations |  | 41\n |  | Financial Condition and Liquidity |  | 45\n |  |  |  | \n |  | Critical Accounting Estimates |  | 46\n |  | Available Information on our Website |  | 46\nItem 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  | 47\nItem 4. |  | Controls and Procedures |  | 47\n |  |  |  | \nPART II. Other Information |  |  |  | 48\n |  |  |  | \nItem 1. |  | Legal Proceedings |  | 48\nItem 1A. |  | Risk Factors |  | 48\nItem 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 48\nItem 5. |  | Other Information |  | 48\nItem 6. |  | Exhibits |  | 49\n |  |  |  | \nSignatures |  |  |  | 49  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue (Note 2) | $ | 9,498.6 |  |  | $ | 6,941.6 |  |  | $ | 24,770.7 |  |  | $ | 21,239.6 | \nCosts, expenses, and other: |  |  |  |  |  |  | \nCost of sales | 1,860.1 |  |  | 1,579.1 |  |  | 5,294.2 |  |  | 5,081.7 | \nResearch and development | 2,409.1 |  |  | 1,802.9 |  |  | 6,750.7 |  |  | 5,194.9 | \nMarketing, selling, and administrative | 1,803.9 |  |  | 1,614.2 |  |  | 5,478.5 |  |  | 4,797.2 | \nAcquired in-process research and development (Note 3) | 2,975.1 |  |  | 62.4 |  |  | 3,177.2 |  |  | 668.4 | \nAsset impairment, restructuring, and other special charges (Note 5) | \u2014 |  |  | 206.5 |  |  | \u2014 |  |  | 206.5 | \nOther\u2013net, (income) expense (Note 11) | 23.2 |  |  | 111.0 |  |  | 24.3 |  |  | 580.9 | \n | 9,071.4 |  |  | 5,376.1 |  |  | 20,724.9 |  |  | 16,529.6 | \nIncome before income taxes | 427.2 |  |  | 1,565.5 |  |  | 4,045.8 |  |  | 4,710.0 | \nIncome taxes (Note 7) | 484.6 |  |  | 113.8 |  |  | 995.1 |  |  | 402.9 | \nNet income (loss) | $ | (57.4) |  |  | $ | 1,451.7 |  |  | $ | 3,050.7 |  |  | $ | 4,307.1 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nEarnings (loss) per share: |  |  |  |  |  |  | \nBasic | $ | (0.06) |  |  | $ | 1.61 |  |  | $ | 3.39 |  |  | $ | 4.78 | \n |  |  |  |  |  |  | \nDiluted | $ | (0.06) |  |  | $ | 1.61 |  |  | $ | 3.38 |  |  | $ | 4.76 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nShares used in calculation of earnings (loss) per share: |  |  |  |  |  |  | \nBasic | 899.8 |  | 900.7 |  | 900.2 |  | 901.8\nDiluted | 899.8 |  | 903.8 |  | 903.1 |  | 904.5  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet income (loss) | $ | (57.4) |  |  | $ | 1,451.7 |  |  | $ | 3,050.7 |  |  | $ | 4,307.1 | \nOther comprehensive income (loss), net of tax (Note 10) | 3.8 |  |  | (8.1) |  |  | 59.7 |  |  | 47.3 | \nComprehensive income (loss) | $ | (53.6) |  |  | $ | 1,443.6 |  |  | $ | 3,110.4 |  |  | $ | 4,354.4 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nAssets | (Unaudited) |  | \nCurrent Assets |  |  | \nCash and cash equivalents (Note 6) | $ | 2,380.8 |  |  | $ | 2,067.0 | \nShort-term investments (Note 6) | 113.1 |  |  | 144.8 | \nAccounts receivable, net of allowances of$13.4(2023)and $16.0(2022) | 8,167.1 |  |  | 6,896.0 | \nOther receivables | 2,196.7 |  |  | 1,662.9 | \nInventories | 4,901.4 |  |  | 4,309.7 | \nPrepaid expenses and other current assets | 5,247.9 |  |  | 2,954.1 | \nTotal current assets | 23,007.0 |  |  | 18,034.5 | \nInvestments (Note 6) | 2,691.7 |  |  | 2,901.8 | \nGoodwill | 4,085.2 |  |  | 4,073.0 | \nOther intangibles, net | 6,781.7 |  |  | 7,206.6 | \nDeferred tax assets | 4,574.8 |  |  | 2,792.9 | \nProperty and equipment, net of accumulated depreciation of$10,767.8(2023)and $10,233.4(2022) | 11,863.2 |  |  | 10,144.0 | \nOther noncurrent assets | 4,911.9 |  |  | 4,337.0 | \nTotal assets | $ | 57,915.5 |  |  | $ | 49,489.8 | \nLiabilities and Equity |  |  | \nCurrent Liabilities |  |  | \nShort-term borrowings and current maturities of long-term debt | $ | 2,244.7 |  |  | $ | 1,501.1 | \nAccounts payable | 2,435.1 |  |  | 1,930.6 | \nEmployee compensation | 1,233.2 |  |  | 1,059.8 | \nSales rebates and discounts | 11,522.3 |  |  | 8,784.1 | \nDividends payable | \u2014 |  |  | 1,017.2 | \nIncome taxes payable | 1,977.5 |  |  | 475.1 | \nOther current liabilities | 2,585.4 |  |  | 2,370.3 | \nTotal current liabilities | 21,998.2 |  |  | 17,138.2 | \nOther Liabilities |  |  | \nLong-term debt | 17,923.6 |  |  | 14,737.5 | \nAccrued retirement benefits (Note 8) | 1,311.9 |  |  | 1,305.1 | \nLong-term income taxes payable | 3,468.3 |  |  | 3,709.6 | \nOther noncurrent liabilities | 1,906.1 |  |  | 1,824.0 | \nTotal other liabilities | 24,609.9 |  |  | 21,576.2 | \nCommitments and Contingencies (Note 9) |  |  | \nEli Lilly and Company Shareholders' Equity |  |  | \nCommon stock | 593.6 |  |  | 594.1 | \nAdditional paid-in capital | 7,160.0 |  |  | 6,921.4 | \nRetained earnings | 10,309.9 |  |  | 10,042.6 | \nEmployee benefit trust | (3,013.2) |  |  | (3,013.2) | \nAccumulated other comprehensive loss (Note 10) | (3,784.9) |  |  | (3,844.6) | \nCost of common stock in treasury | (45.0) |  |  | (50.5) | \nTotal Eli Lilly and Company shareholders' equity | 11,220.4 |  |  | 10,649.8 | \nNoncontrolling interests | 87.0 |  |  | 125.6 | \nTotal equity | 11,307.4 |  |  | 10,775.4 | \nTotal liabilities and equity | $ | 57,915.5 |  |  | $ | 49,489.8 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions, except per-share data, and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at July\u00a01, 2022 | 950,619 |  |  | $ | 594.1 |  |  | $ | 6,746.0 |  |  | $ | 8,556.0 |  |  | $ | (3,013.2) |  |  | $ | (4,287.7) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 114.5 | \nNet income (loss) |  |  |  |  |  |  | 1,451.7 |  |  |  |  |  |  |  |  |  |  | (15.7) | \nOther comprehensive loss, net of tax |  |  |  |  |  |  |  |  |  |  | (8.1) |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIssuance of stock under employee stock plans, net | 8 |  |  |  |  | (2.1) |  |  |  |  |  |  |  |  |  |  |  |  | \nStock-based compensation |  |  |  |  | 85.1 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | (1.2) |  |  |  |  |  |  |  |  |  |  | (3.0) | \nBalance at September\u00a030, 2022 | 950,627 |  |  | $ | 594.1 |  |  | $ | 6,829.0 |  |  | $ | 10,006.5 |  |  | $ | (3,013.2) |  |  | $ | (4,295.8) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 95.8 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at July\u00a01, 2023 | 949,688 |  |  | $ | 593.6 |  |  | $ | 6,948.6 |  |  | $ | 10,368.5 |  |  | $ | (3,013.2) |  |  | $ | (3,788.7) |  |  | 402 |  |  | $ | (45.0) |  |  | $ | 85.5 | \nNet income (loss) |  |  |  |  |  |  | (57.4) |  |  |  |  |  |  |  |  |  |  | 4.1 | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 3.8 |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nIssuance of stock under employee stock plans, net | 17 |  |  |  |  | (4.2) |  |  |  |  |  |  |  |  |  |  |  |  | \nStock-based compensation |  |  |  |  | 215.6 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | (1.2) |  |  |  |  |  |  |  |  |  |  | (2.6) | \nBalance at September\u00a030, 2023 | 949,705 |  |  | $ | 593.6 |  |  | $ | 7,160.0 |  |  | $ | 10,309.9 |  |  | $ | (3,013.2) |  |  | $ | (3,784.9) |  |  | 402 |  |  | $ | (45.0) |  |  | $ | 87.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Equity of Eli Lilly and Company Shareholders |  | \n(Dollars in millions, except per-share data, and shares in thousands) | Common Stock |  | AdditionalPaid-inCapital |  | RetainedEarnings |  | Employee Benefit Trust |  | Accumulated Other Comprehensive Loss |  | Common Stock in Treasury(1) |  | Noncontrolling Interests\nShares |  | Amount | Shares |  | Amount\nBalance at January\u00a01, 2022 | 954,116 |  |  | $ | 596.3 |  |  | $ | 6,833.4 |  |  | $ | 8,958.5 |  |  | $ | (3,013.2) |  |  | $ | (4,343.1) |  |  | 463 |  |  | $ | (52.7) |  |  | $ | 175.6 | \nNet income (loss) |  |  |  |  |  |  | 4,307.1 |  |  |  |  |  |  |  |  |  |  | (63.7) | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 47.3 |  |  |  |  |  |  | \nCash dividends declared per share: $1.96 |  |  |  |  |  |  | (1,765.9) |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (5,607) |  |  | (3.5) |  |  |  |  | (1,496.5) |  |  |  |  |  |  | (5,607) |  |  | 1,500.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 5,607 |  |  | (1,500.0) |  |  | \nIssuance of stock under employee stock plans, net | 2,118 |  |  | 1.3 |  |  | (282.6) |  |  |  |  |  |  |  |  | (13) |  |  | 2.2 |  |  | \nStock-based compensation |  |  |  |  | 278.2 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | 3.3 |  |  |  |  |  |  |  |  |  |  | (16.1) | \nBalance at September\u00a030, 2022 | 950,627 |  |  | $ | 594.1 |  |  | $ | 6,829.0 |  |  | $ | 10,006.5 |  |  | $ | (3,013.2) |  |  | $ | (4,295.8) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 95.8 | \n |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nBalance at January\u00a01, 2023 | 950,632 |  |  | $ | 594.1 |  |  | $ | 6,921.4 |  |  | $ | 10,042.6 |  |  | $ | (3,013.2) |  |  | $ | (3,844.6) |  |  | 450 |  |  | $ | (50.5) |  |  | $ | 125.6 | \nNet income |  |  |  |  |  |  | 3,050.7 |  |  |  |  |  |  |  |  |  |  | 4.6 | \nOther comprehensive income, net of tax |  |  |  |  |  |  |  |  |  |  | 59.7 |  |  |  |  |  |  | \nCash dividends declared per share: $2.26 |  |  |  |  |  |  | (2,034.0) |  |  |  |  |  |  |  |  |  |  | \nRetirement of treasury shares | (2,299) |  |  | (1.4) |  |  |  |  | (748.6) |  |  |  |  |  |  | (2,299) |  |  | 750.0 |  |  | \nPurchase of treasury shares |  |  |  |  |  |  |  |  |  |  |  |  | 2,299 |  |  | (750.0) |  |  | \nIssuance of stock under employee stock plans, net | 1,372 |  |  | 0.9 |  |  | (269.7) |  |  |  |  |  |  |  |  | (48) |  |  | 8.8 |  |  | \nStock-based compensation |  |  |  |  | 508.3 |  |  |  |  |  |  |  |  |  |  |  |  | \nOther |  |  |  |  |  |  | (0.8) |  |  |  |  |  |  |  |  | (3.3) |  |  | (43.2) | \nBalance at September\u00a030, 2023 | 949,705 |  |  | $ | 593.6 |  |  | $ | 7,160.0 |  |  | $ | 10,309.9 |  |  | $ | (3,013.2) |  |  | $ | (3,784.9) |  |  | 402 |  |  | $ | (45.0) |  |  | $ | 87.0 |   |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2023 |  | 2022\nCash Flows from Operating Activities | \nNet income | $ | 3,050.7 |  |  | $ | 4,307.1 | \nAdjustments to Reconcile Net Income to Cash Flows from Operating Activities: |  |  | \n |  |  | \nDepreciation and amortization | 1,139.6 |  |  | 1,147.5 | \nChange in deferred income taxes | (1,834.8) |  |  | (2,195.6) | \n |  |  | \nStock-based compensation expense | 508.3 |  |  | 278.2 | \n |  |  | \nNet investment losses | 144.5 |  |  | 676.4 | \nGains on sale of product rights | (1,853.9) |  |  | (94.5) | \nAcquired in-process research and development | 3,177.2 |  |  | 668.4 | \nOther changes in operating assets and liabilities, net of acquisitions and divestitures | 117.2 |  |  | 823.4 | \nOther operating activities, net | 103.2 |  |  | 312.1 | \nNet Cash Provided by Operating Activities | 4,552.0 |  |  | 5,923.0 | \nCash Flows from Investing Activities |  |  | \nPurchases of property and equipment | (2,377.0) |  |  | (1,353.6) | \nProceeds from sales and maturities of short-term investments | 155.2 |  |  | 83.1 | \nPurchases of short-term investments | (79.2) |  |  | (65.0) | \nProceeds from sales of and distributions from noncurrent investments | 476.2 |  |  | 251.6 | \nPurchases of noncurrent investments | (474.8) |  |  | (474.1) | \n |  |  | \nProceeds from sale of product rights | 1,604.3 |  |  | 65.8 | \nPurchases of in-process research and development | (3,364.0) |  |  | (993.1) | \nOther investing activities, net | (169.1) |  |  | (334.1) | \nNet Cash Used for Investing Activities | (4,228.4) |  |  | (2,819.4) | \nCash Flows from Financing Activities |  |  | \nDividends paid | (3,051.2) |  |  | (2,651.4) | \nNet change in short-term borrowings | 97.0 |  |  | 1,741.3 | \nProceeds from issuance of long-term debt | 3,958.5 |  |  | \u2014 | \nRepayments of long-term debt | \u2014 |  |  | (1,560.0) | \nPurchases of common stock | (750.0) |  |  | (1,500.0) | \n |  |  | \nOther financing activities, net | (303.4) |  |  | (295.2) | \nNet Cash Used for Financing Activities | (49.1) |  |  | (4,265.3) | \nEffect of exchange rate changes on cash and cash equivalents | 39.3 |  |  | (39.4) | \n |  |  | \nNet increase (decrease) in cash and cash equivalents | 313.8 |  |  | (1,201.1) | \nCash and cash equivalents at January\u00a01 | 2,067.0 |  |  | 3,818.5 | \nCash and Cash Equivalents at September 30 | $ | 2,380.8 |  |  | $ | 2,617.4 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet product revenue | $ | 7,306.2 |  |  | $ | 6,119.2 |  |  | $ | 20,524.2 |  |  | $ | 19,123.0 | \nCollaboration and other revenue(1) | 2,192.4 |  |  | 822.4 |  |  | 4,246.5 |  |  | 2,116.6 | \nRevenue | $ | 9,498.6 |  |  | $ | 6,941.6 |  |  | $ | 24,770.7 |  |  | $ | 21,239.6 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nContract liabilities | $ | 200.7 |  |  | $ | 219.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30,\n | 2023 |  | 2022\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\n |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity\u00ae | $ | 1,259.0 |  | $ | 414.6 |  | $ | 1,673.6 |  |  | $ | 1,418.3 |  | $ | 432.0 |  | $ | 1,850.4 | \nMounjaro\u00ae | 1,277.0 |  | 132.4 |  | 1,409.3 |  |  | 97.3 |  | 90.0 |  | 187.3 | \nJardiance(1) | 415.9 |  | 284.8 |  | 700.8 |  |  | 350.9 |  | 222.4 |  | 573.3 | \nHumalog\u00ae (2) | 194.2 |  | 201.2 |  | 395.4 |  |  | 248.1 |  | 198.8 |  | 447.0 | \nHumulin\u00ae | 145.5 |  | 61.2 |  | 206.7 |  |  | 169.5 |  | 68.7 |  | 238.2 | \nBasaglar\u00ae (3) | 111.4 |  | 68.2 |  | 179.6 |  |  | 124.8 |  | 68.1 |  | 193.0 | \nBaqsimi | 3.8 |  | 9.3 |  | 13.1 |  |  | 35.2 |  | 7.8 |  | 43.0 | \nOther diabetes | 53.2 |  | 88.6 |  | 141.9 |  |  | 44.5 |  | 86.2 |  | 130.4 | \nTotal diabetes | 3,460.0 |  | 1,260.3 |  | 4,720.4 |  |  | 2,488.6 |  | 1,174.0 |  | 3,662.6 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio\u00ae | 684.6 |  | 355.7 |  | 1,040.2 |  |  | 414.8 |  | 202.9 |  | 617.7 | \nCyramza\u00ae | 88.0 |  | 136.1 |  | 224.1 |  |  | 87.5 |  | 144.6 |  | 232.1 | \nErbitux\u00ae | 134.0 |  | 19.9 |  | 153.9 |  |  | 126.3 |  | 18.7 |  | 144.9 | \nAlimta\u00ae | 21.2 |  | 32.3 |  | 53.5 |  |  | 64.6 |  | 54.8 |  | 119.4 | \nOther oncology | 73.8 |  | 201.5 |  | 275.4 |  |  | 39.5 |  | 139.6 |  | 179.2 | \nTotal oncology | 1,001.6 |  | 745.5 |  | 1,747.1 |  |  | 732.7 |  | 560.6 |  | 1,293.3 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz\u00ae | 509.3 |  | 234.9 |  | 744.2 |  |  | 493.8 |  | 186.1 |  | 679.9 | \nOlumiant\u00ae (4) | 65.7 |  | 165.7 |  | 231.4 |  |  | 22.9 |  | 160.0 |  | 182.9 | \nOther immunology | \u2014 |  | 11.4 |  | 11.4 |  |  | \u2014 |  | 3.6 |  | 3.6 | \nTotal immunology | 575.0 |  | 412.0 |  | 986.9 |  |  | 516.7 |  | 349.7 |  | 866.4 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nZyprexa(5) | 49.9 |  | 1,431.5 |  | 1,481.4 |  |  | 8.0 |  | 73.4 |  | 81.4 | \nEmgality\u00ae | 126.5 |  | 42.1 |  | 168.5 |  |  | 114.0 |  | 54.6 |  | 168.5 | \nOther neuroscience | 31.0 |  | 87.0 |  | 118.2 |  |  | 23.8 |  | 99.4 |  | 123.3 | \nTotal neuroscience | 207.4 |  | 1,560.6 |  | 1,768.1 |  |  | 145.8 |  | 227.4 |  | 373.2 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nForteo\u00ae | 101.2 |  | 45.2 |  | 146.4 |  |  | 112.7 |  | 64.4 |  | 177.1 | \nCialis\u00ae | 4.9 |  | 82.0 |  | 86.8 |  |  | 8.1 |  | 107.7 |  | 115.7 | \nCOVID-19 antibodies(6) | \u2014 |  | \u2014 |  | \u2014 |  |  | 386.6 |  | \u2014 |  | 386.6 | \nOther | 18.0 |  | 24.8 |  | 42.9 |  |  | 30.9 |  | 35.7 |  | 66.6 | \nTotal other | 124.1 |  | 152.0 |  | 276.1 |  |  | 538.3 |  | 207.8 |  | 746.0 | \nRevenue | $ | 5,368.1 |  | $ | 4,130.5 |  | $ | 9,498.6 |  |  | $ | 4,422.1 |  | $ | 2,519.4 |  | $ | 6,941.6 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30,\n | 2023 |  | 2022\n | U.S. | Outside U.S. | Total |  | U.S. | Outside U.S. | Total\n |  |  |  |  |  |  | \nDiabetes: |  |  |  |  |  |  | \nTrulicity | $ | 4,177.7 |  | $ | 1,285.6 |  | $ | 5,463.2 |  |  | $ | 4,162.4 |  | $ | 1,341.1 |  | $ | 5,503.5 | \nMounjaro | 2,729.1 |  | 228.4 |  | 2,957.5 |  |  | 109.9 |  | 93.3 |  | 203.2 | \nJardiance(1) | 1,131.5 |  | 815.1 |  | 1,946.6 |  |  | 831.4 |  | 622.4 |  | 1,453.7 | \nHumalog(2) | 695.6 |  | 601.2 |  | 1,296.8 |  |  | 855.8 |  | 656.4 |  | 1,512.3 | \nHumulin | 488.6 |  | 175.4 |  | 664.0 |  |  | 562.3 |  | 223.1 |  | 785.4 | \nBaqsimi | 633.1 |  | 25.4 |  | 658.4 |  |  | 79.5 |  | 21.7 |  | 101.2 | \nBasaglar(3) | 329.7 |  | 213.4 |  | 543.1 |  |  | 339.9 |  | 218.8 |  | 558.7 | \nOther diabetes | 131.1 |  | 260.7 |  | 392.0 |  |  | 116.1 |  | 254.8 |  | 371.0 | \nTotal diabetes | 10,316.4 |  | 3,605.2 |  | 13,921.6 |  |  | 7,057.3 |  | 3,431.6 |  | 10,489.0 | \n |  |  |  |  |  |  | \nOncology: |  |  |  |  |  |  | \nVerzenio | 1,734.2 |  | 983.7 |  | 2,717.9 |  |  | 1,100.5 |  | 575.1 |  | 1,675.6 | \nCyramza | 303.6 |  | 417.5 |  | 721.1 |  |  | 259.3 |  | 434.3 |  | 693.6 | \nErbitux | 398.3 |  | 48.0 |  | 446.3 |  |  | 361.0 |  | 47.4 |  | 408.3 | \nAlimta | 59.2 |  | 113.5 |  | 172.6 |  |  | 490.5 |  | 200.5 |  | 691.1 | \nOther oncology | 194.7 |  | 521.4 |  | 716.2 |  |  | 124.1 |  | 422.3 |  | 546.4 | \nTotal oncology | 2,690.0 |  | 2,084.1 |  | 4,774.1 |  |  | 2,335.4 |  | 1,679.6 |  | 4,015.0 | \n |  |  |  |  |  |  | \nImmunology: |  |  |  |  |  |  | \nTaltz | 1,293.8 |  | 681.2 |  | 1,975.0 |  |  | 1,212.6 |  | 561.6 |  | 1,774.2 | \nOlumiant(4) | 158.8 |  | 520.4 |  | 679.2 |  |  | 104.6 |  | 520.1 |  | 624.7 | \nOther immunology | \u2014 |  | 39.0 |  | 39.0 |  |  | 0.1 |  | 12.1 |  | 12.1 | \nTotal immunology | 1,452.6 |  | 1,240.6 |  | 2,693.2 |  |  | 1,317.3 |  | 1,093.8 |  | 2,411.0 | \n |  |  |  |  |  |  | \nNeuroscience: |  |  |  |  |  |  | \nZyprexa(5) | 69.1 |  | 1,581.9 |  | 1,651.0 |  |  | 26.2 |  | 235.5 |  | 261.7 | \nEmgality | 354.0 |  | 138.2 |  | 492.2 |  |  | 330.8 |  | 144.4 |  | 475.2 | \nOther neuroscience | 89.7 |  | 282.9 |  | 372.6 |  |  | 87.0 |  | 337.0 |  | 424.0 | \nTotal neuroscience | 512.8 |  | 2,003.0 |  | 2,515.8 |  |  | 444.0 |  | 716.9 |  | 1,160.9 | \n |  |  |  |  |  |  | \nOther: |  |  |  |  |  |  | \nForteo | 269.2 |  | 147.6 |  | 416.8 |  |  | 261.4 |  | 191.7 |  | 453.0 | \nCialis | 21.6 |  | 281.1 |  | 302.7 |  |  | 25.8 |  | 454.7 |  | 480.4 | \nCOVID-19 antibodies(6) | \u2014 |  | \u2014 |  | \u2014 |  |  | 1,970.9 |  | 14.7 |  | 1,985.5 | \nOther | 73.0 |  | 73.4 |  | 146.5 |  |  | 119.4 |  | 125.1 |  | 244.8 | \nTotal other | 363.8 |  | 502.1 |  | 866.0 |  |  | 2,377.5 |  | 786.2 |  | 3,163.7 | \nRevenue | $ | 15,335.6 |  | $ | 9,435.0 |  | $ | 24,770.7 |  |  | $ | 13,531.5 |  | $ | 7,708.1 |  | $ | 21,239.6 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nRevenue(1): |  |  |  |  |  |  | \nU.S. | $ | 5,368.1 |  |  | $ | 4,422.1 |  |  | $ | 15,335.6 |  |  | $ | 13,531.5 | \nEurope | 2,568.6 |  |  | 1,056.4 |  |  | 4,837.1 |  |  | 3,224.8 | \nJapan | 390.8 |  |  | 487.7 |  |  | 1,233.6 |  |  | 1,352.3 | \nChina | 390.8 |  |  | 343.4 |  |  | 1,162.6 |  |  | 1,102.0 | \nOther foreign countries | 780.3 |  |  | 632.0 |  |  | 2,201.8 |  |  | 2,029.1 | \nRevenue | $ | 9,498.6 |  |  | $ | 6,941.6 |  |  | $ | 24,770.7 |  |  | $ | 21,239.6 |   |  |  |  |  | \nEstimated Fair Value at December 1, 2022 | \nCash | $ | 153.2 | \nAcquired IPR&D(1) | 184.0\nGoodwill(2) | 187.1\n | \nOther assets and liabilities, net | 23.0 | \nAcquisition date fair value of consideration transferred | 547.3\nLess: | \nCash acquired | (153.2) | \nFair value of CVR liability(3) | (66.9) | \nCash paid, net of cash acquired | $ | 327.2 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nCounterparty | Compound(s), Therapy or Asset | Acquisition Month |  | Phase of Development(1) |  | Acquired IPR&D Expense\nDICE Therapeutics, Inc. | DC-806, an oral IL-17 inhibitor for the treatment of chronic diseases in immunology | August 2023 |  | Phase II |  | $ | 1,915.5 | \nVersanis Bio, Inc. | Bimagrumab, a monoclonal antibody for the treatment of people living with obesity and obesity-related complications | August 2023 |  | Phase II |  | 604.1 | \nEmergence Therapeutics AG | ETx-22, a Nectin-4 antibody-drug conjugate for the treatment of urothelial cancer | August 2023 |  | Pre-clinical |  | 406.5 | \n |  |  |  |  |  | \nBioMarin Pharmaceutical Inc. | Priority Review Voucher | February 2022 |  | Not applicable |  | 110.0 |   |  |  |  |  |  |  |  | \n | Net Milestones Capitalized (Deferred)(1)\n | September 30, 2023 | December 31, 2022\nJardiance | $ | 101.3 |  | $ | 116.2 | \nTrajenta | 45.0 |  | 63.5 | \nBasaglar | (116.6) |  | (130.6) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nJardiance | $ | 700.8 |  |  | $ | 573.3 |  |  | $ | 1,946.6 |  |  | $ | 1,453.7 | \nBasaglar | 179.6 |  |  | 193.0 |  |  | 543.1 |  |  | 558.7 | \nTrajenta | 95.2 |  |  | 103.8 |  |  | 284.7 |  |  | 293.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nOlumiant | $ | 231.4 |  |  | $ | 182.9 |  |  | $ | 679.2 |  |  | $ | 624.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Maturities by Period\n | Total |  | Less\u00a0Than1 Year |  | 1-5Years |  | 6-10Years |  | More\u00a0Than10 Years\nFair value of debt securities | $ | 628.3 |  |  | $ | 88.2 |  |  | $ | 201.6 |  |  | $ | 109.4 |  |  | $ | 229.1 |   |  |  |  |  |  |  |  |  |  |  | \n | September 30, 2023 |  | December 31, 2022\nUnrealized gross gains | $ | 0.1 |  |  | $ | 0.6 | \nUnrealized gross losses | 59.7 |  |  | 49.2 | \nFair value of securities in an unrealized gain position | 30.4 |  |  | 46.8 | \nFair value of securities in an unrealized loss position | 559.6 |  |  | 568.7 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nProceeds from sales | $ | 60.0 |  |  | $ | 50.5 |  |  | $ | 121.8 |  |  | $ | 115.6 | \nRealized gross gains on sales | 0.3 |  |  | \u2014 |  |  | 0.6 |  |  | 0.2 | \nRealized gross losses on sales | 1.9 |  |  | 7.5 |  |  | 3.6 |  |  | 9.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Cost(1) |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | Significant OtherObservable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nSeptember 30, 2023 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents(2) | $ | 1,201.4 |  |  | $ | 1,201.4 |  |  | $ | 1,196.5 |  |  | $ | 4.9 |  |  | $ | \u2014 |  |  | $ | 1,201.4 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 30.2 |  |  | $ | 30.6 |  |  | $ | 30.2 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 30.2 | \nCorporate debt securities | 57.4 |  |  | 57.7 |  |  | \u2014 |  |  | 57.4 |  |  | \u2014 |  |  | 57.4 | \n |  |  |  |  |  |  |  |  |  |  | \nAsset-backed securities | 0.6 |  |  | 0.6 |  |  | \u2014 |  |  | 0.6 |  |  | \u2014 |  |  | 0.6 | \nOther securities | 24.9 |  |  | 24.9 |  |  | \u2014 |  |  | 11.0 |  |  | 13.9 |  |  | 24.9 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 113.1 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 139.3 |  |  | $ | 160.0 |  |  | $ | 139.3 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 139.3 | \n |  |  |  |  |  |  |  |  |  |  | \nCorporate debt securities | 198.6 |  |  | 222.3 |  |  | \u2014 |  |  | 198.6 |  |  | \u2014 |  |  | 198.6 | \nMortgage-backed securities | 144.9 |  |  | 161.9 |  |  | \u2014 |  |  | 144.9 |  |  | \u2014 |  |  | 144.9 | \nAsset-backed securities | 57.2 |  |  | 59.5 |  |  | \u2014 |  |  | 57.2 |  |  | \u2014 |  |  | 57.2 | \nOther securities | 171.1 |  |  | 77.0 |  |  | \u2014 |  |  | 6.2 |  |  | 164.9 |  |  | 171.1 | \nMarketable equity securities | 532.0 |  |  | 443.2 |  |  | 532.0 |  |  | \u2014 |  |  | \u2014 |  |  | 532.0 | \nEquity investments without readily determinable fair values(3) | 531.4 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(3) | 917.2 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 2,691.7 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  |  | \nCash equivalents(2) | $ | 657.4 |  |  | $ | 657.4 |  |  | $ | 650.4 |  |  | $ | 7.0 |  |  | $ | \u2014 |  |  | $ | 657.4 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 30.8 |  |  | $ | 31.1 |  |  | $ | 30.8 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 30.8 | \nCorporate debt securities | 53.4 |  |  | 53.5 |  |  | \u2014 |  |  | 53.4 |  |  | \u2014 |  |  | 53.4 | \n |  |  |  |  |  |  |  |  |  |  | \nAsset-backed securities | 2.0 |  |  | 2.0 |  |  | \u2014 |  |  | 2.0 |  |  | \u2014 |  |  | 2.0 | \nOther securities | 58.6 |  |  | 58.6 |  |  | \u2014 |  |  | 39.1 |  |  | 19.5 |  |  | 58.6 | \n |  |  |  |  |  |  |  |  |  |  | \nShort-term investments | $ | 144.8 |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments: |  |  |  |  |  |  |  |  |  |  | \nU.S. government and agency securities | $ | 146.4 |  |  | $ | 163.2 |  |  | $ | 146.4 |  |  | $ | \u2014 |  |  | $ | \u2014 |  |  | $ | 146.4 | \nCorporate debt securities | 213.9 |  |  | 235.8 |  |  | \u2014 |  |  | 213.9 |  |  | \u2014 |  |  | 213.9 | \nMortgage-backed securities | 149.2 |  |  | 161.5 |  |  | \u2014 |  |  | 149.2 |  |  | \u2014 |  |  | 149.2 | \nAsset-backed securities | 50.6 |  |  | 52.5 |  |  | \u2014 |  |  | 50.6 |  |  | \u2014 |  |  | 50.6 | \nOther securities | 398.6 |  |  | 34.5 |  |  | \u2014 |  |  | 311.0 |  |  | 87.6 |  |  | 398.6 | \nMarketable equity securities | 683.6 |  |  | 484.7 |  |  | 683.6 |  |  | \u2014 |  |  | \u2014 |  |  | 683.6 | \nEquity investments without readily determinable fair values(3) | 478.4 |  |  |  |  |  |  |  |  |  |  | \nEquity method investments(3) | 781.1 |  |  |  |  |  |  |  |  |  |  | \nNoncurrent investments | $ | 2,901.8 |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue\nShort-term commercial paper borrowings |  |  |  |  |  |  |  |  | \nSeptember 30, 2023 | $ | (1,594.9) |  |  | $ | \u2014 |  |  | $ | (1,592.5) |  |  | $ | \u2014 |  |  | $ | (1,592.5) | \nDecember 31, 2022 | (1,498.0) |  |  | \u2014 |  |  | (1,492.0) |  |  | \u2014 |  |  | (1,492.0) | \nLong-term debt, including current portion |  |  |  |  |  |  |  |  | \nSeptember 30, 2023 | $ | (18,573.4) |  |  | $ | \u2014 |  |  | $ | (15,412.6) |  |  | $ | \u2014 |  |  | $ | (15,412.6) | \nDecember 31, 2022 | (14,740.6) |  |  | \u2014 |  |  | (12,329.3) |  |  | \u2014 |  |  | (12,329.3) |   |  |  |  |  |  |  |  |  |  |  |  |  |  | \nSeptember 30, 2023\nPurchase |  | Sell\nCurrency | Amount(in millions) |  | Currency | Amount(in millions)\nEuro | 5,774.2 |  | U.S. dollars | 6,170.9\nU.S. dollars | 3,420.4 |  | Euro | 3,224.2\nU.S. dollars | 240.0 |  | Chinese yuan | 1,736.5\n |  |  |  | \nBritish pounds | 185.7 |  | U.S. dollars | 229.7\nU.S. dollars | 200.2 |  | Japanese yen | 29,626.8\n |  |  |  | \n |  |  |  | \n |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nFair value hedges: |  |  |  |  |  |  | \nEffect from hedged fixed-rate debt | $ | (29.9) |  |  | $ | (62.9) |  |  | $ | (29.0) |  |  | $ | (215.7) | \nEffect from interest rate contracts | 29.9 |  |  | 62.9 |  |  | 29.0 |  |  | 215.7 | \nCash flow hedges: |  |  |  |  |  |  | \nEffective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss | 3.2 |  |  | 4.1 |  |  | 10.3 |  |  | 12.3 | \nCross-currency interest rate swaps | 24.7 |  |  | 33.1 |  |  | (5.3) |  |  | 75.0 | \nNet losses on foreign currency exchange contracts not designated as hedging instruments | 201.0 |  |  | 129.6 |  |  | 177.8 |  |  | 280.7 | \nTotal | $ | 228.9 |  |  | $ | 166.8 |  |  | $ | 182.8 |  |  | $ | 368.0 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nNet investment hedges: |  |  |  |  |  |  | \nForeign currency-denominated notes | $ | 183.5 |  |  | $ | 435.1 |  |  | $ | 62.3 |  |  | $ | 822.8 | \nCross-currency interest rate swaps | 28.6 |  |  | 92.1 |  |  | 9.0 |  |  | 171.4 | \nForeign currency forward contracts | 217.7 |  |  | 107.8 |  |  | 199.3 |  |  | 121.4 | \nCash flow hedges: |  |  |  |  |  |  | \nForward-starting interest rate swaps | 84.3 |  |  | 57.5 |  |  | 141.4 |  |  | 337.7 | \nCross-currency interest rate swaps | 16.4 |  |  | 19.9 |  |  | 30.5 |  |  | 38.4 | \n |  |  |  |  |  |  | \n |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  |  |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue |  | \nSeptember 30, 2023 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | $ | (5.6) |  |  | $ | \u2014 |  |  | $ | (5.6) |  |  | $ | \u2014 |  |  | $ | (5.6) |  |  | \nOther noncurrent liabilities | (157.7) |  |  | \u2014 |  |  | (157.7) |  |  | \u2014 |  |  | (157.7) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 346.2 |  |  | \u2014 |  |  | 346.2 |  |  | \u2014 |  |  | 346.2 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 71.3 |  |  | \u2014 |  |  | 71.3 |  |  | \u2014 |  |  | 71.3 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 58.3 |  |  | \u2014 |  |  | 58.3 |  |  | \u2014 |  |  | 58.3 |  |  | \nOther noncurrent assets | 30.7 |  |  | \u2014 |  |  | 30.7 |  |  | \u2014 |  |  | 30.7 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 106.0 |  |  | \u2014 |  |  | 106.0 |  |  | \u2014 |  |  | 106.0 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 32.9 |  |  | \u2014 |  |  | 32.9 |  |  | \u2014 |  |  | 32.9 |  |  | \nOther current liabilities | (100.5) |  |  | \u2014 |  |  | (100.5) |  |  | \u2014 |  |  | (100.5) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nContingent consideration liabilities: |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | (39.0) |  |  | \u2014 |  |  | \u2014 |  |  | (39.0) |  |  | (39.0) |  |  | \nOther noncurrent liabilities | (63.9) |  |  | \u2014 |  |  | \u2014 |  |  | (63.9) |  |  | (63.9) |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  | Fair Value Measurements Using |  |  |  | \n | CarryingAmount |  | Quoted Prices in Active Markets for Identical Assets(Level 1) |  | SignificantOther Observable Inputs(Level 2) |  | SignificantUnobservableInputs(Level 3) |  | FairValue |  | \nDecember 31, 2022 |  |  |  |  |  |  |  |  |  |  | \nRisk-management instruments: |  |  |  |  |  |  |  |  |  |  | \nInterest rate contracts designated as fair value hedges: |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent liabilities | $ | (134.3) |  |  | $ | \u2014 |  |  | $ | (134.3) |  |  | $ | \u2014 |  |  | $ | (134.3) |  |  | \nInterest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 162.9 |  |  | \u2014 |  |  | 162.9 |  |  | \u2014 |  |  | 162.9 |  |  | \nOther noncurrent assets | 246.0 |  |  | \u2014 |  |  | 246.0 |  |  | \u2014 |  |  | 246.0 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as net investment hedges: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 67.6 |  |  | \u2014 |  |  | 67.6 |  |  | \u2014 |  |  | 67.6 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nCross-currency interest rate contracts designated as cash flow hedges: |  |  |  |  |  |  |  |  |  |  | \nOther noncurrent assets | 53.1 |  |  | \u2014 |  |  | 53.1 |  |  | \u2014 |  |  | 53.1 |  |  | \n |  |  |  |  |  |  |  |  |  |  | \nForeign exchange contracts designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | (38.3) |  |  | \u2014 |  |  | (38.3) |  |  | \u2014 |  |  | (38.3) |  |  | \nForeign exchange contracts not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  | \nOther receivables | 26.6 |  |  | \u2014 |  |  | 26.6 |  |  | \u2014 |  |  | 26.6 |  |  | \nOther current liabilities | (21.5) |  |  | \u2014 |  |  | (21.5) |  |  | \u2014 |  |  | (21.5) |  |  | \nContingent consideration liabilities: |  |  |  |  |  |  |  |  |  |  | \nOther current liabilities | (39.5) |  |  | \u2014 |  |  | \u2014 |  |  | (39.5) |  |  | (39.5) |  |  | \nOther noncurrent liabilities | (70.6) |  |  | \u2014 |  |  | \u2014 |  |  | (70.6) |  |  | (70.6) |  |  | \n |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  |  |  |  |  |  |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Defined Benefit Pension Plans\n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nComponents of net periodic cost: |  |  |  |  |  |  | \nService cost | $ | 72.5 |  |  | $ | 87.1 |  |  | $ | 217.8 |  |  | $ | 264.4 | \nInterest cost | 162.3 |  |  | 98.9 |  |  | 486.0 |  |  | 299.0 | \nExpected return on plan assets | (264.0) |  |  | (235.1) |  |  | (791.5) |  |  | (711.6) | \nAmortization of prior service cost | 0.6 |  |  | 0.6 |  |  | 1.8 |  |  | 1.9 | \nRecognized actuarial loss | 30.6 |  |  | 85.3 |  |  | 91.5 |  |  | 256.8 | \n |  |  |  |  |  |  | \nNet periodic cost | $ | 2.0 |  |  | $ | 36.8 |  |  | $ | 5.6 |  |  | $ | 110.5 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Retiree Health Benefit Plans\n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nComponents of net periodic benefit: |  |  |  |  |  |  | \nService cost | $ | 7.9 |  |  | $ | 11.7 |  |  | $ | 23.8 |  |  | $ | 35.0 | \nInterest cost | 15.3 |  |  | 9.4 |  |  | 46.0 |  |  | 28.4 | \nExpected return on plan assets | (45.5) |  |  | (38.0) |  |  | (136.6) |  |  | (114.1) | \nAmortization of prior service benefit | (13.3) |  |  | (13.7) |  |  | (39.7) |  |  | (41.1) | \nRecognized actuarial (gain) loss | (1.5) |  |  | 0.2 |  |  | (4.4) |  |  | 0.7 | \n |  |  |  |  |  |  | \nNet periodic benefit | $ | (37.1) |  |  | $ | (30.4) |  |  | $ | (110.9) |  |  | $ | (91.1) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at July\u00a01, 2023 | $ | (1,885.3) |  |  | $ | (33.5) |  |  | $ | (2,058.8) |  |  | $ | 188.9 |  |  |  |  | $ | (3,788.7) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (88.7) |  |  | (13.5) |  |  | 10.5 |  |  | 79.6 |  |  |  |  | (12.1) | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | 1.4 |  |  | 13.0 |  |  | 1.5 |  |  |  |  | 15.9 | \nNet other comprehensive income (loss) | (88.7) |  |  | (12.1) |  |  | 23.5 |  |  | 81.1 |  |  |  |  | 3.8 | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at September\u00a030, 2023 | $ | (1,974.0) |  |  | $ | (45.6) |  |  | $ | (2,035.3) |  |  | $ | 270.0 |  |  |  |  | $ | (3,784.9) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  |  |  | Accumulated Other Comprehensive Loss\nBalance at July\u00a01, 2022 | $ | (1,844.2) |  |  | $ | (27.9) |  |  | $ | (2,443.2) |  |  | $ | 27.6 |  |  |  |  | $ | (4,287.7) | \n |  |  |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (165.1) |  |  | (24.9) |  |  | 47.8 |  |  | 63.0 |  |  |  |  | (79.2) | \nNet amount reclassified from accumulated other comprehensive loss | \u2014 |  |  | 13.5 |  |  | 57.2 |  |  | 0.4 |  |  |  |  | 71.1 | \nNet other comprehensive income (loss) | (165.1) |  |  | (11.4) |  |  | 105.0 |  |  | 63.4 |  |  |  |  | (8.1) | \n |  |  |  |  |  |  |  |  |  |  | \nBalance at September\u00a030, 2022 | $ | (2,009.3) |  |  | $ | (39.3) |  |  | $ | (2,338.2) |  |  | $ | 91.0 |  |  |  |  | $ | (4,295.8) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  | Accumulated Other Comprehensive Loss\nBalance at January\u00a01, 2023 | $ | (1,874.2) |  |  | $ | (37.1) |  |  | $ | (2,062.3) |  |  | $ | 129.0 |  |  | $ | (3,844.6) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (74.6) |  |  | (11.3) |  |  | (11.9) |  |  | 135.8 |  |  | 38.0 | \nNet amount reclassified from accumulated other comprehensive loss | (25.2) |  |  | 2.8 |  |  | 38.9 |  |  | 5.2 |  |  | 21.7 | \nNet other comprehensive income (loss) | (99.8) |  |  | (8.5) |  |  | 27.0 |  |  | 141.0 |  |  | 59.7 | \n |  |  |  |  |  |  |  |  | \nBalance at September\u00a030, 2023 | $ | (1,974.0) |  |  | $ | (45.6) |  |  | $ | (2,035.3) |  |  | $ | 270.0 |  |  | $ | (3,784.9) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n(Amounts presented net of taxes) | Foreign Currency Translation Gains\u00a0(Losses) |  | Net Unrealized Gains (Losses) on Available-For-Sale\u00a0Securities |  | Defined Benefit Pension and Retiree\u00a0Health Benefit Plans |  | Net Unrealized Gains (Losses) on Cash\u00a0Flow Hedges |  | Accumulated Other Comprehensive Loss\nBalance at January\u00a01, 2022 | $ | (1,550.2) |  |  | $ | 3.7 |  |  | $ | (2,583.6) |  |  | $ | (213.0) |  |  | $ | (4,343.1) | \n |  |  |  |  |  |  |  |  | \nOther comprehensive income (loss) before reclassifications | (459.7) |  |  | (55.5) |  |  | 72.9 |  |  | 297.2 |  |  | (145.1) | \nNet amount reclassified from accumulated other comprehensive loss | 0.6 |  |  | 12.5 |  |  | 172.5 |  |  | 6.8 |  |  | 192.4 | \nNet other comprehensive income (loss) | (459.1) |  |  | (43.0) |  |  | 245.4 |  |  | 304.0 |  |  | 47.3 | \n |  |  |  |  |  |  |  |  | \nBalance at September\u00a030, 2022 | $ | (2,009.3) |  |  | $ | (39.3) |  |  | $ | (2,338.2) |  |  | $ | 91.0 |  |  | $ | (4,295.8) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\nTax benefit (expense) | 2023 |  | 2022 |  | 2023 |  | 2022\nForeign currency translation gains/losses | $ | (90.3) |  |  | $ | (133.3) |  |  | $ | (50.2) |  |  | $ | (234.2) | \nNet unrealized gains/losses on available-for-sale securities | 3.5 |  |  | 3.4 |  |  | 2.5 |  |  | 13.1 | \nDefined benefit pension and retiree health benefit plans | (6.9) |  |  | (22.4) |  |  | (13.9) |  |  | (73.2) | \nNet unrealized gains/losses on cash flow hedges | (21.6) |  |  | (16.9) |  |  | (37.5) |  |  | (80.8) | \nBenefit (expense) for income taxes allocated to other comprehensive income (loss) items | $ | (115.3) |  |  | $ | (169.2) |  |  | $ | (99.1) |  |  | $ | (375.1) |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nDetails about Accumulated Other Comprehensive Loss Components | Three Months Ended September 30, |  | Nine Months Ended September 30, | Affected Line Item in the Consolidated Condensed Statements of Operations\n\n2023 |  | 2022 |  | 2023 |  | 2022\nAmortization of retirement benefit items: |  |  |  |  |  |  |  | \nPrior service benefits, net | $ | (12.7) |  |  | $ | (13.1) |  |  | $ | (37.9) |  |  | $ | (39.2) |  | Other\u2013net, (income) expense\nActuarial losses, net | 29.1 |  |  | 85.5 |  |  | 87.1 |  |  | 257.5 |  | Other\u2013net, (income) expense\nTotal before tax | 16.4 |  |  | 72.4 |  |  | 49.2 |  |  | 218.3 |  | \nTax benefit | (3.4) |  |  | (15.2) |  |  | (10.3) |  |  | (45.8) |  | Income taxes\nNet of tax | 13.0 |  |  | 57.2 |  |  | 38.9 |  |  | 172.5 |  | \n |  |  |  |  |  |  |  | \nOther, net of tax | 2.9 |  |  | 13.9 |  |  | (17.2) |  |  | 19.9 |  | Other\u2013net, (income) expense\n |  |  |  |  |  |  |  | \nTotal reclassifications, net of tax | $ | 15.9 |  |  | $ | 71.1 |  |  | $ | 21.7 |  |  | $ | 192.4 |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 |  | 2022 |  | 2023 |  | 2022\nInterest expense | $ | 124.6 |  |  | $ | 81.5 |  |  | $ | 347.7 |  |  | $ | 247.6 | \nInterest income | (48.9) |  |  | (20.1) |  |  | (129.1) |  |  | (37.3) | \nNet investment losses on equity securities (Note 6) | 62.9 |  |  | 123.3 |  |  | 141.5 |  |  | 667.6 | \nRetirement benefit plans | (115.5) |  |  | (92.4) |  |  | (346.9) |  |  | (280.0) | \n |  |  |  |  |  |  | \nOther (income) expense | 0.1 |  |  | 18.7 |  |  | 11.1 |  |  | (17.0) | \nOther\u2013net, (income) expense | $ | 23.2 |  |  | $ | 111.0 |  |  | $ | 24.3 |  |  | $ | 580.9 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Percent Change |  | Nine Months Ended September 30, |  | Percent Change\n | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \nRevenue | $ | 9,498.6 |  |  | $ | 6,941.6 |  |  | 37 |  | $ | 24,770.7 |  |  | $ | 21,239.6 |  |  | 17\nNet income (loss) | (57.4) |  |  | 1,451.7 |  |  | NM |  | 3,050.7 |  |  | 4,307.1 |  |  | (29)\nEarnings (loss) per share - diluted | (0.06) |  |  | 1.61 |  |  | NM |  | 3.38 |  |  | 4.76 |  |  | (29)  |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication/Study | Status | Developments | \nDiabetes and Obesity | \n |  |  |  | \nEmpagliflozin (Jardiance\u00ae)(1) | Chronic kidney disease | Approved | Approved in the U.S. and in the EU in the third quarter of 2023. Submitted in Japan in 2022. | \nTirzepatide | Obesity | Submitted | Submitted in the EU in the first quarter of 2023 and in the U.S. in the second quarter of 2023. Received Priority Review designation from the U.S. Food and Drug Administration (FDA). Announced in the second and third quarters of 2023 that Phase III trials met all primary and key secondary endpoints. Phase III trials are ongoing. | \nCardiovascular outcomes in type 2 diabetes | Phase III | Phase III trial is ongoing. | \nHeart failure with preserved ejection fraction | Phase III | Phase III trials are ongoing. | \nMorbidity and mortality in obesity | Phase III | Phase III trial is ongoing. | \nObstructive sleep apnea (OSA) | Phase III | Granted FDA Fast Track designation(2). Phase III trial is ongoing. | \nHigher doses | Phase II | Phase II trial initiated in the third quarter of 2023. | \nNonalcoholic steatohepatitis | Phase II | Phase II trial is ongoing. | \nInsulin Efsitora Alfa | Type 1 and 2 diabetes | Phase III | Phase III trials are ongoing. | \nOrforglipron | Obesity | Phase III | Phase III trials initiated in the second quarter of 2023. | \nType 2 diabetes | Phase III | Phase III trials initiated in the second and third quarters of 2023. | \nRetatrutide | Obesity, osteoarthritis, OSA | Phase III | Phase III trials initiated in the second and third quarters of 2023. | \nType 2 diabetes | Phase II | Phase II trial was completed. | \nBimagrumab | Obesity | Phase II | Acquired in the acquisition of Versanis Bio, Inc. (Versanis) in the third quarter of 2023. Phase II trial is ongoing. | \nLepodisiran | Cardiovascular disease | Phase II | Phase II trial is ongoing. | \nMuvalaplin | Cardiovascular disease | Phase II | Phase II trial is ongoing. | \nSolbinsiran | Cardiovascular disease | Phase II | Phase II trial is ongoing. | \nVolenrelaxin (Relaxin-LA) | Heart failure | Phase II | Phase II trial initiated in the first quarter of 2023. |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication/Study | Status | Developments | \nImmunology | \nMirikizumab(OmvohTM) | Ulcerative colitis | Approved | Approved in Japan in the first quarter of 2023, in the EU in the second quarter of 2023, and in the U.S. in October 2023. | \nCrohn's Disease | Phase III | Announced in October 2023 that a Phase III trial met the co-primary and all major secondary endpoints versus placebo. Phase III trials are ongoing. | \nLebrikizumab(3) | Atopic dermatitis | Submitted | Submitted in the U.S. and the EU in 2022 and in Japan in the first quarter of 2023. Announced in October 2023 we received a complete response letter from the FDA based on inspection findings at a third-party manufacturer with no stated concerns about the clinical data package, safety, or label. Phase III trials are ongoing. | \nDC-806 | Psoriasis | Phase II | Acquired in the acquisition of DICE Therapeutics, Inc. (DICE) in the third quarter of 2023. Phase II trial is ongoing. | \nEltrekibart | Hidradenitis suppurativa | Phase II | Phase II trial is ongoing. | \nPeresolimab | Rheumatoid arthritis | Phase II | Phase II trial is ongoing. | \nRIPK1 inhibitor | Rheumatoid arthritis | Phase II | Phase II trial initiated in the second quarter of 2023. | \nUcenprubart | Atopic dermatitis | Phase II | Phase II trial initiated in the second quarter of 2023. | \nBTLA MAB Agonist | Systemic lupus erythematosus | Discontinued | Phase II trial failed to demonstrate efficacy in the third quarter of 2023. | \nNeuroscience | \nDonanemab | Early Alzheimer's disease | Submitted | Submitted for traditional approval in the U.S. in the second quarter of 2023 and in the EU and Japan in the third quarter of 2023. Granted FDA Breakthrough Therapy designation(4). Announced in the second quarter of 2023 that a Phase III trial met primary and all secondary endpoints. Phase III trials are ongoing. | \nPreclinical Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nRemternetug | Early Alzheimer's disease | Phase III | Phase III trial is ongoing. | \nGBA1 Gene Therapy | Gaucher disease Type 1 | Phase II | Phase II trial initiated in the second quarter of 2023. | \nParkinson's disease | Phase II | Granted FDA Fast Track designation(2). Phase II trial is ongoing. | \nGRN Gene Therapy | Frontotemporal dementia | Phase II | Granted FDA Fast Track designation(2). Phase II trial is ongoing. | \nO-GlcNAcase Inh | Alzheimer's disease | Phase II | Phase II trial is ongoing. | \nP2X7 Inhibitor | Pain | Phase II | Phase II trials were recently completed. | \nSSTR4 Agonist | Pain | Phase II | Phase II trials are ongoing. |   |  |  |  |  |  |  |  |  |  |  |  | \nCompound | Indication/Study | Status | Developments | \nOncology | \nPirtobrutinib(Jaypirca\u00ae) | Mantle cell lymphoma | Approved(5) | FDA granted accelerated approval(5)in the U.S. in the first quarter of 2023. Submitted in the EU in 2022 and in Japan in the second quarter of 2023. Received a positive opinion from the Committee for Medicinal Products for Human Use in the EU in the second quarter of 2023. Phase III trial is ongoing. | \nChronic lymphocytic leukemia | Submitted | Submitted in the U.S. in the third quarter of 2023 under the accelerated approval pathway. Phase III trials are ongoing. | \nSelpercatinib (Retevmo\u00ae) | Lung cancer | Approved | Announced in the third quarter of 2023 that a Phase III trial met its primary endpoint. Phase III trial is ongoing. | \nThyroid cancer | Approved | Announced in the third quarter of 2023 that a Phase III trial met its primary endpoint. | \nAbemaciclib | Prostate cancer | Phase III | Phase III trials are ongoing. | \nImlunestrant | Adjuvant breast cancer | Phase III | Phase III trial is ongoing. | \nER+HER2- metastatic breast cancer | Phase III | Phase III trial is ongoing. |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Percent Change | Nine Months Ended September 30, |  | Percent Change\n | 2023 |  | 2022 |  | 2023 |  | 2022 | \nU.S. | $ | 5,368.1 |  |  | $ | 4,422.1 |  |  | 21 | $ | 15,335.6 |  |  | $ | 13,531.5 |  |  | 13\nOutside U.S. | 4,130.5 |  |  | 2,519.4 |  |  | 64 | 9,435.0 |  |  | 7,708.1 |  |  | 22\nRevenue | $ | 9,498.6 |  |  | $ | 6,941.6 |  |  | 37 | $ | 24,770.7 |  |  | $ | 21,239.6 |  |  | 17  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Nine Months Ended September 30,\n | 2023 vs. 2022 |  | 2023 vs. 2022\n | U.S. | Outside U.S. | Consolidated |  | U.S. | Outside U.S. | Consolidated\nVolume | 9 | % | 69 | % | 31 | % |  | 10 | % | 30 | % | 17 | %\nPrice | 13 |  | (7) |  | 6 |  |  | 3 |  | (5) |  | \u2014 | \nForeign exchange rates | \u2014 |  | 2 |  | 1 |  |  | \u2014 |  | (2) |  | (1) | \nPercent change | 21 | % | 64 | % | 37 | % |  | 13 | % | 22 | % | 17 | %  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Percent Change | \n | 2023 |  | 2022 | \nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | \nTrulicity | $ | 1,259.0 |  |  | $ | 414.6 |  |  | $ | 1,673.6 |  |  | $ | 1,850.4 |  |  | (10) | \nZyprexa(1) | 49.9 |  |  | 1,431.5 |  |  | 1,481.4 |  |  | 81.4 |  |  | NM | \nMounjaro | 1,277.0 |  |  | 132.4 |  |  | 1,409.3 |  |  | 187.3 |  |  | NM | \nVerzenio | 684.6 |  |  | 355.7 |  |  | 1,040.2 |  |  | 617.7 |  |  | 68 | \nTaltz | 509.3 |  |  | 234.9 |  |  | 744.2 |  |  | 679.9 |  |  | 9 | \nJardiance(2) | 415.9 |  |  | 284.8 |  |  | 700.8 |  |  | 573.3 |  |  | 22 | \nHumalog(3) | 194.2 |  |  | 201.2 |  |  | 395.4 |  |  | 447.0 |  |  | (12) | \nOlumiant\u00ae(4) | 65.7 |  |  | 165.7 |  |  | 231.4 |  |  | 182.9 |  |  | 27 | \nCyramza\u00ae | 88.0 |  |  | 136.1 |  |  | 224.1 |  |  | 232.1 |  |  | (3) | \nHumulin\u00ae | 145.5 |  |  | 61.2 |  |  | 206.7 |  |  | 238.2 |  |  | (13) | \nBasaglar\u00ae (5) | 111.4 |  |  | 68.2 |  |  | 179.6 |  |  | 193.0 |  |  | (7) | \nEmgality\u00ae | 126.5 |  |  | 42.1 |  |  | 168.5 |  |  | 168.5 |  |  | \u2014 | \nErbitux\u00ae | 134.0 |  |  | 19.9 |  |  | 153.9 |  |  | 144.9 |  |  | 6 | \nForteo\u00ae | 101.2 |  |  | 45.2 |  |  | 146.4 |  |  | 177.1 |  |  | (17) | \nCialis\u00ae | 4.9 |  |  | 82.0 |  |  | 86.8 |  |  | 115.7 |  |  | (25) | \nAlimta | 21.2 |  |  | 32.3 |  |  | 53.5 |  |  | 119.4 |  |  | (55) | \nBaqsimi | 3.8 |  |  | 9.3 |  |  | 13.1 |  |  | 43.0 |  |  | (70) | \nCOVID-19 antibodies(6) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 386.6 |  |  | (100) | \nOther products | 176.0 |  |  | 413.4 |  |  | 589.7 |  |  | 503.2 |  |  | 17 | \nRevenue | $ | 5,368.1 |  |  | $ | 4,130.5 |  |  | $ | 9,498.6 |  |  | $ | 6,941.6 |  |  | 37 |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Nine Months Ended September 30, |  | \n | 2023 |  | 2022\nProduct | U.S. |  | Outside U.S. |  | Total |  | Total | Percent Change\nTrulicity | $ | 4,177.7 |  |  | $ | 1,285.6 |  |  | $ | 5,463.2 |  |  | $ | 5,503.5 |  |  | (1)\nMounjaro | 2,729.1 |  |  | 228.4 |  |  | 2,957.5 |  |  | 203.2 |  |  | NM\nVerzenio | 1,734.2 |  |  | 983.7 |  |  | 2,717.9 |  |  | 1,675.6 |  |  | 62\nTaltz | 1,293.8 |  |  | 681.2 |  |  | 1,975.0 |  |  | 1,774.2 |  |  | 11\nJardiance(1) | 1,131.5 |  |  | 815.1 |  |  | 1,946.6 |  |  | 1,453.7 |  |  | 34\nZyprexa(2) | 69.1 |  |  | 1,581.9 |  |  | 1,651.0 |  |  | 261.7 |  |  | NM\nHumalog(3) | 695.6 |  |  | 601.2 |  |  | 1,296.8 |  |  | 1,512.3 |  |  | (14)\nCyramza | 303.6 |  |  | 417.5 |  |  | 721.1 |  |  | 693.6 |  |  | 4\nOlumiant(4) | 158.8 |  |  | 520.4 |  |  | 679.2 |  |  | 624.7 |  |  | 9\nHumulin | 488.6 |  |  | 175.4 |  |  | 664.0 |  |  | 785.4 |  |  | (15)\nBaqsimi | 633.1 |  |  | 25.4 |  |  | 658.4 |  |  | 101.2 |  |  | NM\nBasaglar(5) | 329.7 |  |  | 213.4 |  |  | 543.1 |  |  | 558.7 |  |  | (3)\nEmgality | 354.0 |  |  | 138.2 |  |  | 492.2 |  |  | 475.2 |  |  | 4\nErbitux | 398.3 |  |  | 48.0 |  |  | 446.3 |  |  | 408.3 |  |  | 9\nForteo | 269.2 |  |  | 147.6 |  |  | 416.8 |  |  | 453.0 |  |  | (8)\nCialis | 21.6 |  |  | 281.1 |  |  | 302.7 |  |  | 480.4 |  |  | (37)\nAlimta | 59.2 |  |  | 113.5 |  |  | 172.6 |  |  | 691.1 |  |  | (75)\nCOVID-19 antibodies(6) | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 1,985.5 |  |  | (100)\nOther products | 488.5 |  |  | 1,177.4 |  |  | 1,666.3 |  |  | 1,598.3 |  |  | 49\nRevenue | $ | 15,335.6 |  |  | $ | 9,435.0 |  |  | $ | 24,770.7 |  |  | $ | 21,239.6 |  |  | 17  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \n | Three Months Ended September 30, |  | Percent Change |  | Nine Months Ended September 30, |  | Percent Change\n | 2023 |  | 2022 |  |  | 2023 |  | 2022 | \n |  |  |  |  |  |  |  |  |  |  | \nGross margin | $ | 7,638.5 |  |  | $ | 5,362.5 |  |  | 42 |  | $ | 19,476.5 |  |  | $ | 16,157.9 |  |  | 21\nGross margin as a percent of revenue | 80.4 | % |  | 77.3 | % |  |  |  | 78.6 | % |  | 76.1 | % |  | \n |  |  |  |  |  |  |  |  |  |  | \nResearch and development | $ | 2,409.1 |  |  | $ | 1,802.9 |  |  | 34 |  | $ | 6,750.7 |  |  | $ | 5,194.9 |  |  | 30\nMarketing, selling, and administrative | 1,803.9 |  |  | 1,614.2 |  |  | 12 |  | 5,478.5 |  |  | 4,797.2 |  |  | 14\nAcquired IPR&D | 2,975.1 |  |  | 62.4 |  |  | NM |  | 3,177.2 |  |  | 668.4 |  |  | NM\nAsset impairment, restructuring, and other special charges | \u2014 |  |  | 206.5 |  |  | (100) |  | \u2014 |  |  | 206.5 |  |  | (100)\nOther\u2013net, (income) expense | 23.2 |  |  | 111.0 |  |  | (79) |  | 24.3 |  |  | 580.9 |  |  | (96)\nIncome taxes | 484.6 |  |  | 113.8 |  |  | NM |  | 995.1 |  |  | 402.9 |  |  | NM\nEffective tax rate | 113.4 | % |  | 7.3 | % |  |  |  | 24.6 | % |  | 8.6 | % |  |   |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \nPeriod | Total Number ofShares Purchased(in thousands) |  | Average\u00a0Price Paidper Share |  | Total\u00a0Number of SharesPurchased\u00a0as Part ofPublicly AnnouncedPlans or Programs(in thousands) |  | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(in millions)\nJuly 2023 | \u2014 |  |  | $ | \u2014 |  |  | \u2014 |  |  | $ | 2,500.0 | \nAugust 2023 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,500.0 | \nSeptember 2023 | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  | 2,500.0 | \nTotal | \u2014 |  |  | \u2014 |  |  | \u2014 |  |  |   |  |  |  |  |  |  |  | \nExhibit |  | Description\n3.1 |  | Amended Articles of Incorporation, incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \n3.2 |  | Bylaws, as amended, incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on May 4, 2022\n |  | \n31.1 |  | Rule\u00a013a-14(a) Certification of David Ricks, Chair, President, and Chief Executive Officer*\n |  | \n31.2 |  | Rule\u00a013a-14(a) Certification of Anat Ashkenazi, Executive Vice President and Chief Financial Officer*\n | \n32 |  | Section 1350 Certification*\n |  | \n101 |  | Interactive Data Files (embedded within the Inline XBRL document)*\n |  | \n104 |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*\n\n* Filed herewith.  |  |  |  |  |  |  |  | \n |  | ELI LILLY AND COMPANY\n |  | (Registrant)\n |  | \nDate: | November 2, 2023 | /s/ Anat Ashkenazi\n |  | Anat Ashkenazi\n |  | Executive Vice President and Chief Financial Officer\nDate: | November 2, 2023 | /s/ Donald Zakrowski\n |  | Donald Zakrowski\n |  | Senior Vice President, Finance, and Chief Accounting Officer"}]}
